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ABSTRACT 
Tumors effectively escape from the immune attack by inhibiting anti-
tumor activities of T cells. This is achieved by at least two mechanisms, although 
there are several others of importance. First, the establishment of inhibitory 
interactions between T and tumor cells through programmed death-1 (PD-1) 
binding to its ligand (PD-L1), among others. Second, by inducing the expansion 
of potent immunosuppressive myeloid-derived suppressor cells (MDSCs). In this 
Ph.D. thesis, I have studied these two key immunosuppressive barriers for 
cancer therapy. 
PD-L1 is one of the most important immunoregulatory molecules 
expressed on the cell surface of many cell types including cancer cells. Apart 
from binding to the inhibitory receptor PD-1 on T cells, it suppresses immune 
responses by the delivery of intrinsic intracellular signaling pathways that 
enhance cancer cell survival, regulates stress responses and in this thesis we 
discover that it confers resistance towards pro-apoptotic stimuli such as 
interferons. The systemic administration of antibodies that block PD-L1/PD-1 
interactions to cancer patients is demonstrating unprecedented clinical success, 
but much is yet to be known on the mechanisms of action. The first aim of this 
thesis was to firsltly identify sequence motifs within the intracytoplasmic domain 
of PD-L1 mediating protection from IFN-β-induced apoptosis. Two motifs 
implicated in the delivery of signals that inhibit IFN-β signal transduction 
pathways were identified. Moreover, it was found that human cancers acquire 
somatic mutations within these motifs that enhance the anti-interferon 
activities of PD-L1, favoring cancer cell growth in vitro. Overall, the results 
presented in this Ph.D. thesis uncovers a mode of action of PD-L1 in cancer cells 
as the first line of defense against IFN cytotoxicity. 
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Myeloid derived suppressor cells (MDSCs) differentiate from bone 
marrow precursors and expand in cancer-bearing hosts. MDSCs infiltrate tumors 
where they exert pro-carcinogenic activities. Identification of specific molecular 
pathways in MDSCs could help the development of novel anti- neoplastic 
treatments. The second aim of this thesis consisted in the in-depth molecular 
study of ex vivo generated murine MDSCs that resemble melanoma tumor-
infiltrating subsets by high-throughput quantitative proteomics. The neoplastic 
MDSC proteome was compared to those of non-neoplastic MDSC controls 
(derived ex vivo from 293T conditionant medium), and conventional bone-
marrow derived dendritic cells (DCs). Our analyses resulted in the most detailed 
interactome map of the murine MDSC to date, and uncovered the networks 
regulating cell lineage and cancer-induced pathways. We propose some kinases 
as MDSC-specific therapeutic targets. The activities of these kinases 
differentially regulate MDSC differentiation and activities and can be specifically 
inhibited in MDSCs while keeping immunogenic DCs largely unaffected. 
Finally, I discuss the potential combination of therapies targeting both 
barriers; inhibition of PD-1-PD-L1 interactions and blockade of MDSC activities 
as an optimal approach for anti-cancer therapies.
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RESUMEN 
Los tumores escapan eficazmente del ataque inmunitario al inhibir las 
actividades antitumorales de las células T. Esto se logra mediante al menos dos 
mecanismos principales. En primer lugar por el establecimiento de 
interacciones inhibitorias entre T y las células tumorales a través de la unión de 
“programed death”-1 (PD-1) y su ligando (PD-L1). En segundo lugar, al inducir la 
expansión de células mieloides inmunosupresoras potentes (MDSC). En esta 
tesis doctoral, he estudiado estas dos barreras inmunosupresoras clave para la 
terapia del cáncer. 
PD-L1 es una de las moléculas inmunorreguladoras más importantes 
expresadas en la superficie celular de muchos tipos de células, incluidas las 
cancerosas. Además de unirse al receptor inhibidor PD-1 en las células T, 
suprime las respuestas inmunes a través de vías de señalización intracelulares 
intrínsecas que mejoran la supervivencia de las células cancerosas, regulan las 
respuestas al estrés y confieren resistencia frente a estímulo proapoptóticos 
tales como los interferones. La administración sistémica de anticuerpos que 
bloquean las interacciones PD-L1 / PD-1 en pacientes con cáncer está 
demostrando un éxito clínico sin precedentes, pero aún queda mucho por 
conocer sobre sus mecanismos de acción. El primer objetivo de esta tesis fue 
identificar qué motivos en la secuencia dentro del dominio intracitoplásmatico 
median la protección mediada por PD-L1 frente a la apoptosis inducida por IFN. 
Se identificaron dos motivos implicados en el suministro de señales que inhiben 
las rutas de transducción de señales de IFN. Además, se descubrió que los 
cánceres humanos adquieren mutaciones somáticas dentro de estos motivos 
que potencian las actividades anti-interferón de PD-L1, favoreciendo el 
crecimiento de células cancerosas in vitro. En general, los resultados 
presentados en esta tesis doctoral descubren un modo de acción de PD-L1 en 
células cancerosas como primera línea de defensa contra la citotoxicidad de IFN. 
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Las MDSC se diferencian de los precursores de la médula ósea y se 
expanden en los enfermos de cáncer. Las MDSC se infiltran en tumores donde 
ejercen actividades procarcinógenicas. La identificación de vías moleculares 
específicas en las MDSC podría ayudar al desarrollo de nuevos tratamientos 
antineoplásicos. El segundo objetivo de esta sección de la tesis consistió en el 
estudio molecular en profundidad de MDSCs murinas generadas ex vivo que se 
asemejan a aquellas infiltrantes de tumores de melanoma mediante 
proteómica cuantitativa de alto rendimiento. Se comparó el proteoma de MDSC 
neoplásicas con los controles de MDSC no neoplásicos (generados ex vivo a 
partir de medio codicionante de 293T) y las células dendríticas (DC) 
convencionales derivadas de médula ósea. Nuestros análisis dieron como 
resultado el mapa del interactoma más detallado del MDSC murinas hasta la 
fecha, y se descubrieron las redes que regulan el linaje celular y las vías inducidas 
por el cáncer. Proponemos algunas quinasas como dianas terapéuticas 
específicas de MDSC. Las actividades de estas quinasas regulan la diferenciación 
y las actividades de las MDSC, y se pueden inhibir específicamente en las MDSC 
mientras que las DC inmunogénicas no se ven afectadas en gran medida. 
Finalmente, discuto la potencial combinación de terapias dirigidas a 
ambas barreras; inhibición de las interacciones PD-1/PD-L1 y el bloqueo de las 
actividades de las MDSC como un enfoque óptimo para las terapias contra el 
cáncer. 
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INTRODUCTION 
1. CANCER AND MELANOMA 
 
Cancer is one of the major leading causes of death as nearly 1 in 6 deaths 
is associated with neoplasms. Indeed, the number of new cases is expected to 
increase by about 70% over the next 2 decades (www.who.int/en/ ). As an 
illustrative example, the total annual cost of cancer in 2010 was estimated by 
the World Health Organization to be on the order of 1.16 trillion US$. 
Cancer is a generic term for a large group of heterogeneous diseases 
that have in common the uncontrolled growth and spread of transformed 
mutant cells that arise through a multistage process. The malignant 
transformation may be started by external agents and/or inherited genetic 
factors that cause deleterious/dysregulating mutations in genes controlling the 
cell cycle, proliferation, survival pathways and apoptosis. These mutant cells 
may originate masses (solid tumors), or uncontrolled proliferation of circulating 
cells in the case of some haematological neoplasms. Cancer cells are 
characterized in many instances by genetic instability, which accelerates the 
acquisition of further mutations that may favour tumor invasion, angiogenesis, 
and metastasis. In time, the uncontrolled spread of cancer cells will originate 
secondary tumors that will interfere with the physiological function of the 
invaded organs, leading to disease and eventually to death. 
This Ph.D. thesis will focus on malignant melanoma as an experimental 
model. Melanoma is a cancer of the skin that arises from melanocytic nevi as a 
result of mutations that confer transformed melanocytes with high invasive 
capacities. Although not the most frequent of skin cancers, melanoma is one of 
the fastest and most aggressive. In fact, the incidence rate of melanoma has 
doubled worldwide since 1973 particularly in regions with a high proportion of 
fair-skinned population. There were an estimated 14.1 million cancer cases 
worldwide in 2012, and this number is expected to increase to 24 million by 
2035 (https://www.wcrf.org/) (Figure 1). 
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Figure 1: Incidence of malignant melanoma. (A) Graph representing the 
increase in incidence of skin melanoma, US. Data are reported as lifetime risk 
and taken from NCI SEER reports. (B) Pie graphs representing the incidence of 
melanoma by race and gender in the US. Incidence rates based on NCI SEER data. 
Irrespective of gender, fair-skinned people have a higher incidence. 
 
 
Melanoma progression is staged following different systems (Figure 2A). 
The Breslow system grades melanoma lesions from I to IV according to thickness 
in mm (1-4 mm) (Figure 2A); The Clark system is the most extensively used and 
classifies melanomas according to tissue invasion (Figure 2A). It defines 
melanoma stages from 0 to IV according to the location of the primary tumor 
and whether it has spread or not. Stage zero corresponds to melanomas present 
only in the outer layer of the skin. Stage I when the primary melanoma lesion is 
thin and present in the epidermis. Stage II corresponds to melanomas that have 
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extended into the dermis and stage III when cancer cells have spread through 
the lymphatic system. All the stages are also subdivided depending on the 
thickness of the neoplastic lesion, the presence of ulceration and in stage III 
according to the number of lymph nodes with metastases. Stage IV describes 
melanomas that have spread to distant organs, and it is further divided into 3 
groups according to the location of the metastases; in lymph nodes (first group), 
skin/soft tissues (second group) and lung, liver, brain, bone or gastrointestinal 
tract (third group). The Clark system has prognostic value. Survival rates in which 
the survival rates decrease significantly for each successive stage (Figure 2B). 
Melanomas are also staged using the TNM classification, with “T”according to 
thickness, “N” the number of invaded lymph nodes, and “M”, presence of 
metastases to distant organs (Santos et al. 1984). 
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Figure 2: Melanoma staging and prognosis. (A) Breslow and Clark systems. In 
vertical, Breslow classification system from I to IV according to thickness and depth 
in the skin, with 0 describing superficial lesions in the epidermis, to 4 for lesions 
affecting the subcutaneous layer. Clark classification is shown horizontally, 
according to tissue invasion: from type I (intradermal) to type V, when lesions invade 
the subcutaneous tissue. Stage III is used for melanomas spreading through the 
lymphatic system and Stage IV when the disease has metastasized to other parts of 
the body. (B) Survival rates of malignant melanoma according to staging of 
disease. The chart represents the overall survival rates as a function of the 
melanoma staging (I through IV). Survival may also be predicted by subclasses 
within each stage. 
 
 
2. ONCOGENESIS IN MELANOMA 
 
Oncogenesis is the process by which malignant transformation occurs in 
a normal cell, and it is driven by the accumulation of gain-of-function mutations 
in genes that regulate proliferation and survival (proto-oncogenes) and 
inactivating mutations in genes that regulate anti-proliferative or apoptotic 
pathways (anti-oncogenes or tumour suppressor genes) (Polsky et al. 2003) 
(Figure 3). These changes can occur through point mutations, translocations, 
gene amplification, deletions and insertions (www.who.int/en/ ). There are 
mutations in proto- and anti-oncogenes that appear with high frequency. Some 
of these changes are required for melanocytic transformation (driver 
mutations). Without any doubt, the most prevalent pro-oncogenic mutations in 
melanoma occur in the GTPase RAS signal transduction pathway. This is a core 
pathway in response to cytokines and growth factors, and it is characterized by 
a RAS-RAF-MEK-ERK kinase cascade that promotes cell division, angiogenesis, 
and evasion from cellular senescence and apoptosis (Karasarides et al. 2004; 
Wellbrock et al. 2004). Gain-of-function RAS mutations occur in most human 
cancers (Santos et al. 1984). Other prevalent activating mutations in melanomas 
are present within the B-RAF gene, which encodes a serine/threonine kinase 
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that activates the mitogen-activated protein kinase (MAPK)/ERK-signalling 
pathway (Pollock et al. 2002). Of these, the B-RAF V600E represents 90% of 
oncogenic RAF mutations in melanomas. C-KIT (receptor for stem cell factor) 
mutations also take place but at a lower frequency, enhancing intrinsic tyrosine 
kinase activities that facilitate cell growth. 
Driver mutations take place in pre-cancerous cells (Figure 3). There are 
some inactivating mutations in tumor-suppressor genes which contribute to 
oncogenic transformation. For example, mutations in CDKN2A, NF1 and PTEN 
genes. P53 is one of the main cellular anti-oncogenes that responds to stress-
induced stimuli including genetic instability (Tímár et al. 2016), that can also be 
disrupted by mutations. In addition, other mutations appear at a lower 
frequency which may contribute to oncogenesis, tumor progression and 
adaptation to pro-inflammatory and hypoxic environments. Amongst these, 
putative oncogenes such as CDK4, Cyclin D1, C- MYC, GNAQ, CTNNB1, ALK, 
EGFR4, BCL2, RAC1, MAPK2K1 or tumor-suppressor genes including WT1, ARID2 
or RB1 (Tímár et al. 2016; Geis et al. 2015). Additionally, genetic instability in 
cancer cells makes them susceptible to accumulating additional somatic 
mutations. Overall, the collection of somatic mutations found in tumors 
(termed “mutanome”) has a significant clinical relevance particularly for 
immunotherapies and targeted therapies (Overwijk et al. 2013; Sahin et al. 
2017) (Figure 3). 
 
Figure 3: Oncogenesis in melanoma. The process of melanocyte transformation 
into malignant melanomas is illustrated. (1) Main mutagens responsible for 
acquisition of driving mutations in normal cells. Changes in proto- or anti-
oncogenes mentioned in (2) cause genetic instability and melanocytic 
transformation by the mechanisms described in (3). Transformed cells acquire 
further mutations leading to the expression of melanoma tumor-associated 
antigens (TAAs) as shown in (4). Cells are selected that are poorly immunogenic, 
efficacious in establishing immune suppression and surviving hypoxia. These 
cells may further progress by promoting angiogenesis and metastasis as shown 
in (5). 
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3. TREATMENTS OF MELANOMA OTHER THAN IMMUNOTHERAPIES 
 
The therapeutic options very much depend on the staging at diagnosis. 
The first line of treatment is the removal by surgery followed by radiotherapy 
and chemotherapy. During the last decade, the development of targeted 
therapies and immune checkpoint blockade therapies has radically changed 
conventional therapeutic approaches. For more than 30 years, chemotherapy 
has been the main therapeutic strategy for patients with advanced malignant 
melanoma, with dacarbazine as the standard of treatment since 1975; however, 
the outcomes are poor with an overall response rate (ORR) of about 20% and a 
median duration of 4 to 6 months (Serrone et al. 2000). Different chemotherapy 
agents such as temozolomide or fotemustine amongst others have failed to 
demonstrate superior efficacies (Middleton et al. 2000; Avril et al. 2004). 
Traditional chemotherapies indiscriminately affect quickly dividing and 
are characterized by high collateral damage and limited long-term efficacy. 
Targeted therapies rebased on small molecules or antibodies that preferentially 
inhibit kinases mutated in malignant cells. Therefore, these agents are more 
selective (Figure 4). 
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Figure 4. Efficacies of melanoma treatment types. The chart represents models 
of Kaplan-Meier survival plots for each type of treatment. Classical 
chemotherapy has a poor overall response rate and limited long-term efficacy. 
Targeted therapies are more selective, exhibiting a delay in progression and 
slightly better survival. Immune checkpoint blockade therapies achieve durable 
long-term responses. Combination therapies of immune checkpoint inhibitors 
approved in metastasic melanoma. Are demonstrating significantly increased 
responses. The right table contains examples of the type of therapies 
represented in the survival plot. 
 
 
B-RAF mutated at codon V600 was one of the first mutant kinases to be 
targeted with selective tyrosine kinase inhibitors (Ott et al. 2013). Two of them 
(vemurafenib and dabrafenib) have been approved by the FDA and EMA for the 
treatment of B-RAFV600E and B-RAFV600K melanomas (Kudchadkar et al. 
2012). The MAP kinase MEK has also attracted interest as a target, with 
trametinib as the only inhibitor accepted for clinical use to date (Flaherty et al. 
2012). Targeted therapies achieve fast responses after administration, but their 
duration is short-lived due to acquired resistances (Ott et al. 2013; Weber et al. 
2015; Johnson et al. 2014) (Figure 4). Other inhibitors such as imatinib and 
nilotinib targeting mutated C-KIT can also be used for the treatment of 
melanoma (Gato-Canas et al. 2016). 
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4. IMMUNOTHERAPIES 
Cancer immunotherapy is based on the stimulation of the immune 
system to selectively identify and kill tumor cells, leading to long-term responses 
and immunological memory. 
Cancer immunotherapies englobe different therapeutic strategies that 
stimulate the natural capacities of the immune system to recognize and 
eradicate tumor cells. Especially desired is the activation of adaptive immune 
responses to achieve immunological memory and long-term control of tumors 
(Figure 4). 
Cancer immunotherapies can be classified into six major strategies, 
which can also be combined: cytokine therapies, tumor vaccines, adoptive 
transfer of immune cells, immune checkpoint modulators, and depletion of 
immunosuppressive cells. 
 
 
4.1. Tumor-associated antigens 
Cancer cells express a collection of mutated self-proteins, neoantigens, 
oncofetal proteins or increased levels of some tissue-specific proteins that 
confer them with a degree of immunogenicity (quasi-antigens). These antigens 
are called tumor- associated antigens (TAAs) (Gato-Canas et al. 2016). The 
acquired immunogenicity confers the immune system the potential to identify 
and destroy transformed cells (Escors et al. 2014). 
 
Melanoma is one of the most immunogenic cancers. In the 1990s, several 
immunogenic TAAs were identified both in murine and human melanomas, such 
as overexpressed endogenous tyrosinase-related proteins 1 and 2 (TRP-1, TRP-
2) (Cohen et al. 1990; Tsukamoto et al. 1992; Wang et al. 1996). Immunological 
tolerance towards them could be broken to drive effective anti-melanoma 
responses (Wang et al. 1998; Parkhurst et al. 1998; Castelli et al. 1999; Noppen 
et al. 2000; Sun et al. 2000; Liu et al. 2009; Osen et al. 2010; Sierro et al. 2011; 
Overwijk et al. 1999). Indeed, TRP- 2 targeted immune responses can lead to 
melanoma regression (Khong et al. 2002; Bronte et al. 2000).  
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Some epitopes of the gp100 protein were recognized by human 
cytotoxic T cells (Vennegoor et al. 1988; Bakker et al. 1994; Adema et al. 1994), 
and have been used in preclinical studies and in human vaccines (Tarhini et al. 
2012). Similarly, several CD8 and CD4 T cell epitopes were identified for NY-ESO-
1 (cancer-testis antigen 1B) (Eikawa et al. 2013; Mizote et al. 2010; Robson et al. 
2010; Escors et al. 2008; Jager et al. 2000; Odunsi et al. 2012; Gnjatic et al. 2006; 
Campos-Perez et al. 2013). T cells modified to express NY-ESO-1-specific TCRs 
induced tumor regression in metastatic synovial cell sarcoma and melanoma in 
human patients (Robbins et al. 2011). Similarly, genetically engineered 
autologous CD8 T cells expressing MART-1-specific TCRs demonstrated their 
capacities to achieve melanoma regression and long-term therapeutic effects in 
animal models and human patients (Abdel-Wahab et al. 2005; Kawakami et al. 
1994; Bobisse et al. 2009; Khong et al. 2002; Overwijk et al. 1999). A large 
collection of TAAs is known nowadays, and the study and exploitation of the 
cancer cell mutanome remains an active area of research (Bakker et al. 1994; 
Cheever et al. 2009). 
 
 
4.2. Oncoimmunology of melanoma 
Oncoimmunology or cancer immunology can be defined as the study of 
the relationship between the immune system and cancer. A significant number 
of tumors including melanoma are certainly immunogenic and subjected to the 
“immunological cycle” of anti-tumor responses (Figure 5). 
The initial phase of recognition is most likely mediated by innate 
immune responses, possibly mediated by NK cells and macrophages that induce 
local inflammation through production of IFNs and other pro-inflammatory 
cytokines and chemokines that in turn attract other immune cells. This initial 
direct cytotoxic attack over cancer cells (Miller et al. 2009; Ichim et al. 2005) 
causes the release of tumor-associated antigens (TAAs) (Figure 5). This phase is 
critical for the initiation of adaptive immune responses against cancer cells, and 
most likely mediated by recruited dendritic cells (DCs), the main professional 
antigen presenting cells (APCs) regulating innate and adaptive immunity 
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(Matzinger et al. 1994). Upon arrival, DCs take up necrotic cancer cells, process 
TAAs into immunogenic peptides, mature, and migrate to tumor-draining lymph 
nodes where they present cancer-derived antigens complexed to class I and class 
II major histocompatibility molecules (MHCs) to CD8 and CD4 T cells, 
respectively (Lipscomb et al. 2002; Goold et al. 2011) (Figure 5 and Figure 6). 
Activation of T helper 1 (Th1) CD4 T cells is critical for anti-cancer immunity 
(Kennedy et al. 2008). Th1 cells secrete IFN, IL2, and IL12 needed for 
differentiation, clonal expansion, and survival of antigen-specific cytotoxic CD8 
T cells. Activated CD8 T cells are recruited to the inflamed tumor site where they 
exert their cytotoxic activities and may also further differentiate into CD8 
memory cells (Curtsinger et al. 2003; Knutson et al. 2005) (Figure 5). 
Both CD4 Th1 and CD8 T cells can directly exert cytotoxic activities 
through the production of IFN-γ, TNF-α, and secretion of perforin and granzyme-
containing granules. Cytotoxic T cells express ligands of the TNF superfamily such 
as FasL on their cell surface, which after ligation with death receptors induce the 
death of targeted cells (Cullen et al. 2008). Secreted IFN-γ within the tumor 
environment up-regulates the expression of MHC-I, MHC-II and co-stimulatory 
molecules on tumor and myeloid cells, enhancing cancer cell recognition and 
elimination (Miller et al. 2009; Diehl et al. 2002) (Figure 5 and Figure 6). Hence, 
the immune system exerts a strong selective pressure by which the most 
immunogenic cancer cells are eliminated leaving less immunogenic cancer cell 
variants. This process is called cancer immunoediting. The surviving cancer cells 
exhibit various selected genetic mutations and epigenetic alterations that often 
result in reduced expression of MHC molecules on the cell surface (Zitvogel et 
al.  2006; Dunn et al. 2004), production of immunosuppressive cytokines that 
skew the immune response to a tolerogenic path (Zitvogel et al. 2006) or 
become insensitive to IFNs (Zaretsky et al. 2016). The growth of solid tumors 
favours a hypoxic, nutrient-poor microenvironment that further suppresses 
immune responses (Chang et al. 2015). Therefore, although many cancer 
patients still contain circulating TAA-specific CD4 and CD8 T cells, these have 
been inactivated through mechanisms of peripheral tolerance and by the 
tolerogenic actions of cancer cells (Bakker et al. 1994). 
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Figure 5. Innate and adaptive immune responses to nascent tumors. (A) Tissue 
remodelling from growing tumors induces inflammation, which then attracts 
innate immune cells, such as NK cells and macrophages. NK cells cause tumor 
cell death through IFN-γ and granzyme-containing granules. Macrophages 
secrete cytokines such as IFN or IL12 which potentiate inflammation and enhance 
further infiltration of immune cells including DCs.  
(B) Attack of the innate immune system leads to release of TAAs by necrotic 
cancer cell death. Tumor-infiltrating DCs and macrophages phagocytose TAAs, 
process them into antigenic peptides and present them to T cells on their 
surface, complexed to MHC molecules. Simultaneous recognition of danger 
signals released by cancer cell death leads to DC maturation by up-regulating 
the surface expression of co-stimulatory molecules.  
(C) Matured DCs home to the tumor-draining lymph nodes where they present 
TAAs to T cells in an activatory co-stimulatory context. Cytokine secretion into 
the immunological synapse leads to T cell polarization and acquisition of effector 
functions. CD4 T cells polarise towards T helper (Th1) differentiation, while CD8 
T cells towards cytotoxic T cells (CTL or cytotoxic T lymphocytes). Some CTLs 
further differentiate to T memory cells. 
 (D) Th1 can license CTLs and both effector T cells infiltrate tumors, where they 
recognize and eliminate cancer cells expressing cognate TAAs by direct 
cytotoxicity.  
(E) Surviving cancer cell variants may arise that contain mutations or epigenetic 
alterations that reduce the expression of MHC molecules or become insensitive 
to IFNs. Moreover, if present, MDSCs and Tregs can inactivate T cells, NKs and 
DCs. Tumor growth favours a hypoxic, nutrient-poor microenvironment that 
further suppresses immune responses. 
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4.2.1. The three-signal model of antigen presentation 
Antigen presentation and T cell activation are highly regulated processes 
to prevent autoimmune disorders or excessive inflammation. DCs are 
considered to be the main professional APCs. When DCs encounter pathogenic 
or tumor-associated antigens, they undergo a phenotypic maturation change 
while homing towards secondary lymphoid organs (Goold et al. 2011; Lipscomb 
et al. 2002; Breckpot et al. 2010; Gallucci et al. 1999; Rescigno et al. 1998; 
Ardeshna et al. 2000; Fong et al. 2000). Then, DCs present antigen to CD4 and 
CD8 T cells, depending on whether the antigens are complexed to MHC II or 
MHC I molecules, respectively. MHC I molecules are complexed to peptides 
derived from intracellularly- expressed antigens such as TAAs or viral antigens. 
These antigens are degraded by the proteasome and loaded onto MHC I in the 
endoplasmic reticulum (ER) before transport to the cell membrane (Fong et al. 
2000). MHC I molecules are recognized by CD8 T cells, which can acquire CTL 
effector functions upon antigen encounter. MHC II molecules are complexed to 
antigens that are usually (but not always) phagocytosed by APCs and degraded 
in endosomes, thus representing peptides from extracellular pathogens (Figure 
6). Peptide-MHC II complexes are recognized by CD4 T cells, and depending on 
the various cytokine signals present during antigen presentation, they promote 
T cell polarization into various subtypes. Th1 and Th17 cells are potent 
stimulators of CTL responses among others like antibody ones; Th2 cells aid 
frequently in the initiation of humoral (B cell) immune responses; and Tregs in 
general terms suppress immune responses, dampens inflammation, and may 
promote other immunological responses like IgAs ones (Cong et al. 2009; 
Liechtenstein et al. 2012). An immunological synapse is formed between APCs 
and T cells upon TCR binding to peptide-MHC complexes. This close cell-to-cell 
interaction allows the APC to deliver all needed signals to the T cell to regulate 
its activation, proliferation, and differentiation (Boisvert et al. 2004; Rothoeft et 
al. 2006; Fooksman et al. 2010; Huppa et al. 2010). These T cell-regulating 
signals can be roughly categorized into three types (Figure 6). 
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Signal 1 is initiated by the specific binding of the TCR to the peptide-MHC 
(p- MHC) complex, but this is not usually sufficient for T cell activation. Quite 
the contrary, TCR triggering alone may lead to T cell anergy, characterized by 
limited expansion and unresponsiveness upon further antigen reencounter 
(Chiang et al. 2000; Bachmaier et al. 2000). Further interactions have to be 
provided to activate T cells, which are termed co-stimulatory signals (or signal 
2). These signals are delivered by binding of DC surface ligands with the 
corresponding receptors on the T cell surface. Positive co-stimulation leads to T 
cell proliferation and acquisition of effector capacities, and are mediated by 
interactions such as CD80/CD86 on DCs with CD28/CD27 on T cells (Nurieva et 
al. 2006).  
However, negative co-stimulation can also take place, for example by 
CD80/CD86 binding to the T cell inhibitory receptor CTLA-4. These signals 
generally initiate T cell anergy or Treg differentiation (Fooksman et al. 2010). 
Amongst negative co-stimulation, one of the most important interaction is 
mediated by PD-L1 binding to PD-1 (Karwacz et al. 2011; Latchman et al. 2004; 
Liang et al. 2006; Butte et al. 2007). Hence, the overall activation status of T cells 
will depend on the integration of positive and negative interactions. Immature 
and tolerogenic DCs express low levels of co-stimulatory molecules and higher 
levels of inhibitory molecules. Therefore, antigen presentation by tolerogenic 
DCs will not lead to T cell activation. This is a key regulatory step (immune 
checkpoint) by which undesired immune reactions are kept at bay in the 
absence of a danger signal. For example, pathogens and host-derived danger-
signal molecules can trigger pathogen pattern recognition receptors such as toll-
like receptors (TLRs) on DCs, leading to up-regulation of co-stimulatory 
molecules and p-MHC complexes (Arce et al. 2011; Escors et al. 2008; Nurieva 
et al. 2006). Tumors can also provide these danger signals inducing DC 
maturation and efficacious T cell activation. 
T cells will also be regulated by a “third” signal provided by cytokines 
(cytokine priming or signal 3) (Figure 6). Depending on the context in which DCs 
encounter pathogenic molecules different cytokines will be secreted into the 
immunological synapse (Kapsenberg et al. 1999; Curtsinger et al 2003). CD4 T 
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cells thereby acquire distinct effector phenotypes and functions (Th1, Th2, 
Th17, Treg). IFN-γ, IL1-β, and IL12 secretion by DC will lead to Th1 
differentiation. CD4 Th1 cells are crucial for the effective activation of anti-
tumor CD8 CTL responses and effective anti-tumor responses, which also aid an 
antibody response towards increased IgG2a vs IgG1 in the murine system 
(Curtsinger et al. 2003; Macatonia et al. 1995; Schmidt et al. 2002; Curtsinger et 
al. 1999; Schmidt et al. 1999; Hernandez et al. 2002; Albert et al. 2001).  
On the other hand, the presence of IL4 and IL10 will lead to Th2 
differentiation, polarizing the immune response to an “antibody response” 
enriched in IgG1 vs IgG2a. IL23, TGF-β, IL17, and IL6 may induce Th17 
differentiation. Th17 cells express IL17 and trigger strong pro-inflammatory 
reactions (McGeachy et al. 2007; Bettelli et al. 2006; Lewkowich et al. 2008; 
Sutton et al. 2006; Larsen et al. 2009; Ortega et al. 2009). Finally, Tregs can be 
differentiated in the presence of IL10 and TGF-β (Arce et al. 2011; Rutella et al. 
2006; Escors et al. 2008; Saraiva et al. 2010; O’Garra et al. 2004; O’Garra et al. 
2004). Hence, appropriate cytokine secretion by APCs is crucial for the 
acquisition of the proper effector functions. In the absence of signal 3, T cells 
acquire a tolerogenic phenotype unless antigen levels are sufficiently high 
(Ramanathan et al. 2011; Gerloni et al. 2005). Thus, signal 3 is particularly 
important when antigen levels are low as it amplifies the T cell response. 
TLR ligation can alter cytokine priming. TLR4 induces DC maturation and 
IL12 secretion, leading to stimulation of anti-tumor immune responses (Apetoh 
et al. 2007; Bekeredjian-Ding et al. 2006; Cisco et al. 2004; Breckpot et al. 2009). 
In contrast, TLR2 stimulation preferentially activates ERK (extracellularly 
regulated protein kinase) signalling, prevents DC maturation and stimulates IL10 
secretion (Re et al. 2004, Re et al. 2001; Qian et al. 2006). TLR2 stimulation will 
lead to other type of responses such as Th2, mucosal immunity and in some 
cases to immune regulation (Dillon et al. 2006; Manicassamy et al. 2009). If not 
provided in cis to DC, inflammatory citokines in the medium (in trans) can 
induce up-regulation of MHC and co-stimulatory molecules in DCs, these will 
stimulate T cell proliferation but is not such efficient in confering significant T 
cell effector functions (Kratky et al. 2011; Santini et al. 2000; Sporri et al. 2005; 
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Nolte et al. 2007; Hou et al. 2008). 
Modulating co-stimulation and cytokine production can expand CTL 
responses efficacious for the treatment of cancer (Liechtenstein et al. 2014) or 
infectious diseases (Shimizu et al. 2011), while induction of Treg responses can 
be used to treat inflammatory disorders (Liechtenstein et al. 2012). 
Efficacious activation of CD8 and CD4 Th1 responses would suffice for 
the recognition of tumors, which would be ultimately killed by secreted cytotoxic 
cytokines such as IFN-γ and apoptosis induced by FAS-FASL interactions and 
granzyme B secretion. However, PD-L1 is expressed constitutively in myeloid 
cells and many tumor cells, and inducible in many cell types after exposure to 
pro-inflammatory stimuli. In this way, many tumors can overexpress PD-L1, 
which contributes to the strong inhibition of anti-cancer T cell responses (Dong 
et al. 2002). 
 
 
 
Figure 6. Three-signal model of antigen presentation in the immunological 
synapse. The figure depicts antigen presentation by DCs (left) to T cells (right). 
Peptide-MHC complexes interact with the TCR of the T cell to initiate signal 1. 
Co-stimulatory (CD80/CD86) or co-inhibitory (CD80/PD-L1) ligands on DCs bind 
to their receptors on T cells (CD28, CTLA-4, PD-1), representing signal 2. 
Furthermore, cytokine secretion (Signal 3) By DCs regulates T cell differentiation. 
Cytokine combinations lead to differentiation of several distinct CD4 T helper 
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types, or enhance CD8 proliferation and acquisition of effector activities. 
Activated CD8 cytotoxic T cells will then recognize antigens on tumor cells by the 
MHC-peptide complex and after kill them by direct cytotoxicity including 
secretion of IFN-γ, Granzyme B or Fas/FasL interactions. To counteract the T cell 
attack, tumor cells protect themselves by upregulating PD-L1. 
 
 
4.3. Cytokine therapies 
Cytokines are hormonal autocrine and paracrine modulators in many 
immune processes and can be divided into interleukins (ILs), chemokines, 
interferons (IFNs), tumor necrosis factors (TNFs), mesenchymal growth factors, 
and adipokines. Cytokines are pleiotropic molecules with multiple biological 
functions (Dinarello et al.  2007). Cytokines have been administered to stimulate 
anti-cancer immunity and several are being evaluated including IL7, IL11, IL12, 
IL15, IL21, IL6, TNF-α, GM-CSF, IFN-β and IFN-γ amongst others (Keilholz et al. 
2002). However, their systemic administration can cause serious side effects. 
Some cytokines are too toxic to be used in clinical therapy, or they can even 
promote tumor growth in vivo and activate immunosuppressive mechanisms by 
negative feedback mechanisms (Steding et al. 2011). 
 
4.3.1. IL2 for the treatment of melanoma 
IL2 was one of the first cytokines to be approved by the FDA for 
treating metastatic renal cell carcinoma and metastatic melanoma (Rosenberg 
et al. 2014). High doses can lead to durable, complete, and curative regressions 
but its clinical application remains restricted by its toxicity and expansion of 
CD4+CD25+Foxp3+ Treg cells (Ahmadzadeh et al. 2005). Nevertheless, IL2 can 
be used to expand large numbers of tumor- infiltrating lymphocytes or 
genetically-modified T cells in vitro for transfer therapies that can be highly 
effective for melanomaand other cancer types (Rosenberg et al. 2014). 
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4.3.2. Type I interferon for the treatment of melanoma 
Interferons are classified in three main classes: type I (IFN- α, β, ε, ω, τ 
and κ), type II (IFN-γ) and type III (IFN-λ1, 2, 3 and 4) (Gangaraju et al. 2009). 
Type I IFNs are strong antiviral agents, drivers of immune cell differentiation and 
inducers of cell senescence and apoptosis (Schreiber 2017). Type I IFNs comprise 
a single IFNβ gene and 14 IFNα genes in humans and mice (Van Pesch et al. 2004) 
Type I IFNs signal through a heterodimeric receptor comprising of 
IFNaR1 and IFNaR2 present on the surface of most cells. IFNs activate the 
kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) which phosphorylate 
signal transducer and activator of transcription (STAT1) 1 and STAT2. In addition 
to canonical STAT1/STAT2 signalling, other STATs can be phosphorylated (e.g., 
STAT 3, 5, and 6) as well as phosphatidylinositol 3- kinase (PI3K) and mitogen-
activated protein kinases (MAPK) ERK1/2 and p38. IFNs also activate some 
protein kinase C isoforms (PKCs) and the multifunctional adaptor protein CrkL 
(Schreiber et al. 2017; Terawaki et al. 2011; Hervas- Stubbs et al. 2011; Porritt 
et al. 2015). Together, these signalling networks converge to the activation of 
IFN regulatory factors (IRFs) which complexed with STATs, transactivate IFN-
stimulated genes (ISGs) (Figure 7). 
Type I IFNs possess anti-tumor capacities although they also promote 
negative feedback immunosuppressive mechanisms. For example, IFN-β 
exposure increases indoleamine 2,3-dioxygenase (IDO) and IL10 expression in 
DCs and macrophages, and upregulates expression of immunosuppressive 
receptors (Tsukamoto et al. 2017; Sharma et al. 2015; Terawaki et al. 2011; 
Rozera et al. 1999; Uehara et al. 2017; Benci et al. 2016). Multiple feedback 
mechanisms on the IFN receptor and signal transduction pathways have been 
described, including receptor endocytosis by ubiquitinylation (Schreiber et al.  
2017; Bhattacharya et al. 2014; Kumar et al. 2007; Kumar et al. 2008), disruption 
of receptor heterodimers by USP18 or TYK2 and JAK1 dephosphorylation by 
suppressor of cytokine signalling (SOCS1-3) or Src homology phosphatases 
(SHP1-2) (Chemnitz et al. 2004). Furthermore, protein tyrosine phosphatases 
(PTP) and protein inhibitors of activated STAT (PIAS) dephosphorylate and /or 
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inhibit STATS in the nucleus. In addition to the role of IRF proteins in inducing 
IFN responses, IRF-2 protein is involved in IFN suppression (Porritt et al. 2015). 
Interference with these mechanisms exacerbates IFN-β signalling leading to 
inflammatory disease (Nyman et al. 2000) (Figure 7). 
Type I IFNs are thought to inhibit tumor progression by a combination of 
cell cycle arrest and cell death (Chawla-Sarkar et al. 2001; Gong et al. 2000; 
Rozera et al. 1999). Hence, IFN-β induces the expression of the TNFα family 
member TRAIL that triggers caspase 8 and 3 dependent apoptosis in melanoma 
and breast cancer cells (Bernardo et al. 2013; Chawla-Sarkar et al. 2001). In 
cervical carcinoma, IFN-β causes proliferative arrest and accumulation of the 
anti- apoptotic protein cFLIP and caspase 8 (Apelbaum et al. 2013). Type I IFNs 
can enhance antigen presentation by up-regulating MHC-I and MHC-II, a 
mechanism that counteracts the frequent cancer-associated MHC-I down-
modulation (Schiavoni et al. 2013; Greiner et al. 1984; Fruci et al. 2012; Wang 
et al. 2017). In many instances, IFN-β upregulates TAA expression (Boyer et al. 
1989; Greiner et al. 1984), activates DCs and macrophages to cross-present TAAs 
to T cells and promotes CD8 T cell effector functions (Nguyen et al. 2002; K. 
Shimizu et al. 2001; Rozera et al. 1999; Kalinski et al. 1999). Moreover, IFN-β 
negatively regulates Treg proliferation (Pace et al. 2010; Hashimoto et al. 2014; 
Bacher et al. 2013; Stewart et al. 2013; M. Sharma et al. 2010) and MDSC 
numbers and their immunosuppressive activities. 
The IFN signal transduction pathway in cancer cells is frequently 
inactivated by deletion of type I IFN genes, down-regulation of their receptors, 
inactivating mutations in JAK1 (Shin et al. 2017) and loss of STAT1 and IRF1 
(Katlinskaya et al. 2016; Pietila et al. 2007; Sakaguchi et al. 2003; Bacher et al. 
2013; Lee et al. 2006; Colamonici et al. 1994). Breaking free from type I IFN-
mediated regulation seems to be critical for cancer progression (Shin et al. 2017; 
Medrano et al. 2017). 
The anti-tumor properties of type I IFNs have been exploited during the 
last decades. Improved survival was demonstrated in combination with 
therapies for chronic myeloid leukaemia (CML) (Guilhot et al. 1997) and 
myeloma (Osterborg et al. 2017). However, results in solid tumors including 
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melanoma are not clear-cut (Alberts et al. 2006, Alberts et al. 2008; Nethersell 
et al. 1984).  Other diverse strategies range from the stimulation of tumor cells 
to produce endogenous IFN-α/β or to deliver IFN to the tumor 
microenvironment (Medrano et al. 2017).  
 
4.3.3. Type II interferon for the treatment of melanoma 
IFN-γ consists of a homodimer molecule that binds to two IFN-γ receptor 
1 (IFNGR1) subunits, which is followed by recruitment of IFNGR2 and its pre-
associated JAK 1-2 (Parker et al. 2016) (Figure 7). STAT1 and STAT3 homo-
heterodimers are preferentially phosphorylated and activated by IFN-γ 
signalling, and translocate to the nucleus where they bind gamma activated 
sequence (GAS) elements in IRG promoters (Parker et al. 2016). It was thought 
that its expression was limited to T cells and NK cells (Parker et al. 2016), 
although there is recent evidence that APCs and B cells secrete IFN-γ (Schroder 
et al. 2004). IFN-γ orchestrates leukocyte attraction and directs growth, 
maturation, and differentiation of many cell types, in addition to enhancing NK 
cell activity and B cell functions such as immunoglobulin (Ig) production and 
class switching (Schroder et al. 2004) (Figure 7). 
Similar multiple layer feedback mechanisms to those of type I IFNs have 
also been described for type II IFNs (Porritt et al. 2015). Surprisingly, IFN-γ 
administration has failed for the treatment of melanoma (Franco et al. 2017), 
although patients harboring DNA lesions in the IFN-γ gene, as well as mice 
carrying tumors mutated in IFNGR1 respond poorly to immunotherapy (Gao et 
al. 2016). A possible explanation is that IFN-γ is involved in the effector phase of 
anti-tumour activities. Ipilimumab-treated patients displayed T cells with 
enhanced production of IFN-γ (Gao et al. 2016), so the mutational status of IFN-
γ signaling genes could be a prognostic tool for selection of patients eligible for 
Ipilimumab therapy (Franco et al. 2017). On the other hand, IFN-γ reduces the 
capability of CD8+ T cells to recognize and kill melanoma cells through different 
mechanisms including PD-L1 up-regulation, explaining its dual role as a pro- and 
anti- tumor effector (Cho et al. 2011; Benci et al. 2016) (Figure 7). 
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Figure 7. Type I and II IFN pathways. Type I IFNs, including IFN- and β, signal 
through a heterodimeric receptor comprising of IFNaR1 and IFNaR2 that 
activates the kinases Janus kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2) which 
phosphorylate signal transducer and activator of transcription (Stat) 1 and 
Stat2. In addition to canonical Stat1/Stat2 signalling, other Stats can be 
phosphorylated (e.g., Stat 3, 5, and 6) as well as phosphatidylinositol3- kinase 
(PI3K) and mitogen-activated protein kinases (MAPK) ERK1/2 and p38. IFNs also 
activate certain protein kinase C (PKC) isoforms and the multifunctional adaptor 
protein CrkL (Delgado 2003; Ivashkiv et al. 2015). Together, these signalling 
networks converge to the activation of IFN regulatory factors (IRFs) which 
together with STATs transactivate IFN-stimulated genes (ISGs). These ISGs are 
usually pro-inflammatory, antiviral and anti-tumor mediators. 
 There is only a single type II IFN, IFN-γ. It forms a homodimer that binds 
to two IFN-γ receptor 1 (IFNGR1) subunits followed by recruitment of IFNGR2 
and its pre-associated Janus kinase 1 and 2(JAK) which phosphorylate signal 
transducer and activator of transcription (Stat) 1 and Stat3. They form homo-
heterodimers, witch translocate to the nucleus where they bind gamma 
activated sequence (GAS) elements in IRG promoters(Delgado et al. 2003). 
MAPK proteins, P38 or PKc signaling pathways could be activated too (Agrawal 
et al. 2006). IFN-γ possess antitumour capacities among others.  
Multiple layer feedback mechanisms on the receptor and on its 
activation and signalling have also been described in both IFN types, including 
endocytosis of IFN-I receptors by ubiquitinilation and disruption of receptor 
heterodimers by USP18124 (Kumar et al. 2007; Kumar et al. 2008). IFN I and II-
TYK2 and JAK1 dephosphorylation by suppressor of cytokine signalling (SOCS1-
3) (Ramanathan et al. 2010) and Src homology phosphatase (SHP1-2) 
(Miyamoto et al. 1988). Furthermore protein tyrosine phosphatases (PTP) and 
protein inhibitors of activated STAT (PIAS) dephosphorylate and /or inhibit STATS 
in the nucleus (Sato et al. 1998).  In addition to the role of IRF proteins in inducing 
IFN responses, IRF-2 protein is involved in type I and II IFN suppression.  
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4.4. Tumor vaccines 
Tumor vaccine formulations have been developed in a manner 
analogous to those for conventional infectious diseases. Tumor vaccines can be 
grouped in three types; protein/peptide vaccines, cell-based vaccines, and 
genetic vaccines. 
Protein/peptide vaccines consist of the administration of TAAs or 
their various peptides containing B and T cell epitopes. To utilize peptide-based 
vaccines, the specific antigenic epitopes for particular MHC genotypes need to 
be known beforehand. Consequently, only individual-specific vaccines can be 
prepared for specific MHC types. These peptides are combined with strong 
adjuvants to overcome their intrinsic poor immunogenicity. Even so, clinical 
efficacy remains rather low (Guo et al. 2013; Zhang et al. 2013). 
Tumor cell-based vaccines incorporate whole cancer cells in the 
formulation. This strategy presents several advantages. Firstly, endogenous 
APCs endocytose and process whole cancer cells. Hence, the whole range of 
TAAs can be supplied without previous knowledge on patient-specific class I and 
class II MHC genotypes. Tumor cell-based vaccines can be either autologous 
irradiated cells or allogeneic (from allogeneic tumors or human tumor cell lines). 
Overall, these vaccines have shown disappointing results in Phase III clinical trials 
(Anguille et al. 2014). 
Genetic vaccines are based on delivery of DNA encoding TAAs, 
TAA-derived epitopes or polyantigenic fusion proteins directly to the subject or 
to APCs (genetic immunotherapies). The approaches for delivery of TAA DNA 
vary from bacterial plasmids, or by virus-based vectors. This latter methodology 
present an additional advantage as virus-like particles frequently possess 
immunostimulatory capacities (Liechtenstein et al. 2013; Dullaers et al. 2006). 
The use of DNA encoding multiple epitopes or mutated TAAs can further 
enhance anti-tumor immune responses (Guevara-Patiño et al. 2006; Liu et al. 
2009). While preclinical studies showed good efficacies, their application in 
human therapy has been disappointing. This lack of efficacy is possibly due to the 
absence of adequate co-stimulation during antigen presentation and to tumor-
induced immune suppression (Guo et al. 2013; Bodey et al. 2000). 
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4.5. Adoptive cellular immunotherapies 
This strategy relies on the administration of either autologous or 
allogeneic cancer- specific effector immune cells or antigen-presenting cells to 
elicit therapeutic responses. These cells can be tumor-reactive T cells, 
professional APCs or natural killer (NK) cells (Gato-Canas et al. 2016). 
 
4.5.1. T cell immunotherapies 
Steven Rosenberg and colleagues in the 1980s isolated tumor-
infiltrating lymphocytes (TILs) and expanded them in vitro with IL2. Then, these 
T cells can be re-infused back to the lymphocyte-depleted patient. Although 
promising results were obtained, problems in TILs isolation, expansion and lack 
of complete responses in melanoma were observed (Rosenberg et al. 2011). 
Gene transfer technologies and T cell engineering have enabled 
more versatile approaches, by genetically modifying T cells to target cancer-
specific antigens, via physiological TCRs or chimeric antigen receptors (CARs) 
(Chan et al. 1991; Kochenderfer et al. 2010; Pule et al. 2008; Kakarla et al. 2013; 
Zhang et al. 2014; Rosenberg et al. 2015; Milone et al. 2018; Balmer et al. 2016). 
TCRs are usually cloned from tumor-reactive TILs specific for TAAs with no or 
very limited expression in normal adult tissue (Sharma et al. 2017; Ascierto et al. 
2016). This approach is MHC-restricted and ineffective for tumors with 
downregulated MHC. To overcome this limitation, CAR technology was 
developed by Eshhar and collaborators in 1993. This strategy relies on 
genetically engineering T cells to express single chain antibodies (scFv) targeting 
tumor cell surface antigens linked to intracellular signalling adaptors from the 
TCR signalosome. This approach has evolved with time, and it has been 
extensively reviewed elsewhere (P. Sharma et al. 2017). CAR T cells do not 
depend on MHC restriction and possess enhanced T cell functions (P. Sharma et 
al. 2017). CARs targeting CD19 have shown significant clinical success in B cell 
malignancies (Maude et al. 2014). Other approaches improve T cell effector 
functions independently of MHC recognition by physically linking T cells to 
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cancer cells, such as the expression of bispecific T cell engagers (BITEs), a 
recombinant molecule made of two scAbs of different specificities fused by a 
peptide linker. BiTEs have shown therapeutic efficacy in tumor/bearing 
humanized mice and in some clinical trials with patients with non-solid tumors 
(Horn et al. 2017; Yu et al. 2017; Dao et al. 2015). 
 
4.5.2. Dendritic cell (DC) immunotherapies 
Autologous DCs can be generated ex vivo in large numbers by 
retrieving monocytes by apheresis and inducing their differentiation with 
recombinant GM-CSF, IL4 and other cytokines (Inaba et al.  1992; Zhou et al. 
1996). DCs can then be either directly loaded with TAAs or expressed from a 
variety of vectors. Classically, DCs are loaded with antigenic peptides, although 
this approach depends on the previous knowledge of epitopes for specific MHC-
restriction. Moreover, the duration of antigen presentation is limited in time 
(Escors et al. 2013; Escors et al. 2014). 
To achieve sustained antigen processing and effective 
presentation, DCs need to be matured by incubation with TLR agonists such as 
LPS and analogues, or by other means including genetic modification (Van Lint 
et al. 2014). This last approach has been used in our group by expressing 
modulators of intracellular signalling pathways associated to TLR ligands. For 
example, lentivector expression of NF-κB and p38 activators such as NIK or KSHV 
Vflip, or the constitutively active MKK6 EE mutant leads to DCs maturation and 
enhance their immunogenicity (Rowe et al. 2009; Enslen et al.  1998; Zhang et 
al. 2013; Arce et al. 2012; Liechtenstein et al. 2013). Expression of dominant 
negative mutants such as MEK1 NES AA that interferes with ERK 
phosphorylation also matures DCs (Burnet et al. 1970). Expression of 
immunostimulatory cytokines such as IL12 is a very effective approach as well 
(Esslinger et al. 2002; Goyvaerts et al. 2015). Direct immunization with 
lentivectors targeted to DCs in vivo has worked well in pre-clinical models (Yang 
et al. 2008). 
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Inhibitory signals in DCs can also be interfered. Thus, PD-L1 
silencing in DCs inhibits TCR down-modulation in T cells and strengthens their 
association to APCs and cancer cells (Liechtenstein et al. 2014; Fife et al. 2009;  
Karwacz et al. 2011, Karwacz et al. 2012) hyperactivating and enhancing T cell 
multifunctionality (Liechtenstein et al. 2014; Karwacz et al. 2011; Pen et al. 
2014). 
Autologous DC and CTL cell transfer therapies in their various forms have 
demonstrated some clinical success and are susceptible of combination. Indeed, 
the combined use of autologous tumor-lysate loaded DCs with TIL transfer leads 
to clinical responses in advanced melanoma patients (Poschke et al. 2014). 
 
 
5. IMMUNOLOGICAL BARRIERS IN MELANOMA 
 
5.1. Failure of classical immunotherapies 
Anti-cancer immunotherapy has been classically developed following 
conventional rationales based on the experience with infectious diseases. 
Despite encouraging results from extensive pre-clinical work, translation into 
the clinic has been characterized more for failures until recently. The key 
difference between classical vaccination approaches and cancer 
immunotherapy is the distinct nature of tumors and their relationship with the 
immune system. Tumor cells form complex tissues that recruit other cell types 
as a result of an initial inflammatory response (Gato-Canas et al. 2016). Tumor 
cells respond to the initial immune attack by triying to counteract antitumor 
inflammation. Tumor-secreted factors suppress anti-tumor effector cells and 
skew infiltrating immune cells to a suppressive phenotype (Hanahan et al. 
2011).  
Furthermore, cytokines and factors produced by growing tumors alter 
myelopoiesis in the bone marrow (BM), leading to the differentiation of 
immunosuppressive myeloid cells which are released to the systemic circulation 
(Rabinovich et al. 2007; Gabrilovich et al. 1996). In addition, inflammation up-
regulates immune checkpoint molecules such as PD-L1, that inhibits cytotoxic T 
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cells by engaging with PD-1 expressed on the surface of antigen-experienced T 
cells. Hence, the expansion of MDSCs and the up-regulation of PD-L1 represent 
two major immunological barriers for anti-cancer immunotherapy. Indeed, the 
recent development of immune checkpoint inhibitors has demonstrated that it 
is possible to achieve truly efficacious cancer immunotherapies. In this Ph.D. 
thesis, I have studied these two major barriers to identify novel targets and ways 
to improve cancer immunotherapies, while at the same time gaining knowledge 
on their biological mechanisms of action. 
 
 
5.2. Myeloid-derived suppressor cells (MDSC) 
Cancer-related natural suppressor cells were first described in 1989 in 
tumor-bearing mice as immature cells of myeloid origin that accumulated in 
tumors and stimulated their vascularization and immune evasion (Talmadge et 
al. 2013). Nowadays, these cancer-induced immunosuppressive myeloid cells 
are termed myeloid-derived suppressor cells (MDSCs) by most investigators. 
MDSCs are comprised of myeloid progenitors and precursors at various stages 
of differentiation (Condamine et al. 2011). Their phenotypic characterization 
remains rather controversial due to cell heterogeneity, investigator-dependent 
phenotypic marker profiles, and tumor-dependent variability. Indeed, MDSCs 
are phenotypically similar to their immunogenic counterparts, such as 
monocytes and neutrophils. Hence, their immunosuppressive activity still 
remains as their key characteristic. Moreover, MDSC-like cells can be found in 
stress conditions exerting physiological functions such as prevention of tissue 
damage and stimulation of wound healing caused by inflammation (Youn et al. 
2010; Bronte et al. 1998). 
MDSCs are classified in two subtypes. MDSCs with a monocytic-like 
phenotype are called monocytic MDSCs (m-MDSCs) and are characterized in 
mice as CD11b+ Ly6Glow/- Ly-6Chigh (Bronte et al. 2000; Youn et al. 2008). 
MDSCs exhibiting a granulocytic-like morphology are called granulocytic MDSCs 
(g-MDSCs) and are characterized in mice as CD11b+ Ly6Ghigh Ly-6Clow/- 
(Bronte et al. 2000; Youn et al. 2008). There is evidence from the Gravilovich 
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group and our own group that murine g-MDSC arise from m-MDSC after a 
maturation process, possibly regulated by HIF1-α-dependent epigenetic 
inhibition of retinoblastoma protein (Corzo et al. 2010; Liechtenstein et al. 
2014). In humans, their phenotype is rather controversial, but they are mostly 
described as expressing CD33, CD11b and low or no HLA-DR (Almand et al. 
2001). CD11b+ CD33+ HLA-DR-/low CD15- CD14+/low correspond to m-MDSCs 
(Youn et al. 2008; Filipazzi et al. 2007), while CD11b+ CD33+ HLA-DR-/low CD15+ 
CD14- CD66b+ correspond to g-MDSCs (Slavin et al. 1979; Ko et al. 2009; Youn 
et al. 2008). Several research groups propose additional markers to describe 
human MDSC (Talmadge et al. 2013; Elliott et al. 2017). 
MDSCs show high phenotypical and functional plasticity, which further 
complicates their classification, isolation, and study. Many variables including 
growth factors, cytokines, chemokines, hypoxia, and glucose levels influence 
their differentiation, accumulation, and function (Gabrilovich et al. 2012). The 
exact combination of signals and mechanisms influencing MDSC accumulation, 
function, and activation remain a subject of current investigation (Gabrilovich et 
al. 2012; Talmadge et al. 2013). 
Nonetheless, MDSC accumulation correlates with cancer progression 
(Solito et al. 2011; Almand et al. 2000) and metastasis (Steding et al. 2011; Diaz-
Montero et al. 2009). There is an inverse correlation between MDSC numbers 
and T cell numbers in tumor-bearing mice (Joice et al. 2014). MDSC depletion 
restores NK and T cell function and numbers in murine models and patients (Li 
et al. 2009; Thaci et al. 2014b; Srivastava et al. 2012; Thaci et al. 2014a). MDSCs 
induce NK cell anergy (Li et al. 2009), and there is evidence demonstrating 
inhibition of effector T cells by both antigen-specific and non-specific 
mechanisms. MDSC-dependent antigen-specific T cell suppression is probably 
mediated during antigen presentation through negative co-stimulation and by 
immunosuppressive cytokines, leading to T cell anergy, apoptosis or Treg 
differentiation (Figure 6). This mechanisms is similar to that of tumor-infiltrating 
tolerogenic DCs. Antigen non-specific inhibition relies on secretion of 
immunosuppressive cytokines such as IL10 and TGF-β, depletion of essential 
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aminoacids such as L-arginine by arginase-1 and/or iNOS (Liechtenstein et al. 
2014) activity or tryptophan by IDO (Gabrilovich et al. 2009), and secretion of 
reactive oxygen and nitrogen species (ROS, RNS and NO) by NOX2 or iNOS 
respectively (Nagaraj et al. 2007; Corzo et al. 2009). These mechanisms can also 
induce Tregs (Gabrilovich et al. 2009; Escors et al. 2010; Nagaraj et al. 2007). 
Extensive interaction exists between MDSCs and tumour cells. MDSCs help 
tumour cells escape the immune system and aid in progression, angiogenesis, 
and metastasis by secreting cytokines, chemokines, and matrix 
metalloproteinases (MMPs) (Liu et al. 2012) (Figure 5). Tumour cells on the 
other hand positively enhance MDSC differentiation from the BM. 
Nonetheless, counteracting their activities strongly enhances anti-
cancer treatments (Sevko et al. 2013). Early observations in cancer patients 
demonstrated that the concentration of peripheral blood MDSCs were 
positively correlated with tumor burden and clinical stage; surgical removal of 
tumors decreased circulating MDSCs numbers (Diaz-Montero et al. 2009; Zhang 
et al. 2013; Almand et al. 2001). Many of the current studies demonstrating the 
efficacies of MDSC-targeted therapies are in murine models or early clinical 
trials. Treatment strategies can be categorized as, some examples are showed 
(Table 1): 
1. Inhibiting MDSC development and expansion: stem cell factor 
blockade by sorafenib (Sevko and Umansky 2013) ; multi kinase inhibitors like 
sunitinib (Ko et al. 2010); JAK2/STAT3 blockade by curcumin or docetaxel  (Lin 
et al. 2010); VEGF inhibition (Fricke et al. 2007); migration blockade by or CSF-
1, (Priceman et al. 2010) or MMP9 (Gnant et al. 2015; Diel et al. 1998; Markowitz 
et al. 2014; Guan et al. 2015); CCR2 (Wang-Gillam et al. 2016), CCR5 (Yang et al. 
2018) and IL8 Inhibitors (Alfaro et al. 2016) and vemurafenib (Curtin et al. 2005). 
2. Differentiating MDSCs into more mature cells: ATRA, IL12 (Repka et 
al. 2003; Ansell et al. 2002; Pen et al. 2013) and PI3K inhibitors (Galloway et al. 
2016; Davis et al. 2017). 
 
3.  Inhibiting MDSC function: via NO inhibition by phosphodiesterase 
(Diaz-Montero et al. 2009) /nitroaspirin (Molon et al. 2011), or ARG-1 inhibition 
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by L-NAME (Reisser et al. 2002) /COX2 inhibitors (Fujita et al. 2011). 
 
4. MDSC destruction: cytotoxic agents like 5-fluorouracil (Vincent et al. 
2010), doxorubicin (Diaz-Montero et al. 2009), gemcitabine (Suzuki et al. 2005), 
cisplatin (Elias et al. 2015), HSP90 inhibitors (Rao et al. 2012) or anti IL13 
(Kalinski et al. 2017). 
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Table 1. Current treatment strategies of MDSC inhibition categorized by 
general mechanisms of action. CSF: colony stimulating factor, COX-2: 
cyclooxigenase-2, HSP: heat shock protein, iNOS: inducible nitric oxide synthase, 
IL: interleukin, JAK: janus kinases, L-NAME: N-nitro-L-arginine methyl ester, 
MMP-9: metalloproteinase-9, MDSC: myeloid derived suppressor cell, PDE-5: 
phosphodiesterase-5, PGE: prostaglandin E, RNS: reactive nitrogen species, ROS: 
reactive oxygen species, STAT: signal transducer and activator of transcription, 
VEGF: vascular endotelial growth factor, CCR2/5: C-C chemokine receptor type 
2/5. 
 
 
However, MDSC differentiation and functions are still poorly 
understood. This is due to the difficulty of isolating them from the tumor, which 
requires very large numbers of mice (Maenhout et al. 2014; Escors et al. 2013; 
Condamine et al. 2014; Thaci et al. 2014b; Youn et al. 2008; Schouppe et al. 
2013; Corzo et al. 2010). Isolation from the spleen (Corzo et al. 2010; Maenhout 
et al. 2014) yields MDSCs that do not faithfully resemble tumor-infiltrating 
subsets. Large batches of intra-tumor MDSCs purified by standard procedures 
are usually contaminated with other myeloid cells, do not proliferate well ex 
vivo, lack plasticity of differentiation and are prone to apoptosis (Youn et al. 
2008; Escors et al. 2013; Condamine et al. 2014). 
Therefore, the molecular study of MDSCs is certainly a challenge. Our 
group devised a highly efficient, rapid and economic method to produce very 
large numbers of MDSCs ex vivo that resembled melanoma-infiltrating subsets 
without inducing tumors in mice (Liechtenstein et al. 2014) (Figure 8). This 
system allowed the study of MDSC biology in controlled conditions at a very low 
cost. 
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Figure 8. Simulation of tumor environment for the ex vivo differentiation of 
MDSCs from BM cultures. Schematic representation of the generation of MDSCs. 
Scheme of the lentivector construct co-expressing murine GM-CSF and 
puromycin resistance genes. Cancer cell lines are transduced with the lentivector 
LV-GMCSF-puroR. Conditioning medium (CM) is collected from GM-CSF-
expressing cells to simulate myelopoiesis within a tumor environment. BM cells 
from healthy C57/Bl6 mice were cultured in the presence of CM for minimum 5 
days. LTR, long terminal repeat; SFFV, spleen focus-forming virus promoter; 
moGM-CSF, mouse GM-CSF gene; Puromycin R, puromycin resistance gene; UBI 
p, ubiquitin promoter; SIN, self-inactivating LTR. 
 
 
In a previous publication that was the basis of this PhD thesis, we initially 
compared these MDSCs to no-neoplastic counterparts and to conventional DC 
using quantitative proteomics and systems biology approaches (Liechtenstein 
et al. 2014). Differentially activated/deactivated pathways caused by cell type 
differences and by the melanoma tumor environment were identified 
(Liechtenstein et al. 2014). MDSCs increased the expression of trafficking 
receptors to sites of inflammation and tumors like c-type lectins, adhesion or 
TLR-associated molecules. MDSCs showed enhanced expression of proteins 
involved in endocytosis and vesicle trafficking, that are linked to the activity 
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of intracellular signaling pathways known to be active in M DSCs (SRC, 
Ras, Stat3, NF-Kb, MAPK…). An increased expression of nucleous 
proteins involved in transcription,splicing and translation was 
observed, which indicates that MDSCs were in an active metabolic 
state, that are furthermore linked to NOS/ROS production and responses to 
hypoxia. In order to obtain energy (as aerobic ATP production in down 
modulated) lipid metabolism is increased by ApoB receptor, Perilipin 3 or 
mitochondrial proteins. All those processes generates highly toxic metabolites, thus, 
detoxification enzymes and ROS scravenger proteins such as P450 reductase or 
Sod2 are upregulated. Differences between tumor enviroment pointed to an 
adaptation to oxidative stress. Neoplasic MDSC upregulate antoxidant enzymes like 
Sod1 and peroxiredoxin 6. Furthermore they increase aminoacid synthesis by D3-
phosphoglycerate dehydrogenase. This study provided more than 60 novel 
potential MDSC-specific therapeutic targets and confirmed known targets such 
as P405R, STAT3 (Emeagi et al. 2013), Sod2 (Hartmann et al. 2013) and S100 
proteins (Qin et al. 2014) (Figure 9). 
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Figure 9: Comparative quantitative proteomics between ex vivo B16-MDSCs 
and conventional immature DCs using Protein Pilot (A) Schematic diagram 
integrating the biological relationships and pathways inferred from the up-
regulated proteins in B16- MDSCs using String 9.1, DAVID and Panther programs. 
All significantly increased proteins are indicated, grouped according to cell 
location. Arrows indicate direct pathways between the indicated protein groups. 
In dark blue, detoxifying enzymes. Proteins within green boxes indicate pathways 
which are predicted to be activated from biological interactions of the up-
regulated proteins. (B) Same as a, but representing differences caused by the 
tumor environment as highlighted after comparing non-neoplastic 293T- MDSCs 
with melanoma-specific B16-MDSCs. 
 
 
To derive human MDSCs in vitro, the starting material is frequently 
peripheral blood mononuclear cells (PBMCs), as the isolation of bone marrow 
precursors is an invasive procedure and not practical for these studies. So the 
differentiation efficiency is much lower compared to murine models, as these 
cells are fairly differentiated to start with.  
 In addition, MDSCs isolated from patients are still poorly characterized 
it is challenging to compare ex vivo differentiated MDSCs with their natural 
counterparts. Therefore, the detailed differentiation and characterization of 
human MDSCs populations is still at very early stages. We are working on that 
issue and maybe soon we are able to obtain human MDSC in an easily, cheap 
and efficiently way. Once, this system is ameliorated, human MDSCs could be 
generated by patient-specific tumor cells and high troughtput analyses could be 
done in order to describe new potential therapeutic targets. 
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5.3. Programmed death-1 ligand 1 (PD-L1)/programmed death-1 
(PD-1) interactions 
T lymphocyte activity is regulated by immune checkpoint interactions. 
Growing tumors harness these inhibitory signals to stop T cell cytotoxicity. My 
Ph.D. thesis will focus on PD-1/PD-L1 interaction, a classical research model in 
our group. 
 
5.3.1. PD-1 and PD-L1 structure, expression and signal 
transduction 
Programmed cell death (PD-1) is a member of the CD28 superfamily 
expressed on T cells after activation (Michael et al. 2017). PD-1 is also expressed 
at low levels on double-negative (CD4-CD8) T cells in the thymus, Tregs, activated 
natural killer T cells and in B cells. There are reports on its expression by 
monocytes and immature Langerhans´cells (Michael et al. 2017), and also by 
some cancer cells including human and murine melanoma (Kleffel et al. 2015). 
This latter claim is rather controversial. PD-1 is a type I transmembrane protein 
consisting on an extracellular N- terminal immunoglobulin variable-like region 
(IgV), a stalk that separates the IgV domain from the plasma membrane, a 
transmembrane domain, and a cytoplasmic tail containing tyrosine-based 
signaling motifs. These motifs consist of an immunoreceptor tyrosine-based 
inhibition motif (ITIM), and an immunoreceptor tyrosine-based switch motif 
(ITSM) (Michael et al. 2017), (Figure10A). These motifs regulate PD-1 signal 
inhibitory functions. More specifically, PD-1 recruits SHP phosphatases to its 
ITIM and ITSM motifs, thereby inducing dephosphorylation of TCR-associated 
kinases such as ZAP70 and PI3K. Consequently, downstream intracellular 
pathways are terminated such as AKT, ERK, and PKCƟ. In addition, PD-1 on 
antigen-activated T cells participates in the internalization of the TCR which 
restrains T cell activities during the exponential phase of T cell expansion 
((Michael et al. 2017; Burnet et al. 1970). This mechanism involves the 
transcriptional up-regulation of E3 ubiquitin ligases of the CBL family, 
consequent ubiquitination and down modulation of the TCR facilitating T cell 
disengagement from APCs (Figure 10A). 
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PD-L1 is a type I transmembrane protein which belongs to the B7 family 
of molecules that regulate antigen presentation to T cells. PD-L1 is expressed 
constitutively by professional APCs and on a wide variety of non-hematopoietic 
cell types, including vascular endothelial cells, pancreatic islet cells, and in cells 
from immune-privileged sites such as the placenta, testes, and eye. PD-L1 
expression can be up-regulated by proinflammatory cytokines including type I 
and type II interferons, tumor necrosis factor (TNF-α), and VEGF2 or induced in 
some PD-L1-negative cell types (Karwacz et al. 2012; Arasanz et al. 2017). It is 
likely that PD-L1 up-regulation at inflammation sites represents a natural 
negative feedback mechanism to restrain T cell activities and minimize collateral 
damage. Many studies have shown that PD-L1 expression is transcriptionally 
regulated by distinct stimuli depending on the cell type, physiological and 
pathological conditions. For example, the PDL1 expression is regulated by Sox2 
in hepatocellular carcinoma (Zhong et al. 2017), STAT3 in human glioma (Kumar 
et al. 2014) and STAT1 in multiple myeloma (Liu et al. 2007). The variety of 
mechanisms that regulate PD-L1 expression is a reflection of roles that this 
molecule is playing in physiological conditions depending on location and cell 
type. 
PD-L1 belongs to the immunoglobulin superfamily, and hence it presents 
an immunoglobulin-like extracellular part, followed by a transmembrane 
domain and a short intracytoplasmic domain (Figure 10B). The extracellular 
domain is composed of an Ig variable (V) distal region and an Ig constant (C) 
proximal region. The variable region shows a standard Ig-like domain which 
includes complementarity determining-like regions (CDRs). PD-L1 binds to PD-1 
in a 1:1 stoichiometry through its V-domain in analogy to antigen recognition by 
antibodies and TCRs (Zak et al. 2015). Interestingly, and in contrast to PD-1, 
there are very scarce studies on intracellular signal transduction events induced 
by PD-L1. Indeed, no obvious sequence motifs in the intracytoplasmic domain 
have been either predicted or identified up until now (Gato-Cañas et al. 2017; 
Azuma et al. 2008) (Figure 10B). 
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In 2008 Azuma et al. provided evidence that PD-L1 possessed intrinsic 
capacities to transmit signals to cancer cells that protected them from T cell-
mediated killing independently from its direct inhibitory action towards T cells 
through PD-1 binding (Azuma et al. 2008). Firstly they tested the susceptibility of 
cancer cell lines to T cell-mediated killing in the presence or absence of anti-PD-
L1 antibodies using cancer cells that expressed a PDL1 molecule in which its 
intracellular domain was replaced by GFP (Azuma et al. 2008). Later, by using T 
cells expressing signal-null PD-1 to prevent its signaling  in co-culture studies 
with cancer cells, the authors demonstrated that the protective action of PD-
L1´s “molecular shield” was absolutely dependent on the intracellular domain 
of PD-L1, whether it engaged PD-1 or not. Nevertheless, Azuma and cols could 
not determine the exact molecular pathways by which PD-L1 was exerting its 
protective activities, nor its motifs regulating signal transduction (Azuma et al. 
2008). Chang et al. 2015 demonstrated that tumors derived from sarcoma cells 
consume large quantities of glucose, depleting the tumor microenvironment of 
glucose (Geng et al. 2008; Palmer et al. 2015). Treatment of cancer cells with a 
PD-L1 blocking antibody or silencing PD-L1 with shRNA inhibited the AKT/mTOR 
signaling axis, leading to reduced translation of mRNAs encoding glycolytic 
enzymes (Palmer et al. 2015). These results strongly suggested that PD-L1 
molecules were regulating the metabolism of cancer cells by controlling 
intracellular pathways such as AKT/mTOR. Shortly after, it was again 
corroborated that PD-L1 delivered intracellular signals in the absence of T cells 
which regulated the mTOR pathway in murine B16 melanoma and ID8agg 
ovarian cancer cells (Clark et al. 2016). However, this study did not directly 
address whether PD-L1 was exerting these effects through signaling or not. 
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Figure 10. PD-1-PD-L1 structure. (A) PD-1-dependent T cell inhibitory 
mechanisms. In the figure, the two main inhibitory mechanisms exerted by PD-
1 ligation are depicted. The TCR complex including the co-stimulatory molecule 
CD28 is associated closely to PD-1, which is up-regulated following antigen 
presentation. SHP phosphatases associate with the phosphorylated ITIM and 
ITSM motifs in the cytoplasmic domain of PD-1, as shown in the figure. These 
proteins de-phosphorylate and inhibit kinases mediating TCR signal transduction 
such as ZAP70 and PI3K (blue arrows). Downstream intracellular pathways are 
terminated as exemplified in the figure with AKT, ERK, and PKCƟ. This 
mechanism is probably activated after the recognition of target cancer cells to 
limit T cell effector activities. The second major mechanism plays a key 
regulatory role during antigen presentation to and activation of naïve T cells. It 
involves the transcriptional up-regulation of CBL E3 ubiquitin ligases as shown, 
that trigger TCR endocytosis by its ubiquitination. Hence, TCRs are removed from 
the T cell surface, facilitating their disengagement from APCs (red arrow). ITM, 
immunoreceptor tyrosine-based activation motif; ITSM, immunoreceptor 
tyrosine-based switch motif. α and β, TCR alpha and beta chains; CBL, casitas B-
lineage lymphoma protein. (B) PD-L1 intracellular signaling. The figure 
represents the main mechanisms by with PD-L1 intrinsically transmits signals to 
tumor cells or APCs before publication of the data from this PhD thesis. PD-L1 
signals inhibit apoptosis and increase mTOR-AKT signaling leading to elevation 
of glucose consumption, inhibition of autophagy inhibition and increased 
proliferation. 
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5.3.2. PD-L1/PD-1 interactions within the tumor environment 
A significant number of tumors constitutively express PD-L1 or can up-
regulate PD-L1 in response to an inflammatory environment (Thomas 
Condamine and Gabrilovich 2011) leading to inhibition of T cell functions and 
cytotoxicity (Fife et al. 2009; Katarzyna Karwacz et al. 2011; Herrmann et al. 
2015; Gato-Cañas et al. 2017). Indeed, oncogenic activation of pathways such 
as AKT-mTOR, EGFR, MEK-ERK signaling axis and possibly the MAPK p38 pathway 
contribute to PD-L1 up-regulation (Lastwika et al. 2016; Minchom et al. 2017; Ota 
et al. 2015; Noh et al. 2015). Genomic amplifications containing the gene 
encoding PD-L1 are also frequently selected in cancer cells, and likely linked to 
increased PD-L1 levels (Straub et al. 2016). PD-L1 expression is also enhanced 
by hypoxia (Noman et al. 2014; Ruf et al. 2016; Chang et al. 2016) and regulated 
through epigenetic mechanisms. For example, microRNA 513 down-modulates 
PD-L1 mRNA translation in human cholangiocytes (Gong et al. 2010) and 
microRNA 152 in gastric carcinoma (Wang et al. 2017). In some cases, the 
structure of the 3´UTR of its mRNA is disrupted in several cancer types, which 
constitutively increases PD-L1 expression levels in cancer cells (Kataoka et al. 
2016). Therefore, there is abundant experimental evidence on the correlation 
between high PD-L1 expression and tumor progression and aggressiveness.  
PD-L1 tumor expression strongly correlates with poor prognosis (Gato- 
Cañas et al. 2017) although not in all tumor types. Overall, the experimental 
evidence points to PD-L1 intrinsic signal transduction as a means to interfere 
with pro-apoptotic stimuli and enhance cancer cell proliferation. Furthermore, 
in 2008 Takeshi et al. proposed PD-L1 as a universal anti-apoptotic receptor 
(Azuma et al. 2008). The authors of this study demonstrated that PD-L1 
expression makes cancer cells refractory to Fas-induced apoptosis, resistant to 
the protein kinase inhibitor Staurosporine and to T cell cytotoxicity following 
binding to PD-1 (Azuma et al. 2008). 
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5.3.3. PD-L1/PD-1 blockade in human anti-cancer therapy 
Monoclonal antibodies (mAbs) that block immune checkpoints can 
restore the anti-tumor activities of cytotoxic T cells (Ito et al. 2015).  
The first clinically efficacious activities for anti-PD-L1 and anti-PD-1 
antibodies were demonstrated in 2012 by Topalian et al. (Brahmer et al. 2010, 
Brahmer et al. 2012) since then anti PD-1 or anti PD-L1 antitibodies have been 
approved for an increasing number of cancers such as melanoma, lung cancer, 
and gastric adenocarcinoma, just to mention a few.  
Antibodies approved for human clinical use include nivolumab and 
pembrolizumab anti–PD-1 agents (Ansell et al. 2015; Robert et al. 2014), and 
atezolizumab, durvalumab, avelumab as anti–PD-L1 (Gato-Canas et al. 2016). 
There are still ongoing many phase II or III clinical trials in numerous cancers. 
 
The first to show significant therapeutic efficacies in human melanoma 
was ipilimumab, a CTLA-4-specific antibody that blocks its interaction with CD80 
(Peggs et al. 2006; Quezada et al. 2006; Herrmann et al. 2014; Walker et al. 2011; 
Pardoll et al. 2012; Hodi et al. 2008; Postow et al. 2015; Weber et al. 2013; 
Tomasini et al. 2012). Focussing on melanoma treatment aproved by the FDA 
and in clinical use, Nivolumab has demonstrated highly durable tumor 
regressions (>1 year) with good safety profiles in metastatic melanoma 
(Topalian et al. 2012; Ansell et al. 2015; Topalian et al. 2014). Pembrolizumab 
has an optimized Fc region that minimizes antibody-dependent cellular 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Moreno et 
al. 2015) with durable responses for advanced melanoma (Hamid et al. 2013). 
Both have superior clinical effects and a better safety profile than 
chemotherapy and ipilimumab monotherapy (Robert et al. 2014; Weber et al. 
2015). Both antibodies are approved as first-line agents in melanoma 
patients(Force et al. 2017; Barnhart et al.  2015), and pembrolizumab recently 
in lung cancer in monotherapy and in combination with platinum chemotherapy  
(Gandhi et al. 2018). Furthermore, last year, the FDA approved pembrolizumab 
for all type of solid tumors with microsatellite instability that have progressed 
with previous treatments (https://www.fda.gov/). Nivolumab is being used in 
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combination therapy with ipilimumab increasing survival rates (Wolchok et al. 
2013) in metastasic melanoma and renal cell carcinoma. (Figure 4).  
 
5.3.4. Resistance to PD-L1/PD-1 blockade 
Two major challenges remain for an optimal management of anti-cancer 
therapies. First, a significant number of patients who are refractory to the 
initial application of the treatment (intrinsic resistance). Secondly, tumor 
progression from cancer cells that have acquired resistance by several means 
after an initial phase of objective responses. Possibly, the major goal in oncology 
is the identification of patients who will benefit from therapies and the 
identification of the mechanisms leading to acquired resistance. Some 
mechanisms of adaptive resistance to PD-L1/PD-1 blockade therapy have 
been described. For example, upregulation of alternative immune checkpoints 
such as TIM-3, to compensate for the PD-1 blockade in T cells (Koyama et al. 
2016; Kim et al. 2016; Shaked et  a l .  2016). The loss of beta2-microglobulin 
(ß2m) through inactivating mutations leading to the elimination of MHC I 
surface expression (Restifo et al. 1996). A role for ß2m in acquired resistance 
to PD-1 blockade in melanoma was recentlysupported by a study reporting a 
ß2m truncating mutation in relapsing lesions (Zaretsky et al. 2016). 
Evaluation of the cancer secretome by proteomics is helping in the 
identification of resistance to immune checkpoint blockade (Skalnikova et al. 
2017; Choi et al. 2012). Recently, several candidate biomarkers have been 
identified that correlate with clinical benefit, including the apelin receptor 
(APLNR) (Patel et al. 2017). Other immune-related genes have been 
demonstrated to be required for efficacious immunotherapies including antigen 
presentation (PD-L1, CD47) and IFN gamma signalling molecules (PTPN2, STAT1, 
JAK1, IFNGR2, IFNGR1, or JAK2) (Manguso et al. 2017). 
An intact interferon signal transduction pathway in cancer cells seems to 
be required for the efficacy of PD-L1/PD-1 blockade therapy. Inactivating 
mutations in JAK1/2 genes were linked to the failure of PD-L1 up-regulation in 
cancer cells, becoming refractory to therapy (Zaretsky et al. 2016; Shin et al. 
2017). The authors of these studies hypothesized that lack of adaptive PD-L1 
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expression was also the cause of primary resistance to PD-1 blockade (Shin et 
al. 2017). 
 
 
 
6. LENTIVECTOR-BASED GENETIC IMMUNOTHERAPIES 
 
In this Ph.D. thesis, lentiviral vectors (lentivectors) are used for genetic 
immunotherapy and as gene-modifying tools. Lentivectors have been 
extensively reviewed elsewhere (Escors et al. 2013; Trono et al. 2000; Escors et 
al. 2010), and here they will only briefly explained for understanding the context 
of the experiments in which they have been used. 
 
6.1. Lentivector structure and production 
Most lentivectors are derived from the HIV-1 genome devoid of 
virulence and replication genes, leaving space for insertion of promoter 
sequences and genes of interest. These vectors have been improved to achieve 
a high degree of biosafety (He and Falo 2007). Most of them are self-inactivating 
lentivectors, in which most of the U3 promoter region is eliminated following 
integration into the target DNA (Zufferey et al.1998), and thereby reducing the 
likelihood of producing replication-competent viruses (Figure 11). 
Lentivectors are usually assembled in 293T cells and secreted to the cell 
culture supernatants following co-transfection of three plasmids: the transfer 
vector plasmid, the packaging plasmid, and the envelope plasmid. The transfer 
vector will produce an RNA encoding the whole vector that will be packaged by 
the structural and non-structural proteins encoded by the packaging plasmid. 
The envelope plasmid will produce a membrane glycoprotein that will cover the 
lentivector particle conferring the desired specificity for different cell receptors 
(Figure 11). 
The packaging plasmid used in this thesis (p8.91) encodes the HIV-1 gag-
pol, rev, and tat genes under the control of the cytomegalovirus early promoter 
(CMV), but lack accessory genes (vif, vpr, vpu, nef) (Zufferey et al. 1997) (Figure 
11). 
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The envelope plasmid used in this thesis is the pMDG and encodes the 
vesicular stomatitis virus G protein (VSV-G) under the control of the CMV 
promoter. VSV-G pseudotypes the lentivector particle conferring the vector a 
wide species and cell type tropism (Akkina et al. 1996; Naldini et al. 1996; Yee 
et al. 1994) (Figure 11). 
The transfer lentivector plasmid used in this thesis is the pSIN vector as 
shown in Figure 11 (Escors et al. 2008). Summarizing, this is a second 
generation, self-inactivating lentivector that contains the spleen focus-forming 
virus promoter (SFFV) followed by the gene of interest. This vector was used as 
the basis for constructing the pDUAL and the pHIV-SIREN lentivector plasmid 
series (Figure 11). Briefly, the pDUAL lentivector contains the SFFV and the 
human ubiquitin promoters to co-express two genes. A pDUAL version 
containing a PD-L1-targeted microRNA was designed by Liechtenstein et at 
(Liechtenstein et al. 2014). The pHIV-SIREN plasmids contain the U6 promoter 
to express shRNAs, and the phosphoglycerate kinase promoter (PGKp) to 
express selection genes (antibiotic resistances) (Gato-Cañas et al. 2017) (Figure 
11). 
An “all-in-one” CRISP/CAS9-sgPD-L1 lentivector was generously donated 
by Prof. Karine Breckpot from the Free University of Brussels (Belgium) to 
disrupt the PD-L1 gene (Figure 11D). 
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Figure 11. Lentivector structure and production. (A) The three lentivector 
production plasmids are shown. The packaging plasmid contains the structural 
and enzymatic genes from HIV required for reverse transcription, integration, 
and assembly, such as Gag-Pol- Rev-Tat. The envelope plasmid encodes VSV-G 
in this case. The transfer vector plasmid lacks all the genes that are provided in 
trans by the packaging plasmid. In this figure the transfer vector is the we use a 
pSIN vector that contains long-terminal repeats or LTRs (U3- R-U5), including a 
self-inactivating 3’ end LTR (SIN-R-U5) and an expression cassette. This cassette 
is made of the spleen focus-forming virus (SFFV) promoter controlling the 
expression of the gene of interest. Ψ, Rev response element (RRE), central 
polypurine flap (cPPT) and woodchuck post-transcriptional response elements 
(WPRE) are shown. 
 (B) pDUAL lentivector contains two promoters to co-express two different 
genes, the SFFV and the human ubiquitin promoter. A version was generated to 
include a PD-L1-targeted microRNA. 
 (C) The pHIV-SIREN plasmid contains the U6 promoter to express shRNAs and the 
SFK promoter encoding the selection antibiotic or other gene of interest.  
(D) “All-in-one” lentivector plasmids to eliminate expression of PD-L1 by 
disrupting the gene using CRISPR-Cas9 technology. The plasmid was generously 
donated by Prof. Karine Breckpot. 
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6.2. Lentivectors for genetic cancer immunotherapy 
Subcutaneous lentivector injection transduces human and mouse APCs 
(Esslinger, Romero, and MacDonald 2002) and displays significant T cell 
adjuvant activities by providing TLR ligands to APCs (Breckpot et al. 2007; 
Breckpot et al. 2010; Esslinger et al. 2003; Rossetti et al. 2011). Our research 
group has been working during the last years to use them as cancer vaccines. 
Lentivectors have a good biosafety profile for their application in human 
therapy. For example, integration-deficient lentivectors remain in the nucleus 
as episomes (Hu, Dai, and Wang 2010; Yanez-Munoz et al. 2006) to prevent 
genotoxicity in human therapy (Hu et al.  2010; Yanez-Munoz et al. 2006). There 
is now extensive experience in production of clinical grade lentivector batches 
with high biosafety profiles (Levine et al. 2006). Hence, lentivectors have been 
used for the treatment of HIV and in human gene therapy clinical trials (X-linked 
adrenoleukodystrophy, β-thalassaemia, and advanced leukaemia) without 
major concerns (Cartier et al. 2009; Levine et al. 2006; Tebas et al. 2013; 
Cavazzana-Calvo et al. 2010; Porter et al. 2011; Kalos et al. 2011). 
Lentivectors are used in two ways for genetic cancer immunotherapies. 
First, they can modify T cells to express TCRs of interest or chimeric antigen 
receptors (CARs). Complete remissions in 90% of relapsed and refractory acute 
lymphoblastic leukemia (ALL) patients were achieved using lentivector-modified 
T cells (Maude et al. 2014). Secondly, lentivectors induce immune responses by 
direct administration as they transduce preferentially conventional DCs leading 
to transgene expression, processing and antigen presentation in draining lymph 
nodes (Goyvaerts et al. 2015). Hence, lentivector transduction of DCs (Bukrinsky 
et al. 1993; Naldini et al. 1996) does not affect their viability or antigen 
presenting capabilities (Breckpot et al. 2003; He et al. 2005; He et al.  2006; 
Gruber et al. 2000; Zarei et al. 2002; Dyall et al. 2001; Karwacz et al. 2012). Direct 
transfer of transduced DCs achieves prolonged in vivo antigen presentation in 
murine models, increasing the potency and duration of CTL responses (He et al. 
2006). 
 
 
73 
 
Escors et al demonstrated that DCs could be effectively transduced and 
matured using lentivectors that expressed MAPK kinase and IFN-pathway 
activators, or ERK inhibitors, thereby boosting anti-lymphoma immunity in 
murine models (Escors et al. 2008). 
The co-expression of some of these DC molecular activators with a PD-
L1-targeted microRNA using lentivectors further enhanced their 
immunogenicity (Karwacz et al. 2011). A new generation of lentivector vaccines 
was also engineered by Lienchtestein et al. co-expressing melanoma antigens, 
the PD-L1 microRNA, and various T cell-polarizing cytokines (Liechtenstein et al. 
2014). The combination of IL12 expression with PD-L1 silencing counteracted 
MDSC suppressive activities and significantly enhanced anti-melanoma 
immunity in prophylactic and therapeutic vaccination strategies (Liechtenstein 
et al. 2014). The group of Prof. Breckpot developed a fusion gene of IFNβ with 
the ectodomain of TGFBR-II (a TGF-β trap), called Fβ2. Its expression from a 
mRNA vaccine reduced tumor cell proliferation, enhanced DC antigen 
presenting capabilities and reduced MDSC suppressive activities (Van der 
Jeught et al. 2014). 
Considering previous results from our group, in this Ph.D. thesis I 
designed lentivector plasmids to study PD-L1 biology and related signal 
transduction pathways, engineering vaccines with superior efficacies against 
melanoma, and modify MDSCs. 
74 
 
 
7. Ph.D. AIMS 
 
The main goals of this Ph.D. thesis were the study of two major immunological 
barriers for melanoma immunotherapy and the identification of novel therapeutic 
targets. In the first part, I characterize and identificate PD-L1 intracellular signaling 
motifs and their anti-interferon functions. In the second part, I describe MDSCs 
proteome and specific signaling pathways involved in its suppressive function. The 
specific aims of the Ph.D. are: 
1. Identification of the mechanisms of melanoma resistance to interferon 
cytotoxicity mediated by PD-L1 intracellular signalling. 
 
2. Quantitative study of the proteome of melanoma-specific MDSC for the 
identification of potential therapeutic targets. 
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SUMMARY 
PDL1 blockade produces remarkable clinical responses, thought to occur 
by T cell reactivation through prevention of PDL1-PD1 T-cell inhibitory 
interactions. Here we find that PDL1 cell-intrinsic signaling protects cancer cells 
from interferon (IFN) cytotoxicity and accelerates tumor progression. PDL1 
inhibited IFN signal transduction through a conserved class of sequence-motifs 
that mediate crosstalk with IFN-signaling. Abrogation of PDL1 expression or 
antibody-mediated PDL1 blockade strongly sensitized cancer cells to IFN 
cytotoxicity through a STAT3/caspase-7 dependent pathway. Moreover, somatic 
mutations found in human carcinomas within these PDL1 sequence-motifs 
disrupted motif-regulation resulting in PDL1 molecules with enhanced protective 
activities from type I and type II IFN cytotoxicity. Overall, our results reveal a 
mode of action of PDL1 in cancer cells as a first line of defence against IFN 
cytotoxicity. 
 
INTRODUCTION 
Programmed death 1 ligand 1 (PDL1) is a member of the B7 family of co-
stimulatory/co-inhibitory molecules expressed by a wide variety of cell types 
including tumors (Sharpe et al., 2007). PDL1 is a transmembrane protein 
consisting of an immunoglobulin-like extracellular part, followed by a 
transmembrane domain and a short intracytoplasmic domain. Programmed 
death 1 (PD1) is its prototypical receptor, which is expressed mainly by effector 
immune cells such as B and T cells (Freeman et al., 2000; Zak et al., 2015). 
However, PDL1 can also bind CD80 (Butte et al., 2007). The physiological role of 
PDL1 is to maintain peripheral tolerance and contribute to antigen presentation 
to T cells by dendritic cells (Karwacz et al., 2011; Sharpe et al., 2007). In neoplastic 
conditions, PDL1 tumor expression strongly correlates with increased 
progression and poor prognosis, being an indicator of resistance to conventional 
treatments such as chemotherapy and radiotherapy. 
It is widely accepted that PDL1 protects cancer cells by engaging with PD1 
expressed on the surface of activated cytotoxic T cells (Fife et al., 2009). This 
engagement is strongly inhibitory to T cells leading to decreased effector 
81 
 
activities. As a consequence, PDL1-engaged PD1 in T cells interferes with the T 
cell receptor (TCR) signalosome stopping T cell cytotoxic activities and production 
of cytokines such as interferons (IFNs) (Fife et al., 2009; Karwacz et al., 2011). 
Recent evidence suggests that PDL1 can activate intrinsic signals in the absence 
of PD1 that enhance cell proliferation and survival through the inhibition of 
autophagy and mTOR activation (Clark et al., 2016; Chang et al., 2015). However, 
in contrast to PD1, there is still very little evidence for specific signal transduction 
events induced by PDL1. No obvious sequence motifs in the intracytoplasmic 
domain with signal transduction capacities have been either predicted or 
identified so far (Azuma et al., 2008). 
PDL1/PD1 blockade therapy has achieved unprecedented therapeutic 
clinical success for a variety of cancers including melanoma. PDL1/PD1 blocking 
antibodies cause the recovery of T cell anti-tumor cytotoxicity and production of 
IFNs that inhibit tumor cell growth and survival. Therefore, a significant number 
of treated patients experience long-lasting anti-tumor responses (Hodi et al., 
2016). However, a large number of patients are still intrinsically resistant to anti-
PDL1/PD1 therapy, or exhibit tumor progression after a period of therapeutic 
responses. Recently, it has been shown that inactivating mutations in JAK1, JAK2 
and β2-microglobulin genes in cancer cells are responsible for primary and 
acquired resistance to anti-PD1 therapy in a cohort of cancer patients (Shin et al., 
2017; Zaretsky et al., 2016). As IFN signals are potent transcriptional 
transactivators of PDL1, these mutations inhibited PDL1 upregulation in cancer 
cells. The authors proposed that the loss of PDL1 up-regulation abrogated the 
antitumor efficacy of PDL1/PD1 blockade in these patients (Sharma et al., 2017).  
Here we demonstrate that PDL1 expression represents a direct line of 
defense for cancer cells by transducing signals that counteract IFN signal 
transduction within cancer cells. Moreover, we demonstrate that the PDL1 
intracytoplasmic domain is essential for its protective functions through the 
activity of regulatory non-classical signal transduction motifs.  
  
82 
 
RESULTS 
IFNβ expression coupled to PDL1 silencing is lethal to melanoma cells 
To engineer an immunogenic cell-based cancer vaccine, we attempted to 
generate a B16F10 melanoma cell line with silenced PDL1 that would secrete 
IFNβ. To achieve this, we cloned the IFNβ gene into a lentivector expressing a 
PDL1-targeted microRNA (µPDL1) and a puromycin selection gene previously 
described (Karwacz et al., 2011; Liechtenstein et al., 2014a) (Figure 1A). 
Strikingly, although puromycin-resistant cells could be obtained, these cells died 
within one or two weeks of culture. To identify the component conferring 
lethality, the IFNβ gene was expressed with or without µPDL1 (Figure 1A). 
Interestingly, it was possible to generate B16 cell lines expressing high levels of 
secreted IFNβ (6 ng/ml) only in the absence of µPDL1. As these cells had very high 
surface PDL1 protein expression (Figure 1B), this indicated that PDL1 
upregulation could be an adaptation to survival from sustained IFNβ signaling. 
These results suggested that cancer cells may utilize PDL1 expression to 
negatively regulate IFN signal transduction. To confirm that toxicity associated to 
PDL1 silencing was mediated through enhanced IFNβ signaling, B16 cells with a 
silenced type I IFN receptor (B16-IFNAR1KD) were generated using lentivector 
delivery of shRNA. Additionally, B16 cells overexpressing a PDL1 mutant with 
reduced complementarity to the µPDL1 (B16-PDL1) were also generated to 
strengthen PDL1 signaling (Figure 1C). B16-IFNAR1KD cells proliferated well 
whether they expressed IFNβ or IFNβ-µPDL1 confirming that lethality was 
conferred by IFN signal transduction (Figure 1C). Importantly, PDL1 
overexpression in B16 cells overcame the inhibitory effects of IFNβ and the 
lethality of the IFNβ-µPDL1 combination (Figure 1C). Type I IFN receptor is a 
homodimer of IFNAR1 and IFNAR2 molecules, of which IFNAR1 is essential for 
signal transduction (Ragimbeau et al., 2003). As B16-PDL1 cells showed levels of 
surface IFNAR1 and IFNAR2 expression comparable to unmodified B16 cells 
(Figure 1C and not shown), we concluded that PDL1 interfered with IFNβ-signal 
transduction rather than causing IFNAR down-modulation. 
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Figure 1. PDL1 protects melanoma cells from IFNβ toxicity. (A) Lentivector 
expression vectors used in the studies. LTR, long terminal repeats; SFFV, spleen 
focus forming virus promoter; PDL1, microRNA targeting murine PDL1; UBIp, 
ubiquitin promoter; PuroR, gene conferring puromycin resistance. (B) Expression 
of surface PDL1 in B16 cells treated with recombinant IFNβ or transduced with 
the IFNβ-expressing lentivector. Data shown as flow cytometry histogram plots. 
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Numbers and percentages indicate mean fluorescent intensities and percentage 
of positive cells compared to the unstained (US) control. (C) Left, flow cytometry 
histograms for PDL1 or IFNAR1 surface expression (as indicated) in the B16 cell 
lines as shown on the right of the histograms. Numbers and percentages indicate 
mean fluorescent intensities and percentage of positive cells. Right, Bar graphs 
representing the mean relative number of cells with error bars (standard error of 
the means) after two weeks of puromycin selection following transduction of the 
indicated B16 cell lines (bottom of the graphs) with lentivectors co-expressing 
IFNβ-PuroR or IFNβ-µPDL1-PuroR. Data obtained from 10 independent 
experiments. (D) Left, flow cytometry histograms for PD1 surface expression in 
the indicated B16 cell lines on the right of the plots. Numbers and percentages 
indicate mean fluorescent intensities and percentage of positive cells. PD1C, 
indicates a PD1 protein lacking the intracytoplasmic signaling domain. On the 
right, bar graphs representing the mean relative number of cells with error bars 
(SEM) after two weeks of puromycin selection following transduction of the 
indicated B16 cell lines (bottom of the graphs) with lentivectors co-expressing 
IFNβ-PuroR or IFNβ-µPDL1-PuroR. Data was obtained from 4 independent 
experiments. (E) Flow cytometry histograms for surface expression of PDL1 (left) 
or IFNAR1 (right) on the indicated cell lines on the right of the plots. Numbers and 
percentages indicate mean fluorescent intensities and percentage of positive 
cells. PDL1C, PDL1 protein without the intracytoplasmic region.  (F) Bar graphs 
representing the mean relative number of cells with error bars (standard error of 
the means) after two weeks of puromycin selection following transduction of the 
indicated B16 cell lines (bottom of the graphs) with lentivectors co-expressing 
IFNβ-µPDL1-PuroR. Relevant statistical comparisons are indicated within the 
graphs from three independent experiments. ** and ***, indicate very significant 
(P<0.01) and highly significant (P<0.001) differences.  
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PDL1 signal transduction counteracts IFNβ toxicity 
To test whether the engagement of PDL1 with its receptor PD1 would 
deliver a protective signal against IFNβ cytotoxicity, B16 cell lines were generated 
that constitutively expressed high levels of PD1 or a mutant with a deletion of its 
intracytoplasmic domain (PD1C) incapable of signal transduction (Figure 1D). 
Both B16-PD1 and B16-PD1C cells significantly overcame the inhibitory effects 
of IFNβ expression, for which only the PD1 extracellular part was required but 
not its intracytoplasmic signaling domain. As expected, expression of IFNβ 
together with PDL1 silencing was still lethal to B16-PD1 and B16-PD1C cells 
(Figure 1D). These results demonstrated the requirement of PDL1 to transmit a 
survival signal that is nevertheless potentiated by PD1 engagement.   
To assess whether PDL1 possessed intrinsic signal transduction capacities 
that protected against IFNβ toxicity, B16 cells overexpressing a deletion mutant 
lacking the intracytoplasmic domain (B16-PDL1ΔC) were generated. This PDL1 
mutant did not have the target sequence for µPDL1 and was efficiently expressed 
on the cell surface. Again, PDL1ΔC overexpression did not alter the surface 
expression of IFNAR1 (Figure 1E and not shown). Unlike the wild-type version, 
the overexpression of PDL1ΔC did not overcome the lethality conferred by the 
co-expression of IFNβ with µPDL1 (Figure 1E). Considering these data, we 
concluded that PDL1 counteracts IFNβ cytotoxicity by signal transduction 
through its intracytoplasmic domain. 
 
Conserved motifs within the intracytoplasmic domain of PDL1 regulate 
protection from IFNβ cytotoxicity  
We then thoroughly analyzed the PDL1 intracytoplasmic domain using 
several bioinformatics tools. PDL1 presents a strongly amphiphilic 
intracytoplasmic domain without any obvious signaling domains (Figure S1). 
After extensive searches using different databases and algorithms, only 
MotifFinder produced a positive hit with a domain present in a bacterial and 
eukaryotic DNA-dependent RNA polymerase β subunit (Figure S1). No sequences 
related to signal transduction were found, suggesting that PDL1 is using non-
conventional signaling motifs. 
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Therefore, to identify PDL1 signal transduction functional domains we 
reasoned that these would be phylogenetically conserved. The intracytoplasmic 
region of 10 mammalian PDL1 molecules were aligned including the 
corresponding sequence from salmon as a divergent control (Figure 2A). Three 
conserved sequences were identified that we termed “RMLDVEKC”, “DTSSK” and 
“QFEET” motifs. PDL1 undergoes ubiquitination which leads to its destabilization 
(Lim et al., 2016), and we found that lysines 271 and 280 within RMLDVEKC and 
DTSSK motifs were putative targets for this post-translational modification 
according to the application of a random forest algorithm (Radivojac et al., 2010)  
(Figure 2A). To test the functionality of these domains, B16 cells lacking PDL1 
(B16-PDL1KO) were generated using CRISPR/Cas9 (supplemental figure 2). Then, 
a PDL1 gene was constructed to prevent its cleavage by Cas9 through mutation 
of the CRISPR/Cas9 target site while conserving the wild-type aminoacid 
sequence (PDL1wt).   PDL1wt and mutants with deletions of each motif were 
expressed in B16-PDL1KO cells (Figures 2A, S2). Two additional PDL1 mutants with 
conservative lysine-to-arginine substitutions were generated to eliminate the 
possibility of PDL1 undergoing ubiquitination within the intracytoplasmic domain 
(Figure 2A). All PDL1 mutants were efficiently transported and expressed on the 
cell surface, as assessed by flow cytometry following surface staining with PDL1-
specific antibodies (Figure S2). Then, the inhibitory activities of recombinant IFNβ 
over these B16 modified cell lines were tested by real-time monitoring of cell 
growth/viability (ACEA RTCA). An IFNβ concentration of 10 ng/ml was chosen as 
it caused at least 50% growth inhibition to B16-PDL1wt cells as assessed by RTCA. 
CRISPR/Cas9 abrogation of PDL1 (B16-PDL1KO) strongly sensitized B16 cells to 
recombinant IFNβ, and even causing cell death (Figure 2B and 2C) in agreement 
with our initial observations based on IFNβ expression with a lentivector, and also 
discarding potential off-target effects of  µPDL1 (Figure 1). PDL1 with a deleted 
QFEET motif retained its protective capacities. In contrast, removal of the 
RMLDVEKC motif completely abrogated the anti-IFNβ activities (Figure 2B). 
Interestingly, deletion of the DTSSK motif as well as lysine-to-arginine mutations 
within the RMLDVEKC or DTSSK motifs significantly enhanced resistance to IFNβ 
(Figure 2B). These results strongly suggested that DTSSK was a regulatory motif 
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that modulates anti-IFN activities. To confirm this, the conserved D, S, and K 
residues in the DTSSK motif were mutated to alanines and the resulting PDL1 
molecule was expressed well on the surface of B16-PDL1KO cells (B16-DA cells). 
The alanine replacement of these residues showed an enhancement of the 
protective functions of PDL1 against IFNβ, strongly reinforcing the evidence that 
DTSSK was an inhibitory motif of PDL1 protective functions (Figure 2C). 
Overall, we concluded that the RMLDVEKC motif was essential for PDL1 
protection against IFNβ, while the DTSSK motif and the lysines 271 and 280 acted 
as negative regulators. 
 
 
Figure 2. PDL1 protection from IFNβ cytotoxicity is regulated by conserved 
sequence motifs. (A) Alignment of the intracytoplasmic domain from PDL1 
molecules of the indicated species. In red and blue, highly conserved residues. The 
consensus sequence is shown on the bottom, with the three conserved motifs 
within open boxes. Lysines predicted to be capable of undergoing ubiquitination 
are indicated with arrows. Below the alignment, schemes indicating deletions or 
arginine substitutions are shown. (B) On the left, real time monitoring cell growth 
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graphs from B16-PDL1KO cells reconstituted with the deletion mutants shown in 
(A), as indicated. Data is shown as means from two independent cultures. On the 
right, bar graphs plotting the cell index during the last 20 hours for each mutant 
as indicated, using means from duplicates as data for the analyses. (C) As in (B), 
but using B16 cells expressing a PDL1 mutant with DSK residues mutated to 
alanines. Relevant statistical comparisons are indicated within the graph. ***, 
highly significant differences (P<0.001). 
 
STAT3-caspase 7 is the main effector pathway conferring IFNβ lethality to PDL1 
silencing 
Type I IFNs exert their activities by engaging with its receptor 
IFNAR1/IFNAR2 on the cell surface. The main signal cascade depends on the 
recruitment of JAK1 and TYK2 that phosphorylates STAT1, STAT2 and STAT3, 
which associate into STAT1/STAT2 heterodimers or STAT1/STAT1 and 
STAT3/STAT3 homodimers. In addition, type I IFNs cause caspase-dependent 
apoptosis although the exact mechanisms are yet unclear. To identify the 
downstream effectors leading to exacerbated toxicity by lack of PDL1, B16 cell 
lines were generated with a selection of key components of the IFN signal 
transduction pathway silenced (Figure 3A). 
These cell lines were tested in the IFNβ survival assay as described above 
(Figure 1). As expected IFNAR1 and JAK1 silencing abrogated IFNβ toxicity. 
Interestingly, silencing of STAT3 and caspase 7 (CASP7) also reduced IFNβ 
inhibitory effects (Figure 3B). Moreover, lethality of the IFNβ-µPDL1 combination 
was only averted by silencing IFNAR1, JAK1, STAT3 and CASP7 (Figure 3C).  To 
find out whether the absence of PDL1 signals enhanced IFNβ signal transduction, 
the expression of STATs was assessed in B16 and CRISPR/Cas9 PDL1 knockout B16 
cells after IFNβ treatment for 24 h (Figure 3D).  STAT1 and STAT2 were 
upregulated to the same extent in B16 and PDL1KO cells. In contrast, STAT3 levels 
increased only in PDL1KO cells in response to IFNβ. Then, we performed a time-
course assay of STAT3 phosphorylation after IFNβ stimulation. Interestingly, 
STAT3 Y705 phosphorylation was stronger and occurred faster in PDL1KO cells, 
while STAT3 S727 phosphorylation remained unchanged in B16 and in B16-
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PDL1KO cells (Figure 3E). These results indicated that PDL1 signals were inhibiting 
STAT3 Y705 phosphorylation and prevented STAT3 up-regulation.  
Survival assays with caspase-silenced B16 cell lines suggested that 
interference with PDL1 expression was causing cell death in response to IFNβ 
through CASP7. Our results also indicated that cell death was largely caused by 
apoptosis rather than caspase-independent necroptosis, although the 
participation of this last mechanism cannot be completely ruled out. To confirm 
these results RTCA was performed with caspase-silenced B16 cells or caspase-
silenced B16-PDL1KO cell lines in response to recombinant IFNβ (Figure 3F). While 
CASP3 silencing did not abrogate toxicity to recombinant IFNβ, CASP7 silencing 
inhibited IFNβ inhibitory actions. The same results were also observed in B16-
PDL1KO cells although in this assay CASP9 silencing counteracted toxicity as well. 
Then, the expression and processing of effector caspases in B16 cells after 
treatment with recombinant IFNβ was compared to B16-PDL1KO cells. Overall, 
basal expression of CASP3, 7 and 9 were increased in B16-PDL1KO cells, especially 
after IFNβ treatment (Figure 3G). In agreement with the shRNA data, the 
processing of CASP7 was strongly enhanced in B16-PDL1KO following IFNβ 
treatment (Figure 3F). Overall, these data suggested that the effector pathway 
for IFNβ cytotoxicity caused by PDL1 silencing was mainly mediated by a 
reinforced STAT3-caspase 7 pathway.  
 
Antibody-mediated PDL1 blockade abrogates the protective functions of PDL1 
in murine and human cancer cell lines 
To test whether direct blockade of PDL1 could sensitize B16 and other 
murine and human cancer cells to IFNβ, the growth and viability of murine B16, 
CT26 colorectal and 4T1 breast cancer cells were monitored by RTCA in the 
presence of increasing concentrations of a PDL1-blocking antibody or an isotype 
control (Figures 4A, 4B, 4C). PDL1 antibody blockade sensitized all three murine 
cancer cell types to recombinant IFNβ. The same results were obtained with 
human B-RAF mutated melanoma HTB72 cells. Taken together these results 
confirmed that the anti-IFNβ mechanism regulated by PDL1 is conserved in 
murine and human cancer cells. 
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Figure 3. IFNβ enhanced cytotoxicity by PDL1 silencing depends on a STAT3-
caspase 7 pathway. (A) Western blots of the specific signal transduction 
molecules as shown on the left in B16 cell lines constitutively expressing shRNAs 
indicated on top. (B) Bar graphs representing the mean relative number of cells 
with error bars (standard error of the means) after two weeks of puromycin 
selection following transduction of the indicated B16 cell lines (with the indicated 
silenced genes as shown) with lentivectors co-expressing IFNβ-PuroR. (C) Same as 
in (B) but transductions were performed with lentivectors co-expressing IFNβ-
µPDL1-PuroR. (D) Detection by western blotting of the indicated STAT molecules 
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in B16 or B16-PDL1KO cells untreated or treated with IFNβ as shown on top. (E) 
Western blot of STAT3 Y705 phosphorylation (top) at the indicated time points in 
B16 and B16-PDL1KO cells after IFNβ stimulation, as indicated. Western blot 
(bottom) of STAT3 S727 phosphorylation in B16 or B16-PDL1KO cells after IFNβ 
stimulation, as indicated. (F) Bar graphs representing RTCA cell index of the 
indicated B16 cell lines with silenced caspases either in an unmodified or PDL1KO 
background as shown in the graphs in the presence of 10 ng/ml of recombinant 
IFNβ. (G) As in (D) but detection of the indicated caspases. (H) Western blot of 
processed caspase 7 on a time course of B16 or B16-PDL1KO cells treated with 10 
ng/ml of recombinant IFNβ as shown on top. Relevant statistical comparisons are 
indicated within the graphs. *, **, ***, indicate significant (P<0.05), very (P<0.01) 
and highly significant differences (P<0.001), respectively. 
 
 
Figure 4. PDL1 blockade sensitizes murine and human cancer cells to IFNβ. (A) 
Left, RTCA graph of murine B16 melanoma cells in the presence of recombinant 
IFNβ and the indicated concentrations of anti-PDL1 antibody. Right, same data as 
a bar graph with means and standard deviations with error bars (n=4). (B) Same 
as (A) with murine CT26 colorectal cancer cells. (C) Same as (A) with murine 4T1 
breast cancer cells. (D) Same as (A) with human HTB72 melanoma cells. 
Calculated IC50s are shown within the graphs. ***, indicates highly significant 
differences (P<0.001). 
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Somatic mutations in human cancers targeting the DTSSK domain strongly 
potentiate global anti-IFN activities of PDL1 
Our data strongly suggested that cancer cells rely on PDL1 signal 
transduction to counteract IFN toxicity. As this could be relevant for human 
immunotherapy, we studied the somatic mutations within the intracytoplasmic 
domain of PDL1 in human neoplastic malignancies. The COSMIC, ICGC, Intogen 
and TCGA catalogues of somatic mutations in cancer were consulted and several 
mutations leading to aminoacid changes were identified in carcinomas including 
skin and lung cancers. Interestingly, the majority of these (5 out of 7) directly 
affected the human homologue of the DTSSK motif (Figure 5A). To test the 
effects of these mutations over PDL1 protective functions, the two most 
disruptive mutations (D276H and K280N) were introduced into the equivalent 
murine PDL1 gene and B16-PDL1KO cells were transduced to express each 
mutant.  
Then, RTCA was used to monitor the growth/survival of the B16 cell lines 
in the presence of recombinant IFNβ (Figure 5B), IFNα (Figure 5C) and IFN 
(Figure 5D). Consistent with our previous results, these mutations within the 
DTSSK motif strongly enhanced resistance to cytotoxicity mediated by type I and 
type II IFNs, while B16-PDL1KO cells were highly sensitive to IFNs  α, β and . These 
results confirmed the regulatory role of the DTSSK motif by selection of variants 
in human carcinomas that disrupt its inhibitory activity leading to hyperactive 
PDL1 proteins. Moreover, these mutations extended wide protection also from 
IFNs α and . Finally, the inhibitory activity of DTSSK was not exclusively 
dependent on lysine 280 as the D276H mutation also enhanced protective 
activity of PDL1. 
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Figure 5. Somatic mutations in the human DTSSK homologue motif leads to 
hyperactive PDL1 molecules that protect cells from type I and type II IFNs. (A) 
Schematics on the distribution of somatic mutations found within the 
intracytoplasmic domain of human PDL1. In blue, green and red are shown the 
homologous human RMLDVEKC, DTSSK and QFEET motifs. Mutations are shown 
below, with conservative changes in green and non-conservative changes in red. 
The specific carcinomas for which mutations were described are indicated within 
boxes. Numbers represent aminoacid positions in the murine and human PDL1 
molecule. (B) The two most disruptive mutations were introduced in the DTSSK 
murine motif and the resulting PDL1 molecules expressed in B16-PDL1KO cells. On 
the left, RTCA plot of the indicated B16 cell lines expressing the PDL1 mutants 
compared to PDL1wt in the presence of 10 ng/ml of recombinant IFNβ. On the 
right, the same data as bar graphs representing the mean of the normalized cell 
index from duplicate cultures together with standard deviations as error bars. (C) 
As in (B) but with IFNα. PDL1KO indicates B16 cells in which PDL1 was disrupted 
with CRISPR/Cas9. (D) As in (B) but with IFN. Relevant statistical comparisons are 
indicated within the graph. ***, indicates very highly significant differences 
(P<0.001). 
 
PDL1 signal transduction in cancer cells is required for in vivo protection against 
IFNβ 
Our data collectively suggested that PDL1 intrinsic signaling within cancer 
cells would confer resistance to IFNs in vivo independently of its inhibitory role 
over T cells. To prove this, we studied in vivo tumor growth from B16 cells in 
which PDL1 expression or signaling were altered, followed by intra-tumor 
administration of IFNβ expressed by a lentivector or a GFP-expressing control. 
First, groups of mice were subcutaneously inoculated with B16, B16-PDL1 and 
B16 cells harboring a published PDL1-targeted shRNA which reduced the basal 
expression of PDL1 (Broos et al., 2017) (Figure 6A). Then, lentivectors expressing 
either GFP (control) or IFNβ-GFP were injected into tumors 7 and 14 days later. 
Intra-tumor expression of IFNβ-GFP delayed B16 melanoma tumor growth 
(Figure 6A). PDL1 overexpression completely abrogated this sensitivity to IFNβ-
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GFP. In contrast, tumors arising from B16-shPDL1 were highly sensitive to LV-
IFNβ-GFP, resulting in a significant delay in tumor growth and increased survival 
(Figure 6A). We repeated the experiment using B16-PDL1KOcells. As expected, 
tumors arising from B16-PDL1KO cells were highly responsive to intra-tumor 
lentivector delivery of IFNβ-GFP, leading to a highly significant increase in survival 
(Figure 6B). In fact, the lack of PDL1 was sufficient to delay tumor progression 
even in the absence of intratumor expression of IFNβ (Figure 6B).  
These results showed a higher sensitivity in these B16 tumors to IFNβ 
when PDL1 expression was interfered with. However, inhibition of PDL1 
expression in cancer cells could still enhance the cytotoxicity of T cells through 
reduced PDL1-PD1 engagement. Therefore, we carried out the same experiments 
but including a group in which B16-PDL1C cells were inoculated. PDL1 in these 
cells can still engage PD1 on the surface of T cells, but with impaired signal 
transduction within cancer cells (Figure 1). Then, tumors from B16, B16-PDL1 and 
B16-PDL1C were inoculated with lentivectors expressing IFNβ-GFP. As 
expected, PDL1 overexpression in B16 cells very significantly counteracted the 
IFNβ inhibitory effects and accelerated tumor progression (Figure 6C). In 
contrast, expression of PDL1C did not confer resistance to intra-tumor delivery 
of IFNβ. As this mutant can still engage PD1 on T cells, these results indicate that 
PDL1 signal transduction contributes significantly to protection of cancer cells 
from type I IFNs. Overall, these results showed that independently from its role 
in inhibiting cytotoxic T cells, PDL1 provides a first protective barrier to cancer 
cells by interfering with IFN signal transduction. 
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Figure 6. PDL1 intrinsic signaling in cancer cell protects tumors from IFNβ in 
vivo. (A) On the left, tumor growth graphs from injected B16 cells followed by 
intratumor injection with the indicated lentivectors, represented as means of 
tumor surfaces from groups of 6 mice with standard deviations as error bars. The 
middle and right graphs as in the left graph but using the indicated B16 cell lines 
overexpressing PDL1 (B16-PDL1) or B16 cell lines expressing a PDL1-targeted 
shRNA (B16-shPDL1). (B) The growth graph as in (A) but using B16 wild-type or 
B16 PDL1 knock-out cells. The graph on the right represents the time of death of 
each mice from the data shown on the left graph. The cell lines and the injected 
lentivectors are shown on the bottom of the graph. (C) Same as in (B) but using 
B16 wild-type, B16-PDL1 or B16-PDL1C cells which express a PDL1 mutant 
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lacking the intracytoplasmic domain. **, *** indicate very (P<0.05) and highly 
(P<0.001) significant differences, respectively. 
 
DISCUSSION  
IFNs are known to exert anti-tumor effects which include caspase-
dependent apoptosis (Apelbaum et al., 2013), cell growth arrest (Vannucchi et 
al., 2000) and cell senescence (Katlinskaya et al., 2016; Yu et al., 2015). IFNs play 
a critical role in anti-cancer immune responses, and contribute to the efficacy of 
conventional treatments and immunotherapies. There is ample evidence on the 
role that IFNs play in tumor repression, immune editing and progression (Zitvogel 
et al., 2015). Many treatments including chemotherapy and targeted therapies 
need an intact IFN signal transduction pathway in cancer cells to exert their anti-
tumor effects. However, type I IFNs in progressing tumors also drive immune 
editing (Smyth, 2005). In fact, acquisition of inactivating mutations affecting IFN 
signaling could be considered a core mechanism for tumor escape and 
progression. Recently, it has been shown that inactivating JAK1, JAK2 and β2-
microglobulin mutations in cancer cells are responsible for primary and acquired 
resistance to anti-PD1 treatment in a cohort of patients (Shin et al., 2017; 
Zaretsky et al., 2016). The authors of these studies proposed that switching off 
IFN signal transduction prevented the adaptive PDL1 expression in cancer cells, 
becoming functionally PDL1-negative and refractory to PDL1/PD1 blockade. 
However, PDL1 itself can transmit signals without engaging PD1 or CD80 through 
mTOR (Clark et al., 2016; Chang et al., 2015). Here we demonstrate that PDL1 
signal transduction in murine and human cancer cells does in fact represent a 
barrier of protection against IFN cytotoxicity by inhibitory crosstalk with the type 
I IFN signal transduction pathway. It is important to emphasize that basal PDL1 
expression reduces IFN cytotoxicity but does not completely abrogate it. 
Therefore, cancer cells respond to IFNs by up-regulating the surface expression 
of PDL1 possibly as a negative feedback mechanism to regulate IFN signaling. It 
has to be taken into account that IFNs are potent transcriptional activators of 
PDL1 (Zaretsky et al., 2016). 
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PDL1 possesses a short intracytoplasmic region without any obvious 
known domains regulating signal transduction. However, it has been shown by 
others and us that there is PDL1 intrinsic signaling regulating cell growth, survival 
and protection against apoptotic signals (Azuma et al., 2008; Clark et al., 2016; 
Chang et al., 2015; Liechtenstein et al., 2014a). We have identified functional 
regulatory sequence motifs within the intracytoplasmic domain responsible for 
PDL1 protection against IFN. The conserved RMLDVEKC motif is required to 
counteract IFNβ toxicity, while the DTSSK motif and arginines 271 and 280 act as 
negative regulators of PDL1 functions. These sequences constitute non-classical 
signal transduction motifs as they do not resemble any known signal transduction 
consensus. Only the sequence EKCGVEDTSSKNR shows high similarity to a 
domain in DNA-directed RNA polymerase subunit β which interestingly includes 
the DTSSK motif (supplemental figure 1). However, the relevance of this 
observation is unclear. 
 
Our findings also show that PD1 expression protects cancer cells from 
IFNβ toxicity by engaging PDL1. Hence, both PDL1 and PD1 blockade would 
sensitize cancer cells to IFN-mediated cytotoxicity. Furthermore, we found that 
antibody-mediated PDL1 blockade is sufficient to sensitize cancer cells to IFNs. 
Therefore, any adaptation of cancer cells to either inhibit the IFN signaling 
pathway (Shin et al., 2017; Zaretsky et al., 2016) or potentiate PDL1 activities will 
favor their escape from the immune attack. Accordingly, a variety of human 
carcinomas select somatic mutations which affect residues within the inhibitory 
DTSSK motif, thereby increasing the anti-IFN activities of PDL1. These cancer cells 
with hyperactive PDL1 mutants are very likely selected in human malignancies as 
a result of immune editing. 
Summarizing, our data demonstrates that PDL1 signal transduction 
through conserved signaling motifs represents a protective barrier of cancer cells 
against IFN cytotoxicity, which would be reinforced by its inhibitory properties to 
T cells when engaged with PD1. A therapeutic approach such as PDL1/PD1 
blockade would cause rapid cancer cell death due to further sensitization to IFN. 
This situation strongly favors the survival of variants resistant to IFN signal 
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transduction. Therefore, cancer cells with mutated JAK1 or JAK2 kinases are 
intrinsically resistant to IFN toxicity and do not show adaptive PDL1 upregulation 
(Shin et al., 2017; Zaretsky et al., 2016).  
 
EXPERIMENTAL PROCEDURES 
Cells and mice 
Human embryonic kidney (HEK) 293T cells were purchased from the 
American Type Cell Culture Collection (ATCC). Murine melanoma B16F10 cells 
were grown as described (Liechtenstein et al., 2014a). Murine CT26 colorectal 
and 4T1 breast cancer cells were grown in DMEM. Human HTB72 cells were 
grown in RPMI. C57BL/6 female mice were purchased from The Jackson 
Laboratories. Approval for animal studies was obtained from the Animal Ethics 
Committee of the University of Navarra (Pamplona, Navarra, Spain), and from 
the Government of Navarra. When indicated, recombinant IFNβ was added to 
the cell cultures at the appropriate concentrations. Cell growth/survival was 
monitored in real time using xCELLigence real-time cell analysis system (RTCA, 
ACEA Biosciences) by seeding between 3000 to 10000 cells as required, in the 
presence or absence of recombinant IFNβ. Inhibitory concentration 50 (IC50) was 
calculated by RTCA for B16 cell lines with increasing concentrations of 
recombinant IFNβ. Experiments of antibody-mediated PDL1 blockade were 
carried out with anti-PD-L1 MAb (clone 10B5) (Dong et al., 2002). For human 
PDL1 blockade, the in-house phage-display engineered humanized IgG1 
recombinant antibody Plimilumab was used. 
 
Plasmids 
The FB2 fusokine transgene is described in (Van der Jeught et al., 2014) 
and consists on a fusion gene between the murine IFN-β and the ectodomain of 
the TGFβ receptor II. The FB2 transgene was cloned into the pDUAL-p1-PuroR 
vector by standard cloning techniques. This vector contains a PDL1-targeted 
microRNA and it as described in (Liechtenstein et al., 2014a). The IFN-β coding 
sequence was amplified by PCR and cloned into pDUAL-µPDL1-PuroR and pDUAL-
GFP (Liechtenstein et al., 2014a). Likewise, the TGFβRII was amplified by PCR 
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introducing the IFN-β signal peptide for secretion at the 5’ end, and cloned into 
pDUAL-p1-PuroR. When required, the same transgenes were expressed without 
the PDL1-targeted microRNA. The pHIV-SIREN lentivectors (Lanna et al., 2014; 
Liechtenstein et al., 2014b) were used to express short-hairpin RNAs targeting 
the indicated genes (supplemental Table 1) together with blasticidin resistance. 
The PDL1 transgene was ordered from Geneart and includes 7 silent mutations 
(ccaaagatctttatg, mutations in bold and underlined) and 6 silent mutations 
(agaaacgacacgcagttt) at the amino and carboxy termini to prevent its silencing by 
either µPDL1 or PDL1-targeted CRISP/CAS9. PDL1C encodes a carboxy-terminal 
deleted PDL1 gene and was generated by PCR using oligos FW 
(ggatccgccaccatgaggatatttgctggc) and RS 
(cggccgcttattgttttctcaagaagaggaggaccg).  PDL1-deletion and single-point 
substitution mutants were generated by overlap-extension PCR as described 
(Escors et al., 2001) using the PDL1 gene as a template and the indicated 
oligonucleotides (supplemental Table 2). The murine PD1 transgene was ordered 
from Genart and cloned into pDUAL-BlastR which expresses blasticidin resistance 
under the control of the ubiquitin promoter. A carboxy terminus-deleted version 
was also generated by PCR using the FW (ggggggatccgccaccatgtgggtccggcaggtacc) 
and RS (gcggccgcttatgagcagaagacagctagggcccaggc) oligos, followed by cloning 
into pDUAL-BlastR. 
The mouse CD274 (PDL1) sgRNA CRISPR/Cas9 'All-in-One' lentiviral 
transfer vector was used to knock-out PDL1 as described (Broos et al., 2017).  
 
Lentivector production, cell transduction and generation of B16 knock-down 
stable cell lines 
Lentivector production and titration were carried out as described 
(Karwacz et al., 2011; Liechtenstein et al. 2014a; Selden et al., 2007). 
Transduction of the indicated cell lines was carried out with a multiplicity of 
transduction of 10, and transduced cells were selected with the appropriate 
concentration of either puromycin (GIBCO) or blasticidin (GIBCO). Transduced 
cells are then analyzed for the expression of the target of interest either by flow 
cytometry or western blot.  
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Western blotting 
Western blots were performed as described (Escors et al., 2008). 
Polyclonal anti-caspase 3, 7, 9 and anti-processed caspase 3, 7 and 9, and anti-
phosphorylated STAT3 molecules were purchased from Cell Signalling. Mouse 
anti-JAK1, STAT1, STAT2 and STAT3 antibodies were purchased from Cell 
Signaling, and anti-GADPH from Calbiochem. Peroxidase-conjugated polyclonal 
anti-mouse and anti-rabbit antibodies were purchased from DAKO and Cell 
Signaling. 
 
Cell staining and flow cytometry 
Surface and intracellular staining were performed as described previously 
(Escors et al., 2008) using the indicated antibodies. PE-Cy7-conjugated 
streptavidin, APC-conjugated streptatividin, PE-conjugated anti-IFNARI were 
purchased from Biolegend. PE-and FITC-conjugated streptavidin from Invitrogen. 
Biotin-conjugated anti-PDL1 was purchased from eBioscience. APC-conjugated 
anti-PD1 from Miltenyi Biotec.  
 
B16-IFNβ cell survival assays 
The goal of this assay is to quantify viable growing B16 cell lines that 
constitutively express IFNβ following lentivector transduction with IFNβ-PuroR or 
IFNβ-µPDL1-PuroR followed by selection with puromycin. For this assay 100000 
of the indicated transduced or non-transduced cells were plated in 6-well culture 
plates in triplicate. Cells were then transduced at a multiplicity of transduction of 
10. One well was left as a non-transduced control. The next day, puromycin was 
added at 1 µg/ml and surviving cells allowed to grow for two weeks. Surviving 
cells were quantified and represented as a percentage compared to the growth 
of non-transduced, non-treated cells. 
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IFN treatment of PDL1 mutants and real-time living cell monitoring (RTCA) 
The appropriate cell types were seeded at a density of 5000 cells per well 
on two L8 cell culture chambers for xCELLingence RTCA monitoring system (ACEA 
biosciences). Cells were grown in DMEM or RPMI medium with recombinant 
murine or human IFNβ (10ng/ml, eBioscience) as required. Murine IFNα (400 
units/ml) and IFN (10 ng/ml) were purchased from (Peprotech). Growth and 
survival of cell lines were monitored by RTCA for a minimum of 3 days. 
 
Vaccination and tumor experiments 
Experiments were usually performed with six C57BL/6 mice per group. 
Mice were subcutaneously inoculated with 106 of the indicated B16 cell lines. 
Tumor size was monitored every 2 days. When required, tumors were injected 
with 106 lentivector transducing particles expressing IFNβ-GFP or with GFP only 
as a control. Mice were sacrificed when tumor surface was above 150 mm2.  
 
In silico sequence analyses 
PDL1 protein sequences from mouse, human, pig, cow, buffalo, cat, dog 
and salmon were aligned using the multialign tool 
(http://multalin.toulouse.inra.fr/multalin/) (Corpet, 1988). Prediction of 
ubiquitination sites was performed with UbPred tool (http://www.ubpred.org/) 
(Radivojac et al., 2010). The search for conserved protein domains was 
performed with MotifFinder (http://www.genome.jp/tools-
bin/search_motif_lib). The data on somatic mutations in PDL1 from human 
cancers was obtained from the COSMIC (http://cancer.sanger.ac.uk/cosmic) and 
TCGA (https://cancergenome.nih.gov/) databases. The following mutations were 
found: R260C (colon and cecum carcinoma; COSU3769). , R262K (Daud et 
al.,2016) (basal cell carcinoma, COSP39263), I274I (lung, cecum carcinoma and 
melanoma,COSP29675,COSU540,COSU17), I274V (colon carcinoma, COSU144), 
D276H (breast invasive carcinoma, TCGA-AR-A0TX-01; COSU414), D276Y (rectum 
carcinoma), T277K (George et al., 2015) (small cell lung cancer; COSP40339), 
T277S (lung carcinoma,COSP40399) , K280N (cervical squamous cell carcinoma; 
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TCGA-FU-A3HZ-01; COSU415), T290M (pancreas and stomach carcinomas, TCGA-
BR-4362-01; COSU541) and T290T (breast cancer, COSU541). 
 
Statistical analyses 
GraphPadPrism was used for plotting data and statistical analyses. No 
data was considered an outlier. Data from B16-IFNβ survival assay was confirmed 
to be normally distributed, therefore analyzed by two-way ANOVAs with a 
random criterium (inter-experiment variability). Two pair comparisons were 
carried out following the ANOVA analyses using either Bonferroni or Tukey´s tests.  
Tumor growth and survival  data  were analyzed as  descr ibed before  
(Karwacz  et  a l . ,  2011 ) . ACEA RTCA cell index data was analyzed for each 
sample in duplicates and plotted as means and standard deviations. The data was 
highly homogeneous and the data normally distributed. For statistical analyses, 
the cell index data collected at 75, 80, 85, 90 hours of cell growth. The data was 
analyzed by two-way ANOVA with time as a random criterium followed by 
Tukey´s pair-wise comparisons. 
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SUPPLEMENTAL FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1, related to Figure 2A. Bioinformatic analysis of the PDL1 
intracytoplasmic domain. On top, Kyte-Doolittle hydrophathy plot of the 
intracytoplasmic domain of PDL1, with a hydrophobic head containing the 
VRMLDV hydrophobic motif and the hydrophilic tail as shown below the 
hydrophathy plot. Serine and threonine phosphorylatable residues by PKC and 
CKII were predicted and indicated with an arrow. Motifinder produced two 
similarity hits with DNA-dependent RNA polymerase beta subunits as shown 
within red boxes. 
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Figure S2, related to Figures 2, 5 and 6. Surface expression of PDL1 molecules in 
B16-PDL1KO cells. The histograms show flow cytometry data on the surface 
expression of the indicated B16 cell lines expressing PDL1 mutants (on the right of the 
graphs). Percentages and numbers represent percentages of PDL1 positive cells 
relative to the background fluorescence from an unstained control (US), and mean 
fluorescent intensities 
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SUPPLEMENTAL TABLES 
Supplemental Table 1, related to Figures 1, 3 and 6. shRNA sequences cloned into pHIV-
SIREN vectors. 
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Supplemental Table 2, related to Figures 1, 2, 5 and 6. Oligonucleotides used to 
generate PDL1 mutants. 
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ABSTRACT 
Myeloid-derived suppressor cells (MDSCs) differentiate from bone 
marrow precursors, expand in cancer-bearing hosts and accelerate tumor 
progression. MDSCs have become attractive therapeutic targets, as their 
elimination strongly enhances anti-neoplastic treatments. Here, immature 
myeloid dendritic cells (DCs), MDSCs modeling tumor-infiltrating subsets or 
modeling non-cancerous (NC)-MDSCs were compared by in-depth quantitative 
proteomics. We found that neoplastic MDSCs differentially expressed a core of 
kinases which controlled lineage-specific (PI3K-AKT and SRC kinases) and cancer-
induced (ERK and PKC kinases) protein interaction networks (interactomes). 
These kinases contributed to some extent    to myeloid differentiation. However, 
only AKT and ERK specifically drove MDSC differentiation from myeloid 
precursors. Interfering with AKT and ERK with selective small molecule inhibitors 
or shRNAs selectively hampered MDSC differentiation and viability. Thus, we 
provide compelling evidence that MDSCs constitute a distinct myeloid lineage 
distinguished by a “kinase signature” and well-defined interactomes. Our results 
define new opportunities for the development of anti-cancer treatments 
targeting these tumor-promoting immune cells. 
 
 
INTRODUCTION 
Anti-cancer treatments are primarily aimed at causing arrest of tumor cell 
growth or tumor cell death. In recent years, immunotherapy has resurfaced as 
anattractive therapeutic alternative [1]. However, the expansion of 
immunosuppressive cell types in cancer patients strongly interferes with anti-
tumor immune responses. These immunosuppressive cells enhance tumor 
progression/metastasis and counteract classical anti-neoplastic treatments. 
Amongst these, myeloid-derived suppressor cells (MDSCs) are major contributors 
to tumor progression. MDSCs differentiate from precursors within the bone 
marrow (BM) in tumor-bearing hosts. MDSCs distribute systemically and 
infiltrate tumors, where they contribute to tumor progression through a variety 
of mechanisms [2, 3]. However, MDSC differentiation and functions are still 
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poorly understood. This is due to the difficulty of isolating them from tumor-
bearing subjects, or differentiating them in vitro so that they faithfully model in 
vivo cell subsets [4]. Nonetheless, counteracting their activities strongly 
enhances anti-cancer treatments [5]. Thus, finding treatments that would 
specifically eliminate MDSCs could improve the efficacy of anti- cancer therapies. 
While the most valuable source of MDSCs for research is the tumor itself, 
their isolation is still a challenge [4, 6]. Therefore, other sources such as spleen 
or blood are widely used. However, these MDSCs are phenotypically and 
functionally different from tumor- infiltrating subsets [6–9]. To overcome these 
difficulties, we developed an ex vivo differentiation system that produces MDSCs 
modeling tumor-infiltrating subsets (B16-MDSCs) and non-cancerous (NC) 
MDSCs (293T-MDSCs) [8]. These ex vivo MDSCs have been phenotypically and 
functionally validated in B16 melanoma and CT26 colorectal cancer models [8–
11]. 
The use of high-throughput analytical techniques for the identification of 
cellular regulatory pathways and novel molecular targets is on the increase. Two 
independent studies on the proteome of blood and spleen MDSCs have been 
published using LC-MS/MS mass spectrometry and label-free quantification [12, 
13]. Although relevant data was obtained, none of these studies included control 
cell types such as myeloid DCs and NC- MDSCs. Therefore, studies that have been 
published so far have not discriminated pathways associated to cell lineage or the 
tumor environment. 
To overcome these issues, we carried out in-depth proteomic analyses 
comparing myeloid   DCs, MDSCs modeling tumor-infiltrating subsets or modeling 
NC-MDSCs. We found a kinase signature that defined neoplastic MDSCs which 
could be specifically targeted to interfere with MDSC differentiation from 
myeloid precursors. 
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RESULTS 
MDSC lineage-specific interactomes  
iTRAQ-based quantitative proteomics were performed on MDSCs 
modeling melanoma-infiltrating subsets (B16-MDSCs), using immature myeloid 
DC proteomes as a comparative standard to identify melanoma MDSC lineage-
specific interactomes. 3609 proteins were unambiguously identified with an FDR 
lower than1%. Differential protein quantification was performed between DCs 
and B16-MDSCs, and the most affected proteins with a significance level of 0.01 
were used for further analyses (Fig. 1a). Expression of 58 proteins was found up-
regulated in MDSCs while 46 were down- modulated (Fig. 1b and Supplementary 
Table 1). Ingenuity Pathway Analysis was used to reconstruct functional 
interactome maps with differentially expressed proteins. Three distinct 
interactomes resulted from the analyses, with highly detailed interaction 
relationships between nodes (Figs. 2, 3, 4). The top canonical pathways which 
separated B16-MDSCs from DCs were: (1) mitochondrial dysfunction (P = 1.5 × 
10−7); (2) leukocyte extravasation signaling (P = 5 × 10−6), (3) caveolar-mediated 
endocytosis signaling (P = 2.6 × 10−5) and (4) integrin signaling (4 × 10−5). These 
pathways were associated to SRC, FYN and HCK kinases, unambiguously 
identified by mass spectrometry (Supplementary Table 1). Protein interactome 
networks predicted a number of regulatory proteins (hubs) including the PI3K-
AKT signaling axis (Fig. 2). Importantly, SRC kinases controlled changes in the 
cytoskeleton and mitochondrial dysfunction through down-regulation of 
complex I NAPDH dehydrogenase subunits (Figs. 2, 3). These kinases were 
directly associated to various molecular nodes such as calmodulin, Hsp90, α-
catenin and the proteasome (Fig. 4). 
Confidence-based protein networks were reconstructed using STRING 
software [14], with up-regulated or down-regulated proteins. Both high and 
medium confidence links were considered (score >0.4), as the number of 
networks was limited to allow careful confirmation. About 10 distinct protein 
networks were organized around a central group of kinases that included SRC 
family members (Supplementary Fig. 1). These networks were associated to 
production of reactive oxygen species (ROS), protection against oxidative 
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damage, intracellular vesicle trafficking and aminoacid metabolism. Decreases in 
spliceseosomal proteins, carbohydrate metabolism, lysosomal function and MHC 
II antigen presentation were also evident. 
KEGG pathway mapping was applied to up- and down-regulated proteins. 
KEGG analyses showed strong inhibition of cellular processes associated to 
inflammatory disorders and a decrease in metabolism of aminoacids (Fig. 5). 
 
 
Figure 1: Differentially expressed proteins in MDSCs caused by lineage and 
cancer. a. Volcano plots representing the fold-change of identified proteins with 
associated P values from the pair-wise quantitative comparisons of DCs vs B16-
MDSCs (lineage differences, left plot) and NC-MDSCs vs B16-MDSCs (cancer-
regulated differences, right plot). In green, very significantly changed proteins (P 
< 0.01), in blue, significantly changed proteins (P < 0.05) and in red, unchanged 
proteins between the pair-wise comparisons. b. Heat map representing the 
degree of change for the differentially expressed proteins (P < 0.01, 
Supplementary Table 1) between the indicated samples (independent biological 
triplicates are indicated as 1, 2 and 3; DCs, dendritic cells; B16-MDSCs, cancerous 
MDSCs; NC-MDSCs, non-cancerous MDSCs), as shown below. Legend (bottom 
right) indicates color-coded fold-change on Log10 scale. Red and green, up- and 
down-regulated proteins, respectively. 
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Cancer-specific interactomes in MDSCs modeling tumor-infiltrating subsets 
Our ex vivo system generates MDSCs that model tumor-infiltrating (B16-
MDSCs) and non-cancerous NC- MDSCs (293T-MDSCs) [8, 9, 11]. It has to be 
pointed out that NC-MDSCs are not precursors of tumor-infiltrating MDSCs, but 
cells differentiated ex vivo in non-neoplastic conditions as described [8, 9]. Thus, a 
quantitative proteomic comparison between these two subsets was performed to 
highlight cancer-regulated pathways. These analyses uncovered 50 up- and 35 
down-regulated proteins in B16-MDSCs compared to NC-MDSCs, and pathway 
reconstruction was performed using Ingenuity (Fig. 6, Supplementary Table 1). The 
top canonical pathways which differentiated neoplastic from non-cancerous MDSCs 
were: (1) the pentose phosphate pathway (P = 6.4 × 10−8), represented by G6PD, 
PGD and TALDO1 up-regulation; (2) epithelial adherence junction signaling with up-
regulation of EZR, DSTN, tubulin and Rho-like proteins (P = 2.4 × 10−3). The two 
top associated molecular and cellular functions were (1) free radical scavenging and 
oxidative stress responses (P = 1.1 × 10−8) as indicated by up- regulation of SOD2, 
MPO, PRDX, GSTM5 and PARK7 amongst others, and (2) carbohydrate metabolism 
which was associated to the pentose phosphate pathway (P = 2.5 × 10−8). 
Interestingly, Ingenuity protein interaction networks included the kinases ERK1 and 
PKC isoforms as regulatory hubs (Fig. 6). 
Similar results were obtained with STRING software (Supplementary Fig. 
2).  Most notably, up-regulation of the pentose phosphate pathway, changes in 
cytoskeletal proteins and down-modulation of oxidative phosphorylation. 
Results from KEGG pathway mapping highlighted increased glutathione 
metabolism, activation of the pentose phosphate pathway and a decrease in 
spliceosomal proteins (Fig. 7). 
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A kinase signature defines the neoplastic MDSC lineage 
Systems biology analyses delineated a kinase signature of the MDSC 
lineage (AKT and the SRC family, which included SRC, HCK and FYN) and 
neoplastic MDSCs (ERK and PKC kinases). Overall, the expression of FYN, HCK and 
total and phosphorylated SRC agreed with proteomic data, as assessed by flow 
cytometry and immunoblotting. The predicted participation of AKT was also 
confirmed (Fig. 8a). AKT expression was particularly high in MDSCs modeling 
tumor-infiltrating subsets as detected by immunoblotting. ERK1 and PKC 
isoforms were predicted to be differentially expressed in tumor-infiltrating 
MDSCs. While total ERK expression was equivalent between B16-MDSCs and NC-
MDSCs, phosphorylated (active) ERK1 was increased in B16-MDSCs (Fig. 8a). The 
expression of phosphorylated PKC isoforms (phosphorylated pan-PKCs) was 
tested by immunoblot. In agreement with proteomic data and Ingenuity 
analyses, phosphorylated PKCs were present at higher levels in MDSCs modeling 
neoplastic subsets (Fig. 8a). 
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Figure 2: Functional MDSC lineage-specific interactome networks controlled by 
SRC, HCK and AKT kinases. Graph represents functional interactomes constructed 
with Ingenuity Pathway Analysis tool using lineage specific (B16-MDSCs vs DCs) 
differentially expressed proteins, which shows detailed interaction relationships 
between the input nodes (differentially expressed proteins between MDSCs and 
DCs), and regulatory kinases encircled in blue. This interactome links AKT/SRC 
kinases with mitochondrial respiration and dysfunction, protection against 
oxidative stress and extracellular matrix remodeling. Nodes in red, up-regulated 
proteins. Nodes in green, down-modulated proteins. In white, predicted protein 
nodes. A, activation; B, binding; C, causes/leads to; CC, chemical- chemical 
interaction; CP, chemical-protein interaction; E, expression; EC, enzyme catalysis; 
I, inhibition; L, proteolysis; LO, localization; M, biochemical modification; MB, 
group/complex; P, phosphorylation/dephosphorylation; PD Protein-DNA binding; 
PP Protein-Protein binding; PR Protein-RNA binding; RB Regulation of Binding; RE 
Reaction; RR RNA-RNA Binding; T Transcription; TR Translocation. Dash arrows, 
indirect interactions. 
 
AKT and ERK1 specifically contribute to MDSC differentiation from myeloid 
precursors 
To assess the contribution of MDSC-associated kinases to myeloid 
differentiation, a collection of kinase inhibitors were added to myeloid 
precursors committed towards DC or B16-MDSC differentiation. Inhibitors were 
added at concentrations reported to interfere with cancer cell growth. High 
resolution impedance-based real-time cell monitoring (RTCA) was used to 
continuously monitor myeloid differentiation, viability and to calculate IC50s (Fig. 
8b and Table 1) [15]. Overall, all tested inhibitors affected equally to myeloid 
precursors differentiating towards DCs and MDSCs (Table 1).  Treatments with 
the specific AKT inhibitor X or the MEK inhibitor PD0325901 were an exception. 
AKT inhibitor X was highly toxic to precursors differentiating towards MDSCs, 
while differentiating DCs remained unaltered (Fig. 8b and Table 1). Treatment 
with the MEK inhibitor PD0325901 selectively inhibited MDSC proliferation. 
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Overall, comparing the IC50s for differentiating DCs and MDSCs, AKT and MEK-
ERK pathways specifically contributed to MDSC differentiation (Fig. 8c). 
Moreover, myeloid precursors committed to MDSC differentiation died within 
hours of adding the AKT inhibitor, strongly suggesting that AKT was involved in 
survival but not differentiation (Fig. 9a). 
The results with kinase inhibitors were also confirmed with silencing 
shRNAs. Thus, myeloid precursors committed towards MDSC differentiation were 
expanded for three days from BM and transduced with   a lentivector delivering 
immunoblot-validated shRNAs against AKT1 or ERK1 as described [8, 16] (Fig. 9b). 
Transduced myeloid precursors died 48 hours after delivery of the AKT1-specific 
shRNA. Likewise, ERK1 silencing significantly inhibited cell growth. 
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Figure 3: Functional MDSC lineage-specific interactome networks regulating 
cytoskeletal changes and controlled  by SRC kinases. Graph presents functional 
interactomes constructed with Ingenuity Pathway Analysis tool using lineage 
specific (B16-MDSCs vs DCs) differentially expressed proteins, which shows 
detailed interaction relationships between the input nodes (differentially 
expressed proteins between MDSCs and DCs), and regulatory kinases encircled in 
blue. This interactome links SRC kinases with protein transport, mRNA processing, 
cytoskeletal re-organization and decreased glycolysis. Nodes in red, up-regulated 
proteins. Nodes in green, down-modulated proteins. In white, predicted protein 
nodes. A, activation; B, binding; C, causes/leads to; CC, chemical- chemical 
interaction; CP, chemical-protein interaction; E, expression; EC, enzyme catalysis; 
I, inhibition; L, proteolysis; LO, localization; M, biochemical modification; MB, 
group/complex; P, phosphorylation/dephosphorylation; PD Protein-DNA binding; 
PP Protein-Protein binding; PR Protein-RNA binding; RB Regulation of Binding; RE 
Reaction; RR RNA-RNA Binding; T Transcription; TR Translocation. Dash arrows, 
indirect interactions. 
Inhibition of the ERK pathway interferes with MDSC differentiation and 
accelerates DC maturation 
Inhibition of the ERK pathway interfered with MDSC growth. As the MEK 
inhibitor PD0325901 is currently used for the treatment of several human 
cancers in clinical trials, its effects on differentiation of myeloid cell lineages 
was further tested. Thus, the three main myeloid cell populations differentiated 
from bone marrow precursors was quantified by flow cytometry after a week of 
PD0325901  treatment;  Namely,  CD11b+ monocytic myeloid cells (Ly6Chigh 
Ly6Gneg), granulocytic myeloid cells (Ly6C+ Ly6Ghigh) and conventional DCs 
(Ly6C+ Ly6Gneg/low CD11c+) (Fig. 9c). Interestingly, PD0325901 treatment 
accelerated conventional CD11c+ DC differentiation.  At the highest tested 
concentration, the MEK inhibitor was strongly cytotoxic to myeloid cells 
committed to MDSC differentiation, but not to those differentiating towards 
DCs which strongly up-regulated CD11c expression. 
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Overall, these results also confirmed that interference with the ERK 
pathway is inhibitory over MDSCs and promotes conventional DC 
differentiation. 
 
Figure 4: Functional MDSC lineage-specific interactome networks controlled by 
PI3K and CDK2 kinases. Graph presents functional interactomes constructed with 
Ingenuity Pathway Analysis tool using lineage specific (B16-MDSCs vs DCs) 
differentially expressed proteins, which shows detailed interaction relationships 
between the input nodes (differentially expressed proteins between MDSCs and 
DCs), and regulatory kinases encircled in blue. This interactome links PI3K with 
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cell cycle, protein synthesis and transport, survival and proliferation. Nodes in red, 
up-regulated proteins. Nodes in green, down-modulated proteins. In white, 
predicted protein nodes. A, activation; B, binding; C, causes/leads to; CC, 
chemical-chemical interaction; CP, chemical-protein interaction; E, expression; 
EC, enzyme catalysis; I, inhibition; L, proteolysis; LO, localization; M, biochemical 
modification; MB, group/complex; P, phosphorylation/ dephosphorylation; PD 
Protein-DNA binding; PP Protein-Protein binding; PR Protein-RNA binding; RB 
Regulation of Binding; RE Reaction; RR RNA-RNA Binding; T Transcription; TR 
Translocation. Dash arrows, indirect interactions. 
 
DISCUSSION 
High-throughput analyses of biological systems provide a unified view of 
biological processes, and can uncover novel molecular targets. However, sorting 
out meaningful information from large datasets is challenging and relies on 
choosing the right controls. In addition, some biological systems such as MDSCs 
are difficult to work with. Here we characterized the neoplastic B16 melanoma 
MDSC proteome by differentiating MDSCs modeling tumor-infiltrating subsets, 
and quantitatively comparing it with the proteomes of myeloid DCs and MDSCs 
modeling non-cancerous MDSCs. Myeloid DCs and NC-MDSCs provide the 
appropriate controls to discriminate pathways regulated by cell lineage or the 
tumor environment. We performed in-depth quantitative proteomics to 
construct highly detailed MDSC interactome maps. Regulatory networks were for 
the first time unambiguously ascribed to cell lineage or to a neoplastic 
environment. 
Cell lineage differences were highlighted by comparing B16 melanoma-MDSCs 
with myeloid DCs. Mitochondrial dysfunction was a   key   characteristic of 
MDSCs, reflecting a shut-down of oxidative phosphorylation. MDSCs modeling 
non-cancerous subsets provided a convenient standard to discriminate cancer-
specific pathways. Of these, the pentose phosphate pathway was one of the most 
prominent, probably used to produce NADPH for biosynthesis in  the  absence of  
oxidative  phosphorylation.  Decreased   expression of mitochondrial NADPH 
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dehydrogenase, up-regulation of free radical scavenging proteins, and cellular 
stress were hallmarks of neoplastic MDSCs compared to NC-MDSCs. 
As we found that NC-MDSCs differed from neoplastic MDSCs in cell stress 
pathways and inflammatory pathways, it is likely that NC-MDSCs are different to 
other subsets differentiated in non-neoplastic conditions such as cell stress and 
infection. Overall, published data agreed with our proteome maps [17–24]. 
Importantly, neoplastic MDSCs presented a specific kinase signature 
which controlled MDSC-related interactomes and clearly separated them from 
the myeloid DC lineage. While SRC, FYN, HCK, PI3K and AKT kinases differentiated 
MDSCs from DCs, ERK and PKC discriminated neoplastic MDSCs from non-
cancerous subsets. The proteomic and systems biology data was confirmed by 
immunoblot and flow cytometry. Ingenuity analyses also predicted the PKC 
isoforms as a differential feature of neoplastic MDSCs. DCs and NC-MDSCs 
presented lower but detectable levels of phospho-PKC. As we used a pan-
phospho-PCK antibody, we cannot rule out that some specific PKC isoforms 
discriminate neoplastic MDSCs from non-neoplastic counterparts. In fact, this is 
the case of 4T1 breast cancer MDSCs, for which there   is evidence that isoforms 
beta and theta are specifically activated [22]. 
AKT was required for the survival of myeloid precursors differentiating 
into MDSCs, but was dispensable in precursors committed to DC differentiation. 
This is in agreement with the requirement of AKT for    in vivo MDSC expansion 
[25], and with its anti-apoptotic role in hematopoietic cells [26]. Additionally, the 
MEK1 inhibitor PD032591 selectively affected differentiating MDSCs, while DC 
maturation was enhanced according to CD11c up-regulation. The ERK pathway is 
known to keep DCs immature and favor tumor progression [27–29]. Here we also 
demonstrated that ERK contributes to MDSC differentiation. Our results show 
that inhibition of ERK and AKT pathways could enhance anti-tumor immune 
responses by depleting MDSCs and activating DCs. Nevertheless, the other 
differentially expressed kinases may still participate in MDSC functions apart 
from differentiation and survival, which could be susceptible of therapeutic 
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intervention. 
   
Figure 5: KEGG pathway analyses of differentially-expressed proteins in MDSCs 
compared to myeloid DCs. Graph represents the percentage of differentially up- 
or down-regulated (as indicated within the graph) proteins ascribed to the 
indicated KEGG pathways. 
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Figure 6: Functional interactomes with cancer-regulated (B16-MDSCs vs NC-
MDSCs) differentially expressed proteins. Ingenuity Analysis interactome linking 
ERK and PKCs with protection against oxidative stress, mitochondrial electron 
transport and NADPH oxidase activity, the pentose phosphate pathway and ROS 
generation. Regulatory kinases are encircled in blue. Nodes in red, up-regulated 
proteins. Nodes in green, down-modulated proteins. In white, predicted protein 
nodes; A, activation; B, binding; C, causes/leads to; CC, chemical-chemical 
interaction; CP, chemical-protein interaction; E, expression; EC, enzyme catalysis; 
I, inhibition; L, proteolysis; LO, localization; M, biochemical modification; MB, 
group/complex; P, phosphorylation/dephosphorylation; PD Protein-DNA binding; 
PP Protein-Protein binding; PR Protein-RNA binding; RB Regulation of Binding; RE 
Reaction; RR RNA-RNA Binding; T Transcription; TR Translocation. Dash arrows, 
indirect interactions. 
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Figure 7: KEGG pathway analyses of differentially-expressed proteins in MDSCs 
modeling tumor-infiltrating subsets compared to NC-MDSCs. The graph shows 
the percentage of differentially up- or down-regulated (as indicated within the 
graph) proteins ascribed to the indicated KEGG pathways. 
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Figure 8: A kinase signature discriminates MDSCs from DCs. a. Graphs on the 
left, flow cytometry histograms with expression profiles of the indicated kinases 
in DCs, NC-MDSCs and B16-MDSCs. Mean fluorescent intensities for each cell 
population are shown within the graphs. US, unstained control; DC, dendritic 
cells; NC, non-cancerous MDSCs; B16, MDSCs modeling tumor-infiltrating 
subsets. Blots on the right, detection of the indicated kinases by immunoblotting. 
Two preparations from the indicated cell populations (top of the immunoblots) 
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were loaded and lanes were labelled as 1 and 2. An immunoblot for GADPH 
detection is shown as a reference control, on the same membrane used for AKT 
detection above. b. Representative real-time cell monitoring (RTCA) results for 
myeloid precursors treated with the indicated concentrations of AKT inhibitor X, 
and grown either in DC-differentiation medium or in B16-MDSC conditioning 
medium as indicated on top. Data is plotted as means of cell index with error bars 
(standard deviations) from duplicate cultures, shown as a function of time. 
Relevant statistical comparisons are shown and indicated with *, **, and *** for 
significant          (P < 0.05), very significant (P < 0.01) and highly significant (P < 
0.001) differences, respectively. c.DC/MDSC IC50 ratios calculated for the 
indicated treatments. Ratios close to 1 (horizontal dotted line) indicate that 
treatments are equally inhibitory over MDSCs and DCs. Ratios higher than 1 
indicate that MDSCs are more sensitive to the specific treatments than DCs. 
 
Table 1: IC50s of small molecule inhibitors over myeloid precursors committed 
towards DC or MDSC differentiation 
 
Inhibitor IC50, DCs IC50, MDSC Targeted kinases 
AKT inhibitor X >100 μM 3.9 ± 0.6 μM AKT 
 
TX1123 
 
3.2 ± 1.4 μM 
 
3.4 ± 3 μM 
SRC 
eEF2-K 
PKA 
Saracatinib 3.5 ± 3.4 μM 8.8 ± 8 μM 
SRC 
FYN 
PP2 46.5 ± 0.7 μM 45.4 ± 2 μM 
FYN 
HCK 
PD0325901 44.7 ± 4.5 nM 6.2 ± 2.8 nM MEK 
SCH772984 86.5 ± 19 nM 21 ± 15 nM ERK1 
VTX-11e 8 ± 0.15 μM 1.3 ± 0.14 μM ERK1 
Gö 6983 5.7 ± 1 μM 5.7 ± 2.3 μM PKCα, β, γ, δ, ζ and μ 
NPC-15437 8 ± 2.3 μM 8 ± 2 μM PKC 
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Figure 9: AKT is required for survival of myeloid cells committed to MDSC 
differentiation, while inhibition of the ERK pathway enhances conventional DC 
differentiation. a. The percentages of viable myeloid precursors treated with the 
indicated concentrations of AKT inhibitor X are indicated as a bar graph with 
standard deviations as error bars. Precursors were committed towards DC or 
MDSC differentiation as indicated on top of the bars. Viable cells were quantified 
following trypan blue staining. Relevant statistical comparisons are shown. b. 
Graph on the left, growth of myeloid cell precursors transduced with a lentivector 
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encoding a control shRNA (shPD1a), or an AKT1-specific shRNA (shAKT1). Data is 
plotted as means and standard deviations as error bars. The same is shown in the 
graph on the right, but delivering an ERK1-specific shRNA (shERK1). Relevant 
statistical comparisons are shown within the graph. b. Phenotype effects of 
sustained MEK inhibition with PD0325901 on myeloid precursors committed to 
MDSC differentiation or to DC differentiation. Ly6C+ cells were gated and the 
Ly6G-CD11c expression profiles are shown in flow cytometry density plots. 
Percentages of CD11c+ myeloid cells after 7 days of culture are highlighted within 
the graphs. ***, very highly significant differences. 
   
MATERIALS AND METHODS 
Cells and mice 
293T, B16F0 cells and BM-DCs were grown as described [8, 27]. Approval 
for animal studies was obtained from the Animal Ethics Committee of the 
University of Navarra,   and   from   the   Government of Navarra. Non-cancerous 
MDSCs (NC-MDSCs, 293T-MDSCs) and B16-MDSCs were obtained from C57BL/6 
murine BM cells as described [8]. 
Drug treatments of myeloid cell cultures and impedance-based real-time living 
cell monitoring (RTCA) 
Myeloid hematopoietic precursors were expanded from BM cells using 
granulocyte-monocyte-colony stimulating factor (GM-CSF), stem cell factor (SCF) 
and leukaemia inhibitory factor (LIF) for 2 to 3 days, following published 
conditions [8, 30]. Then, myeloid precursors were seeded on two L8 cell culture 
chambers for the xCELLingence RTCA monitoring system (ACEA biosciences), at a 
density of 200000 cells per well. DC or B16-MDSC differentiation medium was 
added to myeloid precursors, and treatments were carried out simultaneously in 
duplicates. After 30 min, the indicated chemical inhibitors were added at 
concentrations reported to be cytotoxic to cancer cells. Control well were treated 
with carrier solution (either water or DMSO). The  following  inhibitors  were   
used:  AKT   inhibitor X (Calbiochem), tyrosine kinase inhibitor TX-1123 
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(Calbiochem), MEK inhibitor PD0325901 (SIGMA), ERK inhibitors SCH772984 and 
VTX-11e [31], broad PKC inhibitor GÖ 6983 (Santa Cruz Biotechnology), PKC 
inhibitor NPC-15437 dihydrochloride (Santa Cruz Biotechnology), selective LCK 
and FYN inhibitor PP2 (Santa Cruz Biotechnology), and the SRC and FYN inhibitor 
Saracatinib (MedChem Express). IC50s for each inhibitor were calculated using 
the RTCA data and analysis software, using duplicates for each drug treatment. 
Lentivector production and cell transduction 
Lentivectors    were    produced    and    titrated   by flow cytometry or Q-
PCR as   described   [32].  The   pHIV-SIREN   system   developed   by    our group 
[16]   was   used   as   a   backbone   to clone   the following validated shRNAs 
against ERK1 (GCATGCTTAATTCCAAGGGCTATTCAAGAGATAG 
CCCTTGGAATTAAGCATGTTTTTTACGCGT) and AKT1 
(GTCTGAGACTGACACCAGGTATTTCAAGAG 
AATACCTGGTGTCAGTCTCAGATTTTTTACGCGT). A control shRNA-encoding 
lentivector targeting the human PD1 transcript (SIREN-shPD1a) was used [33]. 
The same shRNAs were cloned into the pSIRACT-GFP shRNA-cloning lentivectors, 
which were derived from pHIV-SIREN constructs by replacing the PGK promoter 
by the Actinin 4 promoter. The lentivector backbone was changed because PGK 
was strongly down-modulated in MDSCs, while actinin4 was strongly expressed. 
Immunoblot 
Immunoblots were performed as described [27]. Anti-GADPH was 
purchased from Calbiochem. Rabbit anti-human HCK was purchased from 
Millipore. From BD bioscience, mouse anti-pan ERK, mouse anti-AKT and mouse 
anti-AKT pT308. From Cell Signaling, rabbit anti-mouse T202/Y204 p-P44/42 
MAPK, phospho-pan-PKC rabbit mAb. Peroxidase-conjugated anti-mouse and 
anti-rabbit antibodies were purchased from DAKO. Membranes were stripped 
and re-probed with antibodies for total and phosphorylated proteins, when 
required. 
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Cell staining and flow cytometry 
Surface and intracellular staining were performed as described previously 
[27] using the indicated antibodies. From BioLegend: Alexa fluor 488-Ly6C, PE-
Cy7-Ly6G, PE-Cy7-streptavidin, APC-streptatividin; From BD Pharmigen: APC-
CD11b, PE-Cy7 anti-mouse CD11c, Rat anti-mouse CD16/CD32, PE-conjugated 
anti-Gr-1, Alexa 647-conjugated anti- PY418 SRC, PE-conjugated ant-AKT1, from 
Invitrogen: APC-CD11c, PE-streptavidin, FITC-streptavidin; from AbDSerotec: PE-
CD62L; From Santa Cruz Biotechnology: PE-conjugated anti-Fyn. From Cell 
Signaling, Alexa 647-conjugated anti-SRC rabbit antibody (clone 36D10) and PE-
conjugated anti-phospho AKT rabbit antibody (Ser473, clone D9E). 
Mass spectrometry-based quantitative proteomics and bioinformatic analyses 
A global experiment was carried out with three biological replicates in 
each experimental condition using B16-MDSC, NC-MDSC and DC cell pellets. The 
specific procedures for sample preparation, proteomic analyses, iTRAQ-based 
proteomic workflows and mass spectrometry using triple-TOF 5600 system (AB 
Sciex) have been published [8]. The mass spectrometry proteomics data were 
deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange. org) via the PRIDE partner 
repository with the data set identifiers PXD001103 and PXD001106. 
Analyses of raw data (.wiff, AB Sciex) were performed with MaxQuant 
software [34].  For peak list generation, default AB Sciex Q-TOF instrument 
parameters were used except the main search peptide tolerance, which was set 
to 0.01 Da, and MS/MS match tolerance, which was increased up to 50 ppm. 
Minimum peptide length was set to 6. Two databases were used.   A contaminant 
database (.fasta) was firstly used for filtering out contaminants. Peak lists were 
searched against UniProt murine database, and Andromeda was used as    a 
search engine [35]. Methionine oxidation was set as variable modification, and 
the carbamidomethylation of cysteine residues was set as fixed modification. 
Maximum false discovery rates (FDR) were set to 0.01 at protein and peptide 
levels. Analyses were limited to peptides of six or more amino acids in length, 
and considering      a maximum of two missed cleavages. Relative protein 
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abundance output data files were managed using R scripts for subsequent 
statistical analyses and representation. Proteins identified by site (identification 
based only on   a modification), reverse proteins (identified by decoy database) 
and potential contaminants were filtered out. Only proteins with more than one 
identified peptide were used for quantification. For possible quantification data 
rescue, up to one missing value for each group was rescued replacing it by the 
mean of the rest in-group samples. Data was normalized and transformed for 
later comparison using quantiles normalization and log2 transform respectively. 
The Limma Bioconductor software package in R was used for ANOVA analyses. 
Significant and differential data were selected by a p-value lower than 0.01, fold 
changes of <0.77 (down-regulation) and >1.3 (up-regulation) in linear scale. 
These parameters were used for differential expression threshold with volcano 
and profile plots. 
The proteomic information was analyzed using bioinformatic tools. 
Studies with the Kyoto Encyclopedia of Genes and Genomes (KEGGS) Pathway 
mapping tool were performed as described (http://www.genome 
.jp/kegg/tool/map_pathway1. html). The identification of specifically up- or 
dysregulated regulatory/metabolic networks in MDSCs was analyzed with the 
open access STRING (Search Tool for the Retrieval of Interacting Genes) analysis 
tool (v.9.1) [14] and with the Ingenuity Pathway Analysis Tool (Qiagen). 
Statistical analyses 
GraphPad Prism and SPSS software packages were used for plotting data 
and statistical analyses. No data was considered an outlier. Real time cell 
monitoring data (RTCA, ACEA biosystems) was analyzed by exporting the Cell 
Index data as a function of time. It was confirmed that Cell Index in a growing 
population of cells was highly homogeneous and normally distributed at any 
given time-point. Therefore, the data was analyzed by one-way ANOVA and 
Tukey’s pair-wise comparisons. IC50s were estimated for each treatment (using 
three published active concentrations per compound) in duplicates by RTCA, and 
means with standard deviations were obtained. IC50s were also highly 
homogeneous and normally distributed. The relative IC50 ratios for DCs vs 
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MDSCs were also calculated, and compared by one-way ANOVA and Tukey’s pair 
wise comparisons. Cell viability was quantified by trypan blue staining and data 
analyzed by one-way ANOVA and Tukey’s pair wise comparisons. Triplicates per 
treatment were used for the analyses. Growth of myeloid cells transduced with 
lentivectors encoding shRNAs was compared by a two-way ANOVA with “time of 
growth” as a random factor with data from four independent transductions, as 
described previously [8]. 
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SUPPLEMENTARY FIGURES AND TABLE 
 
 
Supplementary Figure S1: STRING functional interactomes with lineage-specific 
differentially expressed proteins (B16-MDSC vs DCs). a. Interactome using 
differentially up-regulated proteins as inputs. Medium (thin lines, score of 0.400) 
and   high (thick lines, score of 0.700) confidence relationships between protein 
nodes are indicated in the graph. Internodal relationships were independently 
confirmed. Proteins were encircled and grouped as interconnected networks 
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(NTs) to facilitate interpretation. A central network of kinases (Kin) is shown in 
the middle, which links the other networks. Networks NT1, NT2, NT3 and NT4 
grouped membrane receptors together with associated signal transduction 
proteins. Networks NT6 and NT7 included S100A protein family members, c-type 
lectins, membrane receptors involved in phagocyte migration to sites of 
inflammation and phagocyte-associated enzymes. NT8 included redox proteins 
associated to reactive oxygen species (ROS) and protection against oxidative 
damage and xenobiotics. NT9 comprised ribosomal proteins and regulators of 
nuclear processes and cell division. NT10 included proteins involved in 
intracellular vesicle trafficking, while NT11 consisted in a network of aminoacid 
metabolic pathways. b. Interactome map grouping differentially down-
modulated proteins involved in splicesosome formation (NT12) and carbon 
metabolism (NT13). c. As in (b) with down-modulated proteins involved in MHC II 
antigen presentation (NT15), lysosomal functions (NT18) and mitochondrial 
complex I (NT19). 
 
 
 
 
Supplementary Figure S2: STRING Functional interactomes with tumor-
regulated (B16-MDSCs vs NC-MDSCs) differentially expressed proteins. a. 
STRING interactomes with up-regulated proteins. Medium (thin lines, score of 
0.400) and high (thick lines, score of 0.700) confidence relationships between 
protein nodes are indicated in the graph. Internodal relationships were 
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independently confirmed. Proteins were encircled and grouped as interconnected 
networks (NTs) to facilitate interpretation. NT20 grouped proteins involved in 
inflammatory receptor signaling and ROS scavenging proteins (SOD2, PARK7, 
MPO). NT21 grouped the pentose phosphate pathway. NT22 contained tubulin 
and myosin, pointing to changes in the cell cytoskeleton. NT23 included proteins 
involved in ribosomal RNA transcription, protein translation, folding and 
proteosomal degradation. NT24 contained proteins involved in membrane 
signaling, membrane structure and cytoskeleton rearrangements. b. As in (a), 
NT25 contained proteins involved in gene expression and splicesosome 
organization. NT26 contained mitochondrial NADH dehydrogenase complex I and 
complex III proteins. NT27 contained cell growth-promoting and signal 
transduction proteins. 
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Annexin A5 Anxa5 24 0, 409148995 6, 08E-07 
Rho guanine nucleotide 
exchange factor 2 
Arhgef2 2 0, 414308614 6, 6E-05 
Lactadherin Mfge8 11 0, 429506653 4, 11E-06 
Annexin A1 Anxa1 25 0, 481617476 6, 04E-05 
Twinfilin-1 Twf1 2 0, 489112815 0, 000865 
Tubulin alpha-1C chain Tuba1c 18 0, 49021701 0, 0008 
Class II 
histocompatibility 
antigen, M beta 1 chain 
 
H2-DMb1;H2-DMb2 
 
2 
 
0, 491533209 
 
8, 1E-05 
H-2 class II 
histocompatibility 
antigen, E-U alpha chain 
 
H2-Ea 
 
5 
 
0, 498582303 
 
8, 08E-06 
H-2 class II 
histocompatibility 
antigen, A-D alpha chain 
 
H2-Aa 
 
4 
 
0, 522877994 
 
6, 45E-06 
Myosin regulatory light 
chain 12B 
Myl12b;Myl9 9 0, 536878005 0, 000273 
Glycogen phosphorylase, 
brain form 
Pygb;Pygm 3 0, 538066216 0, 001733 
Lon protease homolog 2, 
peroxisomal 
Lonp2 2 0, 538215926 0, 000881 
Solute carrier family 35 
member F6 
Slc35f6 2 0, 543109435 0, 003618 
H-2 class II 
histocompatibility 
antigen, E-D beta chain 
  
5 
 
0, 557078509 
 
1, 3E-05 
Asparagine—tRNA 
ligase, cytoplasmic 
Nars 4 0, 565052924 0, 000702 
CD63 antigen Cd63 2 0, 578425521 0, 003113 
Fatty acid-binding 
protein, epidermal 
Fabp5 3 0, 600473325 0, 000207 
H-2 class II 
histocompatibility 
antigen, A-D beta chain 
 
H2-Ab1 
 
9 
 
0, 609153728 
 
7, 78E-05 
Myosin-9 Myh9 111 0, 611970692 0, 000644 
V-type proton ATPase 
subunit d 2 
Atp6v0d2 7 0, 630823671 0, 000251 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
Hnrnpa2b1 14 0, 63694467 5, 2E-05 
Myosin-14 Myh14 7 0, 642878205 0, 0003 
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Uncharacterized protein Gm8730;Rplp0 14 0, 648606361 0, 000193 
Neutral cholesterol ester 
hydrolase 1 
Nceh1 7 0, 651305733 4, 73E-05 
Heterogeneous nuclear 
ribonucleoprotein A/B 
Hnrnpab 7 0, 65477646 7, 23E-05 
Monoglyceride lipase Mgll 2 0, 657831546 0, 00342 
Transmembrane 
glycoprotein NMB 
Gpnmb 6 0, 66221021 9, 17E-05 
von Willebrand factor 
A domain-containing 
protein 5A 
 
Vwa5a 
 
4 
 
0, 663896759 
 
0, 001158 
Monoacylglycerol lipase 
ABHD12 
Abhd12 6 0, 677723053 0, 003818 
Ras-related GTP-binding 
protein C 
Rragd;Rragc 2 0, 678167689 0, 004017 
Lysosome membrane 
protein 2 
Scarb2 4 0, 679787707 0, 000251 
Heterogeneous nuclear 
ribonucleoprotein U-like 
protein 2 
 
Hnrnpul2 
 
7 
 
0, 685215928 
 
0, 001169 
Cathepsin D Ctsd 13 0, 691475625 0, 000874 
Putative sodium-coupled 
neutral amino acid 
transporter 10 
 
Slc38a10 
 
3 
 
0, 693741006 
g 
0, 004065 
Signal recognition 
particle subunit SRP68 
Srp68 2 0, 6969969 0, 00223 
Alpha-2-macroglobulin 
receptor-associated 
protein 
 
Lrpap1 
 
20 
 
0, 698359835 
 
0, 000132 
Elongation factor 
1-alpha 1 
Eef1a1;Eef1a2 18 0, 700559018 0, 000256 
Cathepsin S Ctss 6 0, 701751582 0, 001797 
Estradiol 17-beta- 
dehydrogenase 11 
Hsd17b11 4 0, 703096327 0, 000583 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur 
subunit, mitochondrial 
 
Sdhb 
 
9 
 
0, 706493357 
 
0, 000214 
Transforming growth 
factor beta-1 
Tgfb1 2 0, 707417988 0, 002654 
Tropomyosin alpha-3 
chain 
Tpm3;Tpm3-rs7 21 0, 7087286 0, 006006 
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WASH complex subunit 
strumpellin 
Kiaa0196 2 0, 710467852 0, 006814 
Lysosome-associated 
membrane glycoprotein 1 
Lamp1 4 0, 718359696 0, 003244 
ELAV-like protein 1 Elavl1 5 0, 720005557 0, 000596 
LEM domain-containing 
protein 2 
Lemd2 4 0, 723410824 0, 002332 
Aminopeptidase N Anpep 26 0, 724568989 0, 000451 
Heterogeneous nuclear 
ribonucleoprotein A1 
Hnrnpa1 8 0, 728604525 0, 000505 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 10, 
mitochondrial 
 
Ndufa10 
 
6 
 
0, 730876406 
 
0, 003613 
Heterogeneous nuclear 
ribonucleoprotein H2 
Hnrnph2 6 0, 731481958 0, 000661 
Legumain Lgmn 3 0, 733714602 0, 00072 
ER membrane protein 
complex subunit 1 
Emc1 6 0, 736539664 0, 006507 
Serpin B6 Serpinb6a;Serpinb6 8 0, 739418148 0, 002021 
Nicastrin Ncstn 5 0, 739929041 0, 001134 
Cytoplasmic dynein 1 
heavy chain 1 
Dync1 h1 36 0, 746509337 0, 000733 
Macrophage 
metalloelastase 
Mmp12 11 0, 747676988 0, 003364 
L-amino-acid oxidase Il4i1 4 0, 748410986 0, 003715 
DnaJ homolog subfamily 
C member 11 
Dnajc11 3 0, 74862864 0, 001608 
Glutamine— 
fructose-6-phosphate 
aminotransferase 
[isomerizing] 1 
 
Gfpt1 
 
4 
 
0, 749338067 
 
0, 0075 
Lymphocyte antigen 75 Ly75 4 0, 750276114 0, 007796 
Macrophage mannose 
receptor 1 
Mrc1 18 0, 750401561 0, 003811 
Golgi membrane 
protein 1 
Golm1 2 0, 751319227 0, 001423 
Dipeptidyl peptidase 2 Dpp7 2 0, 751371795 0, 002028 
Vam6/Vps39-like protein Vps39 2 0, 753460592 0, 001331 
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Amine oxidase [flavin- 
containing] A 
Maoa 3 0, 753928115 0, 007226 
Creatine kinase B-type Ckb 8 0, 754517987 0, 001915 
Nicotinamide 
phosphoribosyltransferase 
Nampt 2 0, 755875358 0, 00465 
Inosine triphosphate 
pyrophosphatase 
Itpa 2 0, 760176881 0, 008895 
Heterogeneous nuclear 
ribonucleoprotein L 
Hnrnpl 7 0, 76047527 0, 001026 
Ribonuclease inhibitor Rnh1 7 0, 760502021 0, 000888 
B-cell receptor-associated 
protein 31 
Bcap31 11 0, 761263852 0, 00613 
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 4, mitochondrial 
 
Ndufs4 
 
5 
 
0, 762621458 
 
0, 005491 
V-type proton ATPase 
subunit E 1 
Atp6v1e1 16 0, 763478047 0, 004022 
Heterogeneous nuclear 
ribonucleoprotein K 
Hnrnpk;Gm7964 12 0, 763856162 0, 005636 
L-lactate dehydrogenase Ldha 13 0, 764291243 0, 000965 
Putative pre-mRNA- 
splicing factor ATP- 
dependent RNA helicase 
DHX15 
 
Dhx15 
 
7 
 
0, 765273038 
 
0, 001402 
Phosphoglycerate 
kinase 1 
Pgk1 18 0, 766086802 0, 007756 
Glycogen phosphorylase, 
liver form 
Pygl 16 0, 766633266 0, 0034 
NADH dehydrogenase 
[ubiquinone] flavoprotein 
2, mitochondrial 
 
Ndufv2 
 
7 
 
0, 76712425 
 
0, 004833 
NADH dehydrogenase 
[ubiquinone] flavoprotein 
1, mitochondrial 
 
Ndufv1 
 
10 
 
0, 769871468 
 
0, 004625 
Mimitin, mitochondrial Ndufaf2 2 1, 30381531 0, 002611 
Mitochondrial import 
receptor subunit TOM70 
Tomm70a 7 1, 304563258 0, 001894 
Ras-related protein 
Rap-1b 
Rap1b;Rap1a 6 1, 307217616 0, 003029 
Tyrosine-protein 
phosphatase non-receptor 
type 1 
 
Ptpn1 
 
12 
 
1, 310480124 
 
0, 001443 
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Lactotransferrin Ltf 6 1, 311085 0, 009649 
Vacuolar protein sorting- 
associated protein 33A 
Vps33a 2 1, 317391275 0, 000905 
Mitochondrial import 
inner membrane 
translocase subunit 
Tim8 A 
 
Timm8a1;Timm8a2 
 
2 
 
1, 322616616 
 
0, 003141 
Argininosuccinate 
synthase 
Ass1;Gm5424 9 1, 323069518 0, 004604 
Ferritin Ftl1;Ftl2 10 1, 323319619 0, 001567 
Protein S100-A4 S100a4 3 1, 326852892 0, 002104 
Nucleophosmin Npm1;Gm5611 14 1, 328008535 0, 000918 
Integrin alpha-1 Itga1 5 1, 33234292 0, 008921 
Epidermal growth factor 
receptor substrate 15 
Eps15 4 1, 335132857 0, 007084 
Adenylate kinase 2, 
mitochondrial 
Ak2 9 1, 339117363 0, 000355 
Lamin-B receptor Lbr 10 1, 340226149 0, 002185 
Heme oxygenase 1 Hmox1 7 1, 341204992 0, 00124 
Platelet receptor Gi24 4632428N05Rik 4 1, 350347861 0, 002464 
Transgelin-2 Tagln2 12 1, 351776016 0, 001362 
Low affinity 
immunoglobulin gamma 
Fc region receptor II 
 
Fcgr2 
 
6 
 
1, 366625261 
 
0, 002449 
Leukocyte elastase 
inhibitor A 
Serpinb1a 6 1, 37092156 0, 001528 
Perilipin-3 Plin3 3 1, 373402061 0, 002905 
Superoxide dismutase 
[Mn], mitochondrial 
Sod2 8 1, 373760594 0, 001123 
High affinity 
immunoglobulin epsilon 
receptor subunit gamma 
 
Fcer1g 
 
4 
 
1, 374118744 
 
0, 00872 
Embigin Emb 4 1, 377538576 0, 001189 
Formyl peptide receptor 2 Fpr2 3 1, 379093299 0, 000644 
Cytochrome b5 Cyb5a 6 1, 380498718 0, 001192 
Chromobox protein 
homolog 3 
Cbx3 6 1, 380952591 0, 001884 
Acid sphingomyelinase- 
like phosphodiesterase 3b 
Smpdl3b 4 1, 384287037 0, 002606 
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Protein-arginine 
deiminase type-4 
Padi4 9 1, 40155117 0, 000424 
Protein LYRIC Mtdh 7 1, 406115785 0, 002098 
Bcl-2-like protein 13 Bcl2l13 3 1, 408599571 0, 001685 
H-2 class I 
histocompatibility 
antigen, K-B alpha chain 
 
H2-K1 
 
8 
 
1, 41010511 
 
0, 001533 
Napsin-A Napsa 2 1, 411600269 0, 005092 
Coronin-1A Coro1a 12 1, 414013879 0, 00018 
2-amino-3-ketobutyrate 
coenzyme A ligase, 
mitochondrial 
 
Gcat 
 
2 
 
1, 421520698 
 
0, 006462 
Cyclin-dependent 
kinase 2 
Cdk2 2 1, 426124115 0, 009262 
Plexin domain-containing 
protein 2 
Plxdc2 5 1, 42751035 0, 00033 
Rho GTPase-activating 
protein 1 
Arhgap1 5 1, 428460911 0, 000189 
Histone H1.0 H1f0 3 1, 429352055 0, 00982 
Peroxiredoxin-5, 
mitochondrial 
Prdx5 10 1, 43101649 0, 000163 
Cytochrome b-245 light 
chain 
Cyba 5 1, 432458891 0, 000559 
CD44 antigen Cd44 3 1, 443457084 0, 000215 
Zyxin Zyx 4 1, 444345746 0, 008419 
Cytochrome b-245 heavy 
chain 
Cybb 10 1, 455588804 0, 000222 
Chitinase-like protein 3 Chil3 18 1, 46074136 0, 000102 
Tyrosine-protein kinase 
HCK 
Hck 5 1, 464103351 0, 000238 
Leukocyte surface 
antigen CD47 
Cd47 2 1, 465022748 0, 003868 
C-type lectin domain 
family 6 member A 
Clec4n;Clec6a 2 1, 467063188 0, 00017 
CD177 antigen Cd177 5 1, 473425935 0, 002559 
Lamina-associated 
polypeptide 2, isoforms 
beta/delta/epsilon/gamma 
 
Tmpo 
 
11 
 
1, 476178931 
 
0, 00123 
Glycerol kinase Gyk 2 1, 481175737 0, 000568 
Alpha-actinin-4 Actn4 36 1, 485459058 7, 33E-05 
                                                       B16-MDSC vs DC differentially expressed proteins    
     Protein names                  Gene names                     Peptides                   Fold change                    P value              
152 
 
 
  
ATP-dependent 
(S)-NAD(P)H-hydrate 
dehydratase 
 
Carkd 
 
2 
 
1, 487792072 
 
0, 004226 
Actin, alpha skeletal 
muscle 
Acta1 17 1, 490499494 0, 001138 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
 
Serbp1 
 
7 
 
1, 515466638 
 
0, 000249 
Tyrosine-protein kinase 
Fyn 
Fyn;Yes1 3 1, 524885079 0, 003341 
Sodium/potassium- 
transporting ATPase 
subunit alpha-3 
 
Atp1a3;Atp1a2 
 
13 
 
1, 525120684 
 
0, 002015 
60S ribosomal protein L8 Rpl8 5 1, 526316859 0, 00643 
Urokinase plasminogen 
activator surface receptor 
Plaur 2 1, 529089244 0, 000475 
Vesicle-associated 
membrane protein 4 
Vamp4 3 1, 538993145 0, 001874 
ADP-ribosyl cyclase/ 
cyclic ADP-ribose 
hydrolase 1 
 
Cd38 
 
3 
 
1, 539999685 
 
0, 000433 
60S ribosomal protein 
L24 
Rpl24;Gm17430 4 1, 542903394 0, 009811 
Plasminogen activator 
inhibitor 2, macrophage 
Serpinb2 3 1, 562731137 0, 000522 
60S ribosomal protein 
L13 
Rpl13 3 1, 568815619 0, 000839 
Coagulation factor XIII 
A chain 
F13a1 5 1, 575022778 0, 002436 
Protein S100-A9 S100a9 5 1, 585262138 0, 000482 
C-type lectin domain 
family 10 member A 
Clec10a 9 1, 608439704 0, 000107 
3-hydroxyisobutyryl-CoA 
hydrolase, mitochondrial 
Hibch 2 1, 633954389 0, 002052 
Neuronal proto-oncogene 
tyrosine-protein kinase 
Src 
 
Src 
 
3 
 
1, 641084449 
 
0, 000776 
Macrophage galactose 
N-acetyl-galactosamine 
specific lectin 2 
 
Mgl2 
 
13 
 
1, 648910806 
 
3, 73E-05 
Monocyte differentiation 
antigen CD14 
Cd14 3 1, 649302138 0, 000391 
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Signal-regulatory protein 
alpha 
Sirpa 5 1, 667987603 0, 007842 
High affinity cationic 
amino acid transporter 1 
Slc7a1 2 1, 683193993 0, 002121 
Cathepsin G Ctsg 2 1, 684502903 0, 000662 
Zinc transporter ZIP4 Slc39a4 2 1, 701167303 0, 000458 
Ferritin heavy chain Fth1 3 1, 70872916 4, 24E-05 
Phostensin Ppp1r18 4 1, 734747128 0, 001686 
Myeloperoxidase Mpo 14 1, 739785165 1, 48E-05 
Citrate lyase subunit 
beta-like protein, 
mitochondrial 
 
Clybl 
 
2 
 
1, 812987713 
 
0, 00626 
Brain acid soluble 
protein 1 
Basp1 8 1, 855107248 8, 3E-05 
Carbonic anhydrase 4 Ca4;Car4 10 1, 910244551 4, 79E-06 
Lymphocyte-specific 
protein 1 
Lsp1 12 1, 914761621 2, 34E-06 
Protein DEK Dek 3 1, 924824794 6, 07E-05 
Talin-2 Tln2 7 1, 958388414 0, 002108 
Protein Ahnak Ahnak 95 2, 08080018 2, 1E-06 
60S ribosomal protein 
L14 
Rpl14 3 2, 097473177 0, 00187 
Protein S100-A8 S100a8 6 2, 162403323 6, 12E-05 
Eosinophil peroxidase Epx 16 2, 166652695 3, 09E-05 
Myeloid bactenecin (F1) Ngp 3 2, 254673881 4, 64E-06 
Interferon-induced 
transmembrane protein 3 
Ifitm3 3 2, 270237035 2, 09E-06 
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MCG130182, isoform CRA_a Gm5483 3 0, 589206137 0, 000126 
26S proteasome non-ATPase 
regulatory subunit 5 
Psmd5 2 0, 598593317 0, 000267 
Eukaryotic translation initiation 
factor 4H 
Eif4 h 4 0, 611736747 0, 001747 
CapZ-interacting protein Rcsd1 3 0, 612295734 0, 000745 
Protein S100-A6 S100a6 2 0, 617006908 0, 008245 
Rho GDP-dissociation inhibitor 2 Arhgdib 7 0, 618770272 0, 000466 
Tubulin alpha-4A chain Tuba4a 10 0, 626186143 0, 003667 
Superoxide dismutase [Cu-Zn] Sod1 3 0, 631095674 0, 000772 
Nucleosome assembly protein 
1-like 1 
Nap1l1 5 0, 640182294 0, 004251 
Protein S100-A9 S100a9 5 0, 648160088 0, 001437 
Prothymosin alpha Ptma 3 0, 651999552 0, 00052 
Myosin light polypeptide 6 Myl6 8 0, 656424969 0, 005285 
Astrocytic phosphoprotein 
PEA-15 
Pea15 2 0, 666877728 0, 003191 
DNA-directed RNA polymerases I 
and III subunit RPAC1 
Polr1c 2 0, 67045724 0, 006728 
Glucose-6-phosphate 
1-dehydrogenase X 
G6pdx 13 0, 670989902 0, 001161 
Spermine synthase Sms 2 0, 673833379 0, 005298 
Leukotriene A-4 hydrolase Lta4 h 13 0, 686384982 0, 001508 
Myeloperoxidase Mpo 7 0, 688935214 0, 005634 
Alpha-N-acetylglucosaminidase Naglu 3 0, 6900478 0, 009688 
Eukaryotic initiation factor 4A-I Eif4a1 13 0, 694111659 0, 001646 
Tubulin beta-4B chain Tubb4b;Tubb4a 14 0, 696428165 0, 005599 
Transaldolase Taldo1 10 0, 703041508 0, 001204 
Rho GDP-dissociation inhibitor 1 Arhgdia 5 0, 708523919 0, 002027 
6-phosphogluconate 
dehydrogenase, decarboxylating 
Pgd 13 0, 709492257 0, 003216 
Glutathione S-transferase P 1 Gstp1 3 0, 715568979 0, 006782 
Alanine—tRNA ligase, 
cytoplasmic 
Aars 9 0, 724055571 0, 00406 
T-complex protein 1 subunit 
epsilon 
Cct5 7 0, 725355973 0, 008302 
Destrin Dstn 4 0, 726632332 0, 005658 
Ubiquitin-like modifier-activating 
enzyme 1 
Uba1 16 0, 727024557 0, 005177 
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ATPase Asna1 Asna1 2 0, 72757609 0, 007588 
Ezrin Ezr 26 0, 730834893 0, 005634 
Phosphatidylethanolamine-binding 
protein 1 
Pebp1 3 0, 734400826 0, 005071 
Ribosomal RNA processing 
protein 1 homolog A 
Rrp1 2 0, 738249657 0, 006636 
Transketolase Tkt 11 0, 741843927 0, 00586 
Peroxiredoxin-6 Prdx6 8 0, 743801046 0, 002992 
Protein DJ-1 Park7 5 0, 749901306 0, 007964 
Heat shock protein HSP 90-alpha Hsp90aa1 23 0, 750975375 0, 003701 
Chloride intracellular channel 
protein 1 
Clic1 8 0, 751762163 0, 005866 
40S ribosomal protein S18 Rps18;Gm10260 4 0, 753299597 0, 005027 
Glutathione S-transferase Mu 1 Gstm1 7 0, 753382783 0, 008871 
Ras suppressor protein 1 Rsu1 2 0, 753677287 0, 004846 
Proteasome subunit alpha type-1 Psma1 6 0, 761777735 0, 007526 
Bifunctional purine biosynthesis 
protein PURH 
Atic 9 0, 765684291 0, 00599 
Macrophage scavenger receptor 
types I and II 
Msr1 6 1, 303825752 0, 009559 
Protein Sf3b2 Sf3b2 8 1, 310630121 0, 004769 
Malate dehydrogenase, 
mitochondrial 
Mdh2 10 1, 316433466 0, 005662 
ATP-dependent RNA helicase 
DDX42 
Ddx42 2 1, 326602896 0, 0084 
Beta-1, 4 
N-acetylgalactosaminyltransferase 
1 
 
B4galnt1 
 
5 
 
1, 328280926 
 
0, 003965 
Legumain Lgmn 5 1, 363515033 0, 003449 
E3 UFM1-protein ligase 1 Ufl1 3 1, 368089173 0, 005859 
Brain acid soluble protein 1 Basp1 8 1, 369738842 0, 007428 
Cytochrome b-245 heavy chain Cybb 8 1, 379745693 0, 007504 
NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex 
subunit 8, mitochondrial 
 
Ndufb8 
 
2 
 
1, 379768717 
 
0, 009965 
RNA-binding protein FUS Fus 4 1, 383579198 0, 003469 
Annexin A2 Anxa2 23 1, 387238034 0, 001975 
Hexokinase-2 Hk2 12 1, 391029042 0, 004338 
Protein Ahnak Maoa 82 1, 397110044 0, 003518 
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Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial 
 
Ckb 
 
11 
 
1, 400581193 
 
0, 007454 
Chromodomain-helicase-DNA- 
binding protein 4 
Nampt 5 1, 401800102 0, 004666 
Plasminogen receptor (KT) Itpa 3 1, 417180455 0, 003521 
Thyroid hormone receptor- 
associated protein 3 
Hnrnpl 5 1, 418157791 0, 002434 
Zinc-binding alcohol 
dehydrogenase domain-containing 
protein 2 
 
Rnh1 
 
5 
 
1, 432808549 
 
0, 002205 
Normal mucosa of esophagus- 
specific gene 1 protein 
Bcap31 2 1, 447669214 0, 006718 
Pro-cathepsin H Ndufs4 2 1, 448045875 0, 0024 
Annexin A4 Atp6v1e1 20 1, 469858566 0, 004418 
Isopentenyl-diphosphate Delta- 
isomerase 1 
Hnrnpk;Gm7964 4 1, 484479927 0, 007223 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
Ldha 7 1, 512224046 0, 003377 
Cytochrome b-c1 complex subunit 
Rieske, mitochondrial 
Dhx15 6 1, 514801192 0, 000731 
RNA-binding protein 25 Pgk1 3 1, 519285254 0, 005808 
Lysosome-associated membrane 
glycoprotein 1 
Pygl 4 1, 528207246 0, 005381 
Dhx16 protein Ndufv2 2 1, 535132714 0, 006593 
Probable ATP-dependent RNA 
helicase DDX6 
Ndufv1 2 1, 624024139 0, 006046 
Cell division cycle 5-like protein Ndufaf2 2 1, 657520224 0, 006832 
Lysosome-associated membrane 
glycoprotein 2 
Tomm70a 3 1, 684964459 0, 007944 
ADP/ATP translocase 1 Rap1b;Rap1a 5 1, 714237166 0, 009989 
Epoxide hydrolase 1 Ptpn1 2 1, 800951684 0, 001541 
Metastasis-associated protein 
MTA1 
Ltf 3 2, 002434335 0, 005013 
Arginase-1 Vps33a 10 2, 305826701 4, 13E-06 
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Myosin-4 Myh2;Myh4;Myh1 3 0, 272566219 0, 00017 
Lymphocyte-specific protein 1 Lsp1 6 0, 421060939 0, 000113 
MCG130173 Stfa2l1 2 0, 513643456 4, 06E-05 
2010005H15Rik protein 2010005H15Rik 3 0, 525149229 5, 18E-05 
Chitinase-like protein 3 Chil3 12 0, 550932031 0, 000314 
D-3-phosphoglycerate 
dehydrogenase 
Phgdh 5 0, 564754318 8, 73E-05 
MCG130175, isoform CRA_b BC100530 5 0, 579007568 8, 97E-05 
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DISCUSSION 
 
Tumors escape from the immune attack by several means. In this Ph.D 
thesis I studied two of the mechanisms of tumor escape and disease 
progression; the establishment of immunosuppressive interactions between T 
cells and tumor cells, and the biology of MDSCs. 
 
1. PD-L1 INTRACELLULAR SIGNALLING AS A MECHANISM OF TUMOR 
PROGRESSION 
The first immunosuppressive barrier that I studied was the PD-L1/PD-1 
interaction. The results from this Ph.D thesis have contributed to the 
understanding of this key interaction in two major points. First, PD-L1 
expression in cancer cells contribute to the survival of cancer cells by conferring 
resistance to IFN toxicity. Second, two sequence motifs have been mapped 
within the intracytoplasmic domain of PD-L1 that participate in IFN-β resistance 
by transmitting putative intracellular signals to the cancer cell. 
Surprisingly, very little is still known on the biological mechanisms of 
action of PD-L1/PD-1 interactions, compared to the extent to which PD-L1/PD-
1 blockade is utilized in the clinic.  Although this might be practical for the point 
of view of the patient, the lack of knowledge on how these interactions work 
can make several opportunities for therapeutic interventions to be missed.  
There is a general consensus on the association of PD-L1 expression with 
tumor progression. The direct inhibition of T cells by PD-L1 has a strong 
enhancing effect on tumor progression by counteracting the immunological 
attack. Here, the direct participation of PD-L1 expression in the survival of 
cancer cells was studied. 
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1.1. PD-L1 intracellular motifs 
Before this Ph.D thesis, there was a somewhat surprising lack of studies 
on PD-L1 intracellular signal transduction. Only a very few previous studies 
addressed this issue, some of them in a rather indirect manner. For example, 
there was evidence that PD-L1 intracellular signals to cancer cells favored their 
survival (Azuma et al. 2008), and  regulated cancer cell aerobic glycolysis and 
autophagy through the AKT/mTOR signaling  (Chen et al. 2014; Shi et al. 2013; 
Chang et al. 2016; Palmer et al. 2015; Thompson et al. 2004) (Figures 10 and 
7B). 
Indeed, no signaling motifs had been identified or mapped in the 
intracytoplasmic domain of PD-L1 before. While addressing this issue, we 
decided to employ a classical approach to identify specific motifs with potential 
signal transduction capacities. An alignment of the cytoplasmic region of 10 
mammalian PD-L1 molecules readily highlighted three highly conserved 
sequence motifs. One of these motifs was the “RMLDVEKC” sequence. Its 
removal eliminated the capacities of PD-L1 to counteract IFN-β cytotoxicity, 
leading to cell death. The second motif, the “DTSSK” sequence was a strong 
inhibitor of PD-L1 anti-IFN-β functions. Its removal potentiated the growth and 
survival of cancer cells in the presence of IFN-β, suggesting that it was a negative 
regulator of PD-L1 functions. The third motif “QFEET” could be removed without 
having any functional consequence at least on cell growth and survival. Of note, 
the importance of the RMLDVEKC sequence was also indirectly highlighted by 
two facts: (1) The salmon PD-L1 molecule was a DTSSK/QFEET-deleted version 
of the mammalian counterparts; (2) no somatic mutations were found in 
databases of human cancer genomic sequences affecting any of the residues 
comprising this sequence.  In contrast, most of the mutations affected the 
DTSSK motif. Indeed, considering mutations leading to disrupting aminoacid 
changes, 5 out of the 7 directly affected the human homolog of the inhibitory 
motif DTSSK (Figure 5A Cell Reports). These changes were potentially highly 
disruptive, and I tested two of them in the murine PD-L1 homologue positions 
(D276H and K280N). These mutations disrupted the inhibitory functions of 
167 
 
DTSSK, strongly enhancing resistance to type I and type II IFNs. Although there 
was no time to check the other mutations, it is likely that these may disrupt 
DTSSK inhibitory capacities.  
Hence, selected somatic mutations in the PD-L1 gene in human 
carcinomas keep the RMLDVEKC motif unaltered, while disrupting the DTSSK 
inhibitory motif. These cancer cells will probably express hyperactivated PD-L1 
mutants conferring cancer cells stronger resistance to IFN cytotoxicity. In this 
Ph.D thesis, I also tested if alternative sequence motifs could be found using 
bioinformatics databases. Interestingly, only Motif finder 
(http://www.genome.jp/tools-bin/search_motif_lib) identified a sequence in 
the intracellular domain of the murine PD-L1 gene with high similarity to a 
domain present in DNA-dependent RNA polymerase beta subunits. Even more, 
this polymerase-like sequence spanned the two of the motifs found in this Ph.D 
with signal-transduction activities (Figure 12). This result may indicate 
convergence towards a particular structural feature, although this is only 
speculation.  
Other motifs that can affect PD-L1 functions are ubiquitination 
sequences, which may regulate PD-L1 stability. Indeed, cancer cells subjected 
to TNF-α upregulate COP9 signalosome 5 (CSN5), which stabilizes PD-L1 by 
favoring its de-ubiquitination (Lim et al. 2016). It has also been recently shown 
that the stability and functions of PD-L1 are regulated by stabilizing interactions 
with membrane proteins such as CMTM6 and CMTM4 (Mezzadra et al. 2017). 
These proteins inhibit PD-L1 ubiquitination by STUB1 at the plasma membrane, 
preventing its degradation in lysosomes (Burr et al. 2018; Mezzadra et al. 2017).  
Interestingly, the exact lysine residues that get ubiquitinated were not 
identified in any of the previous studies. In this Ph.D thesis I also addressed the 
possibility of ubiquitination to regulate PD-L1 intracellular signaling. There are 
three lysine residues susceptible of ubiquitination, two of them within the 
murine RMLDVEKC and DTSSK motifs, and one of them at the transmembrane-
cytoplasmic interphase. By mutating the RMLDVEKC/DTSSK lysine residues to 
arginines (a similar aminoacid that cannot get ubiquitinated) I found them to be 
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negative regulators of the anti-IFN-β capacities of PD-L1. However, in this thesis 
it was not directly demonstrated whether these lysines do get ubiquitinated. 
Nevertheless, it could be hypothesized that PD-L1 ubiquitination is a major 
regulatory mechanism of its functions by either degrading it and inhibiting signal 
transduction (Sathianathen et al. 2017) or by modulating the recruitment of 
other signaling components (Powles et al. 2018). The existence of this 
regulation is strengthen by our data demonstrating that the inhibitory activity 
of DTSSK also depended on its lysine, and that one selected somatic mutation 
in the human DTSSK homologue disrupted the lysine residue in a cervix 
carcinoma.  It could be interesting to test whether for example STUB1 can 
introduce ubiquitination in lysines 271 and 280 or CSN5 prevent their 
ubiquitination. 
 
 
1.2. PD-L1 cross-talk with interferon signaling in cancer cells  
The elucidation of the exact molecular mechanisms behind the signal 
transduction capacities of the motifs identified in this Ph.D thesis can be 
challenging. It could be possible that kinases or phosphatases physically bind 
these domains either directly or through adaptor proteins that may crosstalk 
with other signal transduction pathways. Proteins belonging to the mTOR 
signaling pathway may be good candidates according to the experimental 
evidence so far. 
Therefore, I decided to approach this problem by first elucidating the 
stage at which PD-L1 interfered with IFN-β signal transduction, a common 
theme utilized by cancer cells for tumor progression. One of such mechanisms 
is IFNAR1 down-modulation, that overcomes oncogene-induced senescence in 
melanoma (Katlinskaya et al. 2016). However, PD-L1 overexpression did not 
alter IFNAR1 and IFNAR2 surface levels in B16 melanoma cells (Figure 1 Cell 
reports). Nevertheless, silencing of IFNAR1 or JAK1 completely protected 
melanoma cells from IFN-β-dependent apoptosis, similarly to the effects 
observed by PD-L1 overexpression (Figure 1 Cell reports).  
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The evidence provided in this thesis shows that lack of PD-L1 enhanced 
STAT3 expression and its tyrosine 705 phosphorylation without affecting STAT1 
or STAT2 after IFN-β stimulation (Figure 3 Cell reports). Pfeffer et al showed that 
non-phosphorylated STAT3 also plays an important role in the IFN I response 
pathway (Pfeffer et al. 2017) and Ren et al proposed that apoptosis caused by 
IFN-β could be driven through STAT3 in breast cancer (Ren et al. 2017).  
Caspases 7 and 9 were strongly up-regulated and required for IFN-β-dependent 
apoptosis (Figure 13, Figure 3 Cell Reports). Recently, our results were 
corroborated by Luo et al. and Garcia-Diaz et al. using shRNA-based or CRISPR-
based genetic screenings, respectively (Garcia-Diaz et al. 2017; Luo et al. 2018). 
JAK1 but not JAK2 was found to be the primary and essential mediator of STAT1, 
STAT3 and STAT5 phosphorylation following IFN-ϒ stimulation, resulting in PD-
L1 upregulation. PD-L1 is transcriptionally up-regulated by STAT1/STAT2 and 
STAT3 (Garcia-Diaz et al. 2017) after IFN exposure. Our data adds that PD-L1 up-
regulation would counteract the apoptotic branch of the IFN-signalling 
pathway, allowing cancer cells to survive. As many studies show that STAT3 and 
STAT5 phosphorylation in cancer cells are indeed pro-tumorigenic, especially 
when induced by JAK2 (Wellbrock et al. 2005; Yu et al. 2016), it could be tested 
whether this is in part caused by the anti-apoptotic effects of PD-L1 up-
regulation. Indeed, these authors propose that PTPN2 (JAK2) inhibitors would 
potentiate JAK1 activities and the enhancement of IFN cytotoxicity (Luo et al. 
2018; Manguso et al. 2017). 
IFN-β induces the expression of TRAIL that triggers caspase 8 and 3 
dependent apoptosis in melanoma and breast cancer cells (Bernardo et al. 
2013; Chawla-Sarkar et al. 2001).  In cervical carcinoma, IFN-β causes 
proliferative arrest and accumulation of the anti-apoptotic protein cFLIP and 
caspase 8  (Apelbaum et al. 2013). Our data shows that STAT3 clearly has an 
anti-oncogenic function by promoting apoptosis through caspases 7 and 9 in 
melanoma cells after IFN-β exposure. 
As mentioned above, this seems to be a discrepancy with other 
published work. Phospho-STAT3 Y705 and sometimes S754 has been linked to 
oncogenic and anti-apoptotic capacities in several cancers (Hsia et al. 2017; 
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Ganguly et al. 2018; Ni 2018; Liu et al. 2018; Zhang et al. 2011; Bowman et al. 
2000; Darnell et al.  2005; Bharti et al. 2013; Couronné et al. 2013; Pencik et al. 
2016). Inhibition of the STAT3 pathway counteracts tumor progression in vitro, 
in vivo and in some clinical trials. Some examples are  a phase I study of an oral 
STAT3 inhibitor OPB-31121, in patients with advanced solid tumours witch 
concluded preliminary antitumour activity and safety of it (Oh et al. 2015) and 
a phase I clinical trial of an oral STAT3 direct inhibitor (C188-9) for patients with 
advanced cancers that is currently on 
(https://clinicaltrials.gov/ct2/show/NCT03195699).  
 These discrepancies could have several explanations. First, STAT3 could 
have different functions within cancer cells, depending on the initiating 
stimulus. In our case, IFN-β is the initiating stimulus and its antitumor and pro-
apoptotic functions through JAK/STAT pathway are well-known. Second, STAT3 
can be phosphorylated in several sites, and here our data strongly suggests that 
tyrosine 705 phosphorylation is directly linked to apoptosis. Other authors link 
this phosphorylation to anti-apoptotic responses (Ganguly et al. 2018; Zhang et 
al. 2011). However, it could well be that specific combinations of 
phosphorylated/non-phosphorylated sites may confer differential functions to 
STAT3. Third, STAT3 could play a dual role by having a pro-apoptotic function 
first, but triggering a pro-tumorigenic effect by further causing PD-L1 
transcriptional up-regulation. Indeed, there is evidence that lentiviruses-
transduced-microRNA-3127-5p expression leads to PD-L1 elevation and 
suppresses autophagy through increase STAT3 phosphorylation, promoting 
human non-small lung cell carcinoma growth. However, the specific mechanism 
by which this mircroRNA achieves these effects were not described by the 
authors of the study (Tang et al. 2018). Other studies have demonstrated that 
STAT3 is involved in PD-L1 upregulation in several cancers (Fujita et al. 2015; 
Horlad et al. 2016). Our data corroborate those results but points to caspase 7 
mainly and caspase 9. Four, other factors that were not studied in this thesis 
may also influence the outcome. For example, in head and neck cancer STAT3 
SUMOylation increases STAT3 Y705 phosphorilation (Zhou et al. 2016). Other 
pathways such as MAPKs, PI3K, or NF-B cooperate with JAK/STAT signaling 
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(Gough et al. 2008). IFNs also activate some protein kinase C isoforms (PKCs) 
and the multifunctional adaptor protein CrkL (Schreiber al. 2017; Suda et al. 
2012; Barbosa et al. 2014). The contribution of some of these pathways was 
part of this PhD thesis, which is currently undergoing.  
 
 
 
 
Figure 12. PD-L1 domains and cross-talk with interferon signaling in cancer 
cells. (A) The domain structure of PD-L1 is represented in the figure. Ig, the 
extracellular immunoglobulin domain; TM, transmembrane domain. The 
RMLDVEKC, DTSSK and QFEET motifs are represented in the intracytoplasmic 
region of PD- L1. The RNApol-like motif identified by MotifFinder is indicated, 
which contains part of the RMLDVEKC motif and the whole DTSSK motif. Red 
arrows point the inhibitory lysines. (B) The mechanism by which PD- L1 
counteracts interferon-mediated apoptosis is represented in the figure.  A 
function associated to the RMLDVEKC motif is required to inhibit STAT3 
phosphorylation, which in turns stops caspase7-mediated apoptosis. The DTSSK 
motif acts as a negative regulator of the RMLDVEKC motif. 
 
 
172 
 
1.3.  Consequences of PD-L1-dependent inhibition of the ifn signaling 
pathway in cancer cells 
It is highly likely that PD-L1/PD-1 blockade with antibodies may sensitize 
cancer cells to IFN-β cytotoxicity similarly to silencing or abrogation of PD-L1. 
This has been shown in vitro in this Ph.D thesis by using anti-PD-L1 antibodies. 
Indeed, inactivating mutations in components of the IFNs signal transduction 
pathway enhance cancer progression, pointing to the necessity of disrupting 
this pathway in many cases for tumor progression (Nakanishi et al. 2007; Yao et 
al. 2009; Gao et al. 2016; Zaretsky et al. 2016). Some of these mutations 
contribute to resistance to anti-PD-1 therapy (Shin et al. 2017; Zaretsky et al. 
2016). Other mechanisms of tumor escape include downregulation of IFN 
receptors after ubiquitination by SCF-bTrcp2/HOS E3 ubiquitin ligase (Kumar et 
al. 2003; Splawski et al. 2004; Kumar et al. 2007; Katlinskaya et al. 2016).  
The group led by Dr Antoni Ribas proposed that loss of IFN signaling in 
cancer cells prevented adaptive up-regulation of PD-L1, becoming “PD-L1” 
negative tumors (Zaretsky et al. 2016). These tumors then would be intrinsically 
resistant to PD-L1/PD-1 blockade. However, this idea is difficult to reconcile 
with our current understanding of PD-L1/PD-1 interactions. It would be 
expected that PD-1+ T cells would be “free” to exert their cytotoxic activities 
over PD-L1-negative tumors. The data obtained in this Ph.D thesis offers a 
complementary interpretation. PD-L1/PD-1 blockade would sensitize cancer 
cells to IFN-induced apoptosis leading to cancer cell death. Only cancer cell 
variants with mutations in the IFN signal transduction pathway would be 
selected because no apoptosis will occur, in analogy to the B16 melanoma cells 
with silenced IFNAR1 or JAK1. These cells thrive even in non-physiologically high 
concentrations of IFNs (Gato-Cañas et al. 2017). 
The data presented in this Ph.D thesis also offers mechanistic bases for 
combining PD-L1 blockade and IFN treatment. IFN-β has been used to treat 
melanoma as an adjuvant therapy prolonging survival (Uehara et al. 2017). 
Although most of the evidence suggests that IFNs are not effective at priming T 
cell responses, they are required when produced by T cells as they induce tumor 
cell apoptosis, neoantigen release, destruction of tumor vasculature and 
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increasing immune cell tumor infiltration (Fujimura et al. 2009; Escors et al. 
2013). IFNs possess immunomodulatory activities by the induction of CCL5 and 
CXCR3 ligands (CXCL9-11)  in melanoma, which could play a role in T-cell 
recruitment, enhancing anti-PD-L1 mAb treatment (Hong et al. 2011; Liu et al. 
2015; Kakizaki et al. 2015). Increased tumor destruction by IFN-β provokes the 
priming of neoantigen-specific T-cells that can be mobilized with anti-PD-L1 
mAb (Uehara et al. 2017).  In agreement with this model, in this thesis cancer 
cells expressing a signal-null PD-L1 combined with intratumor delivery of 
lentivector encoding IFN-β was sufficient to counteract tumor growth even if 
PD-L1 could still engage PD-1 on T cells. Indeed, there is not a need to directly 
use IFNs. Type I IFN stimulators have potent anti-cancer activities that synergize 
with PD-L1/PD-1 blockade, including TLR3 agonists and  STING (Stimulator of 
IFN genes) agonists (Woo et al.  2015; Leach et al. 2018; Curran et al. 2016; Allen 
et al 2017; Brockwell et al. 2017). This synergistic effect could be the result of a 
potentiated IFN signal transduction in cancer cells (Ager et al. 2017). Indeed, it 
has been recently demonstrated that murine lung cancer and melanoma tumors 
treated with local radiation activate the IFNβ-MHC I pathway, releasing 
neoantigens and  synergizing with PD-1 blockade (Overwijk et al. 2013). There 
is evidence that radiation induces IFN-β production by tumor infiltrating DCs in 
a B16 melanoma model (Zhao et al. 2013). 
 
 
1.4.  Towards a complete mechanistic model 
A key goal that could not be accomplished in this thesis was the 
immunoprecipitation of PD-L1 protein complexes from cancer cells after IFN-β 
treatment followed by mass spectrometry. Nevertheless, this has been carried 
out from human HEK 293T cells (Huttlin et al., 2015) and found that PD-L1 was 
associated to mTOR and kinases regulating DNA damage (such as ATR and ATM). 
A recent review by our group proposes a mechanism that integrates the results 
from Huttlin et al, and those obtained in this thesis. Briefly, mTOR and ATM 
bound to PD-L1 could associate with and regulate STAT1 and STAT3 and 
indirectly CASP3, CASP9 and CASP7 (Figure 13). Overall, PD-L1 could regulate 
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the anti-apoptotic response by the mTOR-AKT signaling core (Huttlin et al. 
2015). A key question remains whether mTOR, ATM or any of the components 
co-immunocaptured with PD-L1 directly interacts with either RMLDVEKC or 
DTSSK sequence motifs. Or how these putative interactions activate mTOR-AKT. 
Nevertheless, the physical association of each component identified by Huttlin 
et al with PD-L1 will have to be independently validated in future experiments. 
 
 
 
Figure 13: PD-L1 protection from IFNβ toxicity is mTOR dependent. 
STRING functional interactome integrating type I IFN signal transduction 
components and PD-L1-interacting proteins. PD-L1-interacting protein mTOR 
can probably regulate STAT1 and STAT3 and indirectly CASP3, CASP9 and CASP7.  
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2. MDSCs AS A MECHANISM OF RESISTANCE TO IMMUNOTHERAPY 
 
The second theme of my Ph.D. thesis was the molecular study of MDSCs 
using an ex vivo differentiation system developed by our group, and 
quantitative proteomics. These cells are broad suppressors of immune 
responses, and negatively correlate with the efficacy of immune checkpoint 
blockade. 
Using the same datasets obtained in a study published before the start 
of this Ph.D. thesis (Liechtenstein et al. 2014).  The proteomic data was re-
analyzed using MaxQuant, an integrated suite of algorithms specifically 
developed for high-resolution, quantitative MS data, which achieves mass 
accuracy in the part per billion range, a six-fold increase over standard 
techniques (Cox et al. 2008). The top molecular and cellular pathways in MDSC 
modelling melanoma subsets compared to DCs correlated with previous 
analyses by Liechtenstein et al. (Figure 9). The most important were cellular 
growth and proliferation (NPM1, CDK2), cell-to-cell signalling (Ctsg, Icam), 
migration to inflammatory sites (s100), angiogenesis, invasion/metastasis (c-
type lectins), endocytosis (Clta, Actn4) and integrin signalling (TLR). These 
differentially-activated pathways correlated with most of the published 
literature on MDSC (Trikha et al. 2014; Rausch et al.  2012; Wesolowski et al.  
2013; Dilek et al. 2012; Youn et al. 2010; Peranzoni et al. 2010) highlighting their 
importance for the differentiation, migration, and function of MDSCs within 
tumor-bearing hosts. These processes require high energy levels, but 
interestingly MDSCs down-regulated proteins participating in aerobic ATP 
production, aerobic cellular respiration, and glycogen/glucose metabolism, 
relative to BM-DCs. This could be observed by a decrease in expression levels of 
such proteins as coenzyme Q10 (ubiquinone), glycogen phosphorylase (Pygl) 
and phosphoglucomutase-1 (Pgm1).  
Probably as a compensation mechanism, proteins that enhanced lipid 
metabolism (ApoB R, Perilipin-3) were increased in MDSCs, which provides 
energy and contributes to amino acid synthesis (D3-PGDH). This data was also 
confirmed by several other studies highlighting the lipid metabolism in MDSC as 
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an energy source (Boutte et al. 2011; Liechtenstein et al. 2014). However, these 
metabolic pathways produce a large number of toxic metabolites. Thus, MDSCs 
also exhibited high levels of detoxifying enzymes including P450R, ROS 
scavenger proteins such as Sod2 and free radical scavenging proteins (NADPH 
oxidase I). This data was recently corroborated by others (Hossain et al. 2015). 
 
It is important to note that mitochondrial dysfunction by 
downmodulation of NADPH dehydrogenase complex I and III was a 
characteristic of MDSCs compared to conventional DCs, possibly as a reflection 
of the shut-down of oxidative phosphorylation. As expected, and compared to 
conventional DCs, MDSCs showed a decrease in proteins regulating antigen 
presentation by MHC II, including lysosomal proteins and enzymes (Ctsd, 
Lamp1, Lgmn…).MHC I molecule was up-regulated (H2-K1). This may be related 
to MDSC suppressive activities on CD8 T cells (by inducing anergy), which was 
shown to be mediated in an antigen-dependent way (Kusmartsev et al. 2005). 
 
These functions indicate that MDSCs are highly active cells that obtain 
energy from lipid catabolism and as a result protect themselves from oxidative 
stress, in agreement with a previous study by our group and others (Gato-Canas 
et al. 2015; Liechtenstein et al. 2014; Boutte et al. 2011; Hossain et al. 2015; 
Trikha et al. 2014)(Figure 5 and suplem. 1 Oncotarget). 
 
To study functions specifically associated to cancer-regulated pathways 
in MDSCs, we had first to generate MDSCs modelling non-neoplastic subsets, 
which is rather challenging. In a study previous to this Ph.D. thesis, we 
generated these no-neoplasic MDSCs using conditioning medium from the 
supernatant of 293T human cells modified with lentivectors to express GMCSF. 
Using this supernatant, MDSC-like cells can be generated from murine bone 
marrow. 293T cells are human embryonic kidney cells modified to express the 
T antigen of the SV40 virus, and immortalized with an integrated adenovirus. 
Although these are non-cancerous cells per se, they are immortal and of human 
origin. The choice of the producer cell line was not originally made for the 
177 
 
purposes described in this Ph.D. thesis, or the published studies. However, it 
was found some years ago that this supernatant generated conditioning media 
that differentiated MDSCs without some of the characteristics typical of cancer-
specific MDSCs (Liechtenstein et al. 2014). Later, I developed a 3T3 murine 
fibroblast-based GM-CSF producer cell line with which I generated similar 
phenotypic and functional results. This 3T3-based model may provide a more 
adequate model for murine non-neoplastic MDSC differentiation. 
 
Nevertheless, using this comparative control, the up-regulation of the 
pentose phosphate pathway (PPP) was one of the most prominent features 
(Figure 6 Oncotarget). This result agrees with the need of obtaining NADPH for 
biosynthesis in the absence of oxidative phosphorylation. Furthermore, the 
decreased expression of mitochondrial NADPH dehydrogenase complex I and III, 
the up-regulation of free radical scavenging proteins (SOD1), responses to 
cellular stress (Peroxiredoxin 6), epithelial adherence junction signaling 
(Tubulin, Myosin), DNA methylation (CHD4) and transcriptional repression 
pathways were all hallmarks of MDSCs modelling melanoma-infiltrating subsets 
compared to non-neoplastic MDSCs (Figure 6 Oncotarget). In addition, the 
glutathione metabolism was also a prominent feature, possibly in coordination 
with the PPP as an energy source, or for participation in the production of 
reactive oxygen and nitrogen species (Figure 7 Oncotarget). 
Overall, published data agree with our results (Hitosugi et al. 2016; 
Aliper et al. 2014; Pilon-Thomas et al. 2011; Sawant et al. 2013; Wu et al. 2012; 
Cheng et al. 2014; Zhang et al. 2017; Zhai et al. 2017; Hammami et al. 2012; 
Sinha et al. 2008;  Youn et al. 2012). 
Importantly, the data provided in this Ph.D. thesis highlights a group of 
kinases that differentiate MDSCs from DCs which included SRC family members 
and the predicted implication of PI3K-AKT signalling axis (Figure 2-4 
Oncotarget). ERK, PKC, and AMPK kinases were predicted to play major roles 
regulating neoplastic-specific MDSC functions, which also agrees with the role 
of these kinases in cells of the tumor microenvironment (Zhai et al. 2017; Pilon-
Thomas et al. 2011; Mao et al. 2017; Slack et al. 2007; Thiel et al. 2007; Barbosa 
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et al. 2014)(Figure 6 Oncotarget). All these analyses provide a unified view of 
biological processes in MDSCs and uncover a large list of molecular targets 
susceptible of therapeutic intervention. Some multi kinase inhibitors were used 
to inhibit MDSC expansion like sunitinib (Ko et al. 2010). 
By silencing or activating genes of interest or inhibiting enzymes, insight 
into each specific pathway over MDSC biology will be gained, followed by 
validation of attractive MDSC-specific targets. 
 
Again, most of the published data agrees with the core MDSC-specific 
kinases as found in this thesis. SRC kinases were predicted to regulate MDSC 
differentiation when compared to conventional DCs, linked to mitochondrial 
dysfunction and changes in the cytoskeleton (Figure 8 Oncotarget). Using broad 
inhibitors of SRC, MDSC differentiation was also inhibited (Figure 8 Oncotarget), 
in agreement with other studies (Aliper et al. 2014; Mao et al. 2017). 
PI3K signalling is known to regulate chemotaxis, phagocytosis, ROS 
production, and apoptosis in macrophages and neutrophils (Trikha et al. 2014). 
Murine and human monocytes can be converted into m-MDSC by activation of 
the PI3K-AKT-mTOR pathway following GM-CSF and IFN-ϒ treatment (Ribechini 
et al. 2017). The PI3K pathway regulates transcription factors that control 
proliferation and survival of MDSCs; it, therefore, has been suggested that PI3K 
may play a central role in controlling MDSCs and that it may be an effective 
MDSC-depleting target (Trikha et al. 2014). Targeting PI3K with an inhibitor 
(NCT02637531) in myeloid cells overcoes resistance to checkpoint blocade 
therapy in various cancers (Henau et al. 2016).  
AKT was predicted to regulate melanoma-specific MDSCs activity and 
proliferation according to our data, in agreement with most studies (Figure 4 
Oncotarget) (Liu et al. 2012; Zhu et al. 2014; Zhai et al. 2017).  
AKT and MEK/ERK inhibitors are being tested in human clinical trials for 
the treatment of several cancers (Arce et al. 2011; Arce et al. 2012; Escors et al. 
2008) (NCT01781429 , NCT01392521, NCT01229150, NCT01668017 )  We 
confirmed that inhibition of the ERK pathway preferentially affected MDSCs 
over conventional DCs (Figure 8, 9 Oncotarget). In our data, ERK upregulation 
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discriminated neoplastic from non-neoplastic MDSCs, in agreement with other 
published studies (Fang et al. 2015). Protein kinase C (PKC) proteins were also 
upregulated in MDSCs modelling neoplastic subsets (Figure 6 Oncotarget) them 
are involved in MDSC suppressive cascade (Wang et al. 2016) and identified in 
other interactome analyses (Aliper et al. 2014).
Interestingly, AMPK appeared as another core regulatory kinase of 
MDSC functions, in agreement with Hammami et al. (Figure 6 Oncotarget) 
(Hammami et al. 2012). AMPK is induced by hypoxia, low glucose levels, or H2O2 
oxidation and counteracts metabolic stress as it plays a crucial role in NADPH 
homeostasis (Kang et al. 2015). 
Changes in mitochondria were remarkable. The MDSC mitochondrial 
machinery was turned to high ROS production, while MDSCs up-regulated 
protective proteins towards oxidative damage. Indeed, ROS can also drive the 
carbohydrate flux to the PPP. Hydrogen peroxide can activate by oxidation 
G6pdx, which is up-regulated in our melanoma MDSCs (Figure 6 Oncotarget) 
(Hitosugi et al. 2016). G6pdx is a key regulatory enzyme of the PPP and its 
activation increases NADPH levels and can thereby counteracts ROS damage 
(Hitosugi et al. 2016). It is worth noting that similar processes take place in 
cancer cells, which exhibit mitochondrial metabolic reprogramming, production 
of ROS and glucose metabolism through the PPP (Martin- Bernabe et al. 2014). 
Overall, the detrimental effects of ROS and RNS on NK and T cells are well 
established, which potentiate immune suppression in the tumor 
microenvironment by MDSCs and other tumor-infiltrating myeloid cells. 
The data presented in this Ph.D. thesis includes several different proteins 
related to MDSC activities that could be targeted. These include HSP70, HSP90 
(Figure 1-3 Oncotarget), shown to expand and activate MDSCs following pro-
inflammatory responses (Ociennikowska et al. 2015; Diao et al. 2015). HSP90 
inhibitors are used to deplete MDSC (Rao et al. 2012). Retinoblastoma (Rb) 
regulates m-MDSC to g-MDSC differentiation (Youn et al. 2013), and the S100 
family of UP-regulated MDSC proteins. These last family of proteins participate 
in MDSC migration to sites of inflammation (KO et al. 2010; Sinha et al. 2008) 
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and enhanced ROS production (Gabrilovich et al. 2012). 
Several studies have analyzed MDSCs by mass spectrometry or gene 
expression arrays in different experimental models (Boutté et al. 2011; Burke et 
al. 2014; Chornoguz et al. 2011), particularly of circulating and peripheral 
MDSCs which differ significantly from tumor-infiltrating subsets (Aliper et al. 
2014). A study compared splenic and tumor-infiltrating MDSCs by gene arrays, 
further emphasizing the difference between these MDSC populations. This 
study predicted key transcription factors, kinases, and proteases within the 
MDSC populations following the inferred interactomes from the gene expression 
arrays (Aliper et al. 2014). While it is important to assess MDSCs in vivo, the use 
of our ex vivo MDSCs substantially facilitates their study and use.  
 
 
3. COMBINATION OF THERAPIES TARGETING BOTH BARRIERS 
 
Therapeutic targeting of the MDSC pathways could be used in 
combination with PD-L1/PD-1 blockade. Preclinical studies indicate that this is 
a promising approach (Clavijo et al. 2017; Meyer et al. 2014; Martens et al. 2018; 
Ajona et al. 2017). Indeed, these strategies may synergize as some studies show 
that PD-L1 blockade attenuates the suppressive activity of MDSCs (Toor and 
Elkord 2018). Some examples of these strategies are enumerated as follows: 
PI3K targeting with PD-1 inhibitors in murine models of colorectal and breast 
cancers (Kim et al. 2014); Anti-PD-L1 efficacy enhanced by Inhibition of MDSCs 
with a selective inhibitor of PI3Kδ/γ (Yang et al. 2015); PI3Kδ/γ inhibition and 
PD-L1 blockade in head and neck cancer (Medsker et al. 2016); depletion of g-
MDSC with CXCR2-specific antibodies and anti-PD-1 in a murine 
rhabdomyosarcoma (Highfill et al. 2014); MDSC depletion with anti-GR-1 
antibody in combination with anti-PD-1 antibody in glioma (Kamran et al. 2017); 
and histone deacetilases with anti-PD-1 or anti-PD-L1 in lung and renal 
carcinoma models or small cell lung cancer (Orillion et al. 2017; Briere et al. 
2018). Other strategies combine several anti-MDSC agents, some of them are 
multi-kinase inhibitors, in combination with PD-L1/PD-1 blockers with positive 
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outcomes in several experimental models (Guan et al. 2017; Yang et al. 2018; 
Larkin et al. 2015; Zhou et al. 2018). These last studies corroborate the 
importance of kinase activities in MDSCs function and survival as I have 
concluded in this thesis. 
In contrast, few studies have targeted MDSC in combination with 
immune checkpoint inhibitors in cancer patients yet (Martens et al. 2018; 
Meyer et al. 2014; Noelle et al. 2014; J. Zhou et al. 2018; Eissler et al. 2016). A 
summary of some MDSC-targeting approaches with immune checkpoint 
inhibition in clinical trials is shown in Table 2. 
 
 
 
 
Table 2. Combination therapies of MDSC inhibition or depletion and Immune 
Checkpoint Inhibitors. Specific examples of studies using combination of anti-
MDSC with immune checkpoint inhibitors are enumerated. NSCLC,no-small-cell-
lung-cancer; CXCR2, IL8receptor; PI3K, phosphatidylinositol-3-kinase; VISTA, V-
domain Ig suppressor of T cell activation; CSF1R, colony stimulating factor 1 
receptor; LY6G, Lymphocyte antigen 6 complex locus G6D; Ab,antibody; 
Inh,inhibitor; HDAC, histone deacetylase; MEK, mapkinase; CCR5, chemokine 
receptor type 5; CCRK,cell cycle-related kinase; CDK,cyclin-dependent kinase; 
IL18,interleukin. 
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CONCLUSIONS 
 
 
CONCLUSIONS PART I 
 
1. PD-L1 delivers intrinsic intracellular signals to cancer cells that promote 
their growth and survival. It represents a barrier against IFN cytotoxicity 
that can reinforce its inhibitory properties to T cells when engaged to 
PD-1 on T cells. 
 
2. PD-L1 contains two phylogenetically conserved sequence motifs within 
its carboxy terminus which regulate signal transduction capacities and 
cross-talk with the IFN signal transduction pathway in cancer cells. 
Somatic mutations affecting the inhibitory DTSSK motif are selected in 
some human carcinomas that disrupt its regulatory functions and 
hyperactivate PD-L1 anti-IFN activities. 
 
3. PD-L1 inhibits IFN signal transduction in cancer cells at the STAT3 
phosphorylation step and inhibits IFN-dependent apoptosis mainly 
affecting caspase 7 expression. 
 
4. Intrinsic signal activities of PD-L1 contribute to tumor progression in vivo 
and protect cancer cells against IFNs in the tumor environment. 
 
5. PD-L1 silencing or blockade with antibodies is sufficient to sensitize 
cancer cells to IFNs. Therefore, any adaptation of cancer cells to either 
inhibit the IFN signaling pathway or potentiate PD-L1 activities will favor 
their escape from the immune attack. 
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CONCLUSIONS PART II 
 
1. Differential proteomes from conventional ex vivo-differentiated murine 
DCs and MDSCs resembling melanoma tumor-infiltrating and no-
tumoral subsets have been obtained and quantitatively compared. 
 
2. MDSC-specific targets affecting MDSC differentiation and functions 
were identified. 
 
3. MDSCs exhibit an altered metabolism adapted to energy consumption 
in the absence of oxygen, high production of ROS and NOS species, and 
activation of protective pathways against oxidative stress. 
 
4. MDSCs express a core of specific kinases that regulate their 
differentiation from conventional DCs (AKT, PI3K, and SRC) or their 
immunosuppressive functions within the tumor environment (ERK, PKC, 
AMPK). 
 
5. MDSC-specific kinases can be targeted with inhibitors that selectively 
affect MDSCs and not conventional DCs in vitro. 
 
 
OVERALL CONCLUSION 
 
I propose that targeting/depleting MDSCs in cancer patients could be a 
prerequisite for initiation of immune checkpoint therapies. 
Additionally, enhancenment of IFN responses in combination with PD-
L1 blockade should improve therapeutic responses in human patients 
compared to monotherapies. 
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CONCLUSIONES PARTE I 
 
1. PD-L1 transmite intrínsecamente señales intracelulares a las células 
cancerosas que promueven su crecimiento y supervivencia. Representa 
una barrera frente la citotoxicidad del IFN y puede reforzar sus 
propiedades inhibitorias frente las células T cuando se une a PD-1 en las 
células T. 
2.  PD-L1 contiene dos motivos en su secuencia filogenéticamente 
conservados dentro de su extremo carboxi que regulan las capacidades 
de transducción de señal e interaccionan con la vía de transducción de 
señal de IFN en células cancerosas. Las mutaciones somáticas que afectan 
el motivo inhibidor de DTSSK se seleccionan en algunos carcinomas 
humanos, estos alteran sus funciones reguladoras e hiperactivan las 
actividades anti-IFN de PD-L1. 
3.  PD-L1 inhibe la transducción de señal de IFN en células cancerosas en la 
el paso de fosforilación de STAT3 e inhibe la apoptosis dependiente de IFN 
que afecta principalmente a la expresión de caspasa 7. 
4. Las señalizcion intrínseca de PD-L1 contribuye a la progresión tumoral in 
vivo y protege a las células cancerosas contra los IFN en el entorno 
tumoral. 
5. El silenciamiento o bloqueo de PD-L1 con anticuerpos es suficiente para 
sensibilizar las células cancerosas a los IFN. Por lo tanto, cualquier 
adaptación de las células cancerosas para inhibir la vía de señalización de 
IFN o potenciar las actividades de PD-L1 favorecerá su escape del ataque 
inmune. 
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CONCLUSIONES PARTE II  
 
1. Se han obtenido los proteomas de DCs murinas convencionales 
diferenciadas ex vivo y MDSCs de melanoma infiltrantes de tumor y otras 
MDSCs no tumorales y se han comparado cuantitativamente. 
2. Se identificaron dianas específicas de MDSC que afectan la diferenciación 
y funciones de MDSC. 
3. Las MDSC exhiben un metabolismo alterado adaptado al consumo de 
energía en ausencia de oxígeno, alta producción de especies ROS y NOS, 
y activación de vías protectoras contra el estrés oxidativo. 
4. Los MDSC expresan un núcleo de quinasas específicas que regulan su 
diferenciación de las DC convencionales (AKT, PI3K, SRC) o sus funciones 
inmunosupresoras dentro del entorno tumoral (ERK, PKC, AMPK). 
5. Las quinasas específicas de MDSC se pueden tarjetear con inhibidores que 
afectan selectivamente a los MDSC y a las DC convencionales in vitro. 
 
 
 
  
CONCLUSIÓN GENERAL 
 
Propongo que tarjetear / eliminar las MDSC en pacientes con cáncer 
podría ser un requisito previo para el inicio de las terapias de “immune 
checkpoint inhibitors”.  
Además, la potenciación de las respuestas de IFN en combinación con el 
bloqueo de PD-L1 debería mejorar las respuestas terapéuticas en 
pacientes humanos en comparación con las monoterapias. 
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